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Abstract 
Conditions of GH excess and deficiency cause significant morbidity and mortality. 
Treatments for both situations have evolved considerably in recent years, but 
heterogeneity in therapeutic responses remains poorly understood. An improved 
understanding of the role of the growth hormone receptor’ (GHR) has the potential 
to advance future clinical management. Deletion of exon 3 in the GH receptor (d3-
GHR) has been linked to enhanced rhGH responsiveness in children; the effect in 
adults with GH deficiency and acromegaly in adults is less well understood.  
Pegvisomant, a GHR antagonist is a highly effective treatment for acromegaly but 
monitoring of treatment is limited by the potential imprecision of IGF-I as the sole 
marker of response.   
The aim of this work was two-fold; to investigate the effect of the d3-GHR in 
determining an individual’s response to GH in GH deficiency and acromegaly and to 
investigate the effect of supraphysiological doses of pegvisomant on IGF-I and the 
physiological markers of GH activity in patients with acromegaly.  
194 GHD patients and 79 acromegaly patients were genotyped for d3-GHR and 
results correlated with clinical and biochemical response to GH. Homozygosity for 
d3-GHR confers a marginal increase in GH responsiveness in GH deficiency and 
acromegaly but without significant clinical effects. Both d3 alleles are required to 
achieve this response; given that only 10% of the population are d3 homozygotes, 
d3-GHR does not explain heterogeneity in GH responsiveness.  
Investigation of supra-physiological doses of pegvisomant revealed unexpected and 
previously unpublished findings; despite two to four fold increases in dose, six of the 
nine patients failed to achieve target subnormal IGF-I levels.  
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The absence of a significant role for d3-GHR in determining GH response and the 
unexpected difficulty in causing GH deficiency with high dose GH receptor 
antagonism highlights the need for further study of the GHR in determining an 
individual’s response to GH.   
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Chapter 1  
 
Introduction
17 
 
Although the original study of endocrinology started in 200BC in China, 
endocrinology is a relatively young medical specialty with advances in our 
understanding occurring largely over the past century. Historically, the pituitary was 
believed to be responsible for the regulation of the secretion of phlegm until the 17th 
century when Richard Lower speculated that substances passed from the brain to 
the pituitary and thence to the blood. The term “hormone” only came into use 100 
years ago following Starling’s work, demonstrating the presence of a substance 
obtained from pancreas which produced biological effects in the absence of 
innervation.  
The development of modern clinical neuroendocrinology dates back to the early 20th 
century as a result of the observations and experiments of Harvey Cushing, a 
Baltimore and Boston neurosurgeon. He performed hypophysectomies on dogs, 
establishing the true function of the pituitary by recording the consequences of this 
intervention. He coined the terms hyper- and hypopituitarism to describe the 
consequences of pathological pituitary function (Cushing 1910). In 1912 he 
proposed the existence of a “hormone of growth” the primary action of which was to 
control and promote skeletal growth. Furthermore he also identified the causative 
link between pituitary tumours and conditions of pituitary hyperfunction, namely 
acromegaly and ACTH excess, now commonly referred to as Cushing’s disease.  
The identification of a somatic growth enhancing factor arising from the pituitary 
occurred in 1921 following the intraperitoneal administration of crushed bovine 
pituitary tissue into rats (Evans and Long Anatomy Record 21, 62-63). Human 
Growth hormone (GH) was first isolated from human pituitaries obtained at autopsy 
in 1951 (Raben 1962) and since then has been used in the treatment of conditions 
of GH deficiency and short stature, originally as a cadaveric extract and more 
recently in its recombinant form.  
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The last two decades have seen an exponential increase in our appreciation and 
understanding of the effects of GH on the body. The translation of our 
understanding into clinical practice has resulted in the development of effective 
treatments for conditions of GH deficiency (GHD) and GH excess.  
In spite of our improved understanding, important and obvious questions remain 
unanswered. We cannot yet explain why there is such variability in an individual’s 
response to treatment. For example doses of recombinant GH (rhGH) used in the 
treatment of adult GHD can vary up to four-fold. Questions also persist with regards 
to conditions of GH excess; there is great variability in disease severity but also a 
significant discrepancy in the biochemical presentation of the disease with variability 
in the levels of IGF-I generated for a given level of GH. Another question is how we 
might optimise our treatment regimens for patients with difficult to control GH 
excess; a significant proportion of patients remain uncured despite surgery and 
radiotherapy and require ongoing treatment. The development of newer agents 
such as the GH receptor antagonist pegvisomant has led to a significant 
improvement in symptom and biochemical control, but there remain unanswered 
questions regarding its usage; how can we refine our monitoring of treatment when 
serum IGF-I remains our only guide, and why is there such variability in dose 
requirements.  
This thesis aims to investigate the factors potentially responsible for governing 
variability in clinical response to treatment and to investigate the optimal method of 
monitoring response to treatment, using models of GH deficiency and GH excess as 
examples. By improving our understanding of these underlying mechanisms, this 
will potentially allow the future optimisation and tailoring of treatment to an 
individual’s needs.  
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1.1 Growth Hormone: Production and Regulation 
Growth hormone (GH) is a protein-based peptide hormone responsible for 
stimulating growth, cell reproduction and regeneration. It is structurally and 
functionally similar to prolactin and placental lactogens (Nicoll 1982); (Goffin and 
Kelly 1996). The genes that encode GH and other members of this hormone family 
are believed to have evolved over the last 350 million years via the duplication of a 
common ancestral gene (Miller and Eberhardt 1983).  
The GH gene is located on the long arm of chromosome 17 and is approximately 
3kb long, consisting of 5 exons and 4 introns. This encodes a 217 amino acid 
precursor protein (Miller and Eberhardt 1983) which generates a single chain 
polypeptide containing 191 amino acids following proteolytic cleavage of the 
aminoterminal signal peptide. The majority of GH is the 22kDa isoform, however as 
a result of alternate splicing of the GH precursor mRNA up to 25% consists of 
20kDa and other isoforms (Baumann 1991).   
GH is synthesised, stored, and secreted by the somatotroph cells within the lateral 
wings of the anterior pituitary gland. The morphological characteristics and number 
of these cells are remarkably constant throughout life; it is the level of secretion that 
varies according to physiological requirements. GH is secreted in a pulsatile 
fashion, pulses occurring every 3-4 hours with maximal secretion occurring in the 
second half of the night. Secretion is predominantly regulated by two hypothalamic 
hormones; Growth Hormone Releasing Hormone (GHRH) and somatostatin (SST).  
The importance of the hypothalamus in regulating GH secretion was recognised by 
Reichlin’s experiments in 1961 (Reichlin 1961) demonstrating a reduction of GH 
content of the pituitary and a reduction in growth in rats with lesions of the ventral 
hypothalamus. Furthermore, Deuben and Meites demonstrated that rat 
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hypothalamic extracts could stimulate GH release from the rat pituitary in vitro in 
1964 (Deuben and Meites 1964). GHRH has since been isolated and confirmed as 
the main stimulant of GH synthesis. It is released from neurosecretory nerve 
terminals of these arcuate neurons, and is carried by the hypothalamo-hypophyseal 
portal system to the anterior pituitary gland. It then stimulates the growth hormone 
releasing hormone receptor (GHRHR), causing an increase in cytosolic calcium 
which leads to GH release.  
The primary function of somatostatin (SST) is to inhibit GH release but not its 
synthesis. Its existence was first postulated by Krulich et al in 1968 using 
hypothalamic extracts that were able to inhibit the GH secretion (Krulich, Dhariwal et 
al. 1968). SST was first isolated in 1973 by Brazeau (Brazeau, Vale et al. 1973) with 
the gene sequence characterised in 1984 (Shen and Rutter 1984). It binds to a 
family of specific receptors; all subtypes are expressed in pituitary tumours and in 
normal foetal pituitary tissue (Miller, Alexander et al. 1995).  
Other GH stimulating and inhibitory factors exist including physiological factors such 
as stress, hypoglycaemia and ingestion of protein induce GH release and 
hyperglycaemia and raised free fatty acids inhibits GH secretion. Over recent years 
a class of molecules known as GH releasing peptides including ghrelin, have been 
found to be a potent stimulator of GH secretion increasing the release of GHRH and 
inhibiting SST action. The identification of ghrelin which is secreted and acts via the 
the GH secretagogue receptor in the stomach, suggests that GH release can be 
regulated in the periphery rather than purely by the hypothalamus (Adams, Huang 
et al. 1998) (Howard, Feighner et al. 1996). 
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1.2 GHR  
The GHR is a member of the class I cytokine receptor superfamily which includes 
receptors for prolactin, erythropoietin and the interleukins. The human GHR gene is 
located on the short arm of chromosome 5 in the region p13.1-p12 and contains 9 
coding exons; the 5’ untranslated region of this gene contains multiple exons that 
alternatively serve as exon 1, exon 2 codes for the signal peptide, exons 3–7 
encode the extracellular domain, exon 8 codes the transmembrane domain and 
exons 9 and 10 code the cytoplasmic domain (Godowski, Leung et al. 1989) (Figure 
1.1). 
The GHRs comprise a single polypeptide chain 614–626 amino acids in length with 
a predicted molecular mass of approximately 70 kDa. They were first identified in 
hepatic tissue but are located in a variety of tissues such as bone, heart, kidney, 
muscle and adipose tissue, and more recently in immune tissue such as the spleen 
and thymus (Kelly et al 1991; (Mertani, Delehaye-Zervas et al. 1995); (Ohlsson, 
Nilsson et al. 1993); (Nyberg and Burman 1996); (Hill, Riley et al. 1992); (Hull, 
Thiagarajah et al. 1996); (Rapaport, Sills et al. 1995).  
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Figure 1.1 The GH Receptor and mRNA transcript 
This diagram is a representation of the GHR gene which is located on the short arm 
of chromosome 5 (p13.1-p12) and contains nine coding exons, with exons 3-7 
encoding the extracellular ligand binding domain and the mRNA transcript.  
 
 
 
 
 
23 
 
1.2.1 Activation of the GHR 
A molecule of GH binds to two GH receptors, a high affinity site on one GHR 
monomer causing rotation of the intracellular domains to allow the lower affinity 
binding of this molecule to a second GHR monomer. This increases affinity of both 
receptors for JAK2 tyrosine kinase, which phosphorylates the GHR leading, in turn, 
to phosphorylation of a number of intracellular proteins including the signal 
transducers and activators of transcription or STATs. These form homo or 
heterodimers, enter the nucleus and regulate GH specific gene transcription. This 
allows the expression of genes involved in anabolic processes including protein 
synthesis, lipid degradation, immune function, muscle mass, and bone turnover 
(Wang, Moller et al. 1993); (Argetsinger, Hsu et al. 1995); (Frank, Gilliland et al. 
1994); (Wang, Darus et al. 1996); (Wang, Xu et al. 1994, Wang, Souza et al. 1995). 
Intracellular growth hormone signalling is suppressed by several proteins, especially 
the suppressors of cytokine signalling (SOCS) (Krebs, Uren et al. 2002).  
 
1.2.2 GHBP 
Under normal physiological conditions half of circulating GH is bound to a specific 
binding protein GHBP (Baumann, Amburn et al. 1988, Baumann, Vance et al. 
1990). This comprises the cleaved extracellular portion of the GHR in the peripheral 
circulation. This serves to act as buffer in the circulation to smooth out oscillations in 
GH levels resulting from pulsatile GH secretion by prolonging half-life and reducing 
renal clearance.  
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1.2.3 Biological effects of GH  
The somatomedin hypothesis was originally proposed in 1957 by Salmon and 
Daughaday; this states that the observed effects of GH are mediated by the 
activation of IGF-I (Salmon and Daughaday 1957). The dual effector of GH action 
theory was postulated in 1985; this states that the action of GH is to induce 
differentiation of target cells directly but also to induce secretion of IGF-I (Green, 
Morikawa et al. 1985). It remains unclear which of the effects of GH are directly 
mediated and which are IGF-I mediated.  
GH is responsible for promoting linear growth in childhood. It acts on the germinal 
zone of the growth plate to stimulate proliferation and differentiation of 
prechondrocytes and also promotes protein synthesis and mineral retention in bone 
and calcium absorption from the gut. It also has a complex range of physiological 
effects that continue after childhood which have become more clinically apparent 
over recent years. GH promotes protein anabolism and the diversion of amino acids 
from oxidative to protein synthetic pathways (Griffin and Miller 1974), (Fain, 
Kovacev et al. 1965). Lipolysis occurs with an increase in fat oxidation with 
consequent reduction in subcutaneous fat (Clemmons, Snyder et al. 1987). GH also 
reduces insulin sensitivity; excessive levels can therefore induce type 2 diabetes 
mellitus.  
 
1.2.4 IGF-I  
IGF-I is a mediator of the metabolic actions of growth hormone. It is synthesised in 
the liver and also in the periphery. It is a 70 amino acid peptide with a molecular 
weight of 7.6kDa and has a high degree of sequence homology with human 
proinsulin (Daughaday, Hall et al. 1972), (Rinderknecht and Humbel 1978). 
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Production is stimulated by GH and a variety of factors may inhibit its production 
such as malnutrition and GH insensitivity.  Approximately 98% of IGF-I is bound to 
one of the six binding proteins in the circulation. The majority of IGF-I is bound to 
IGFBP-3 and an acid labile subunit (ALS) forming a 150 KDa complex; this is 
unable to pass through endothelium and acts as an intravascular reservoir of 
inactive IGF-I. The half-life of IGF-I in the complex with IGFBP-3 and ALS is 12-15 
hours compared with 10-12 minutes for free IGF-I (Jones and Clemmons 1995). 
IGF-I acts via the IGF-I receptor (IGF-IR), present on a range of cells throughout the 
body. Binding of the IGF-IR initiates intracellular signalling such as the AKT 
signalling pathway which is a stimulator of cell growth and proliferation and inhibits 
apoptosis. IGF-I also binds to the insulin receptor albeit at a much lower affinity; 
activating the insulin receptor at 0.1x the potency of insulin.   
Although hepatic-derived IGF-I acting via its endocrine effects is responsible for the 
majority of the actions of GH, it has been clearly demonstrated that local production 
of IGF-I acting locally in a paracrine or autocrine manner, has important functions, in 
particular stimulation of cell proliferation and prevention of apoptosis. Gene 
knockout experiments demonstrated that animals with selective hepatic IGF-I loss 
have a normal phenotype and growth, despite marked reduction in serum IGF-I 
levels (Butler and Le Roith 2001). 
 Although its primary role is in the promotion of somatic growth, more recently IGF-I 
has been confirmed to have a diverse range of effects including the regulation of 
neural development; this has led to the investigation of potential therapeutic roles 
such as the treatment of neurological conditions such as amyotrophic lateral 
sclerosis.   
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IGFBP3 
Insulin like growth factor binding protein 3 (IGFBP3) is a 264 amino acid peptide 
produced by the liver. It is the most abundant of a group of IGFBPs that transport 
and control bioavailability and half-life of insulin like growth factors (IGF) and in 
particular IGF-I. The half-life of unbound IGFI is 10 minutes whilst the complex of 
IGF-I/IGFBP3 is cleared more slowly with a half-life of 12 hours. As such they 
provide more stable levels compared to the pulsatile nature of GH secretion. Use of 
IGFBP3 clinically is limited by variability in assay quality particularly as heterophilic 
antibodies can interfere with the assay. 
 
1.3 Conditions of Abnormal GH function 
Tales of giants and dwarfs are often recounted in the literature of many cultures. 
There is speculation that Goliath, the giant from the biblical story, suffered from a 
pituitary tumour causing excessive GH secretion and possibly also causing a visual 
field defect which could have prevented him from seeing the stone from David’s 
slingshot that caused his death.  
In the present time, the clinical conditions commonly seen relating to GH are those 
of under and overproduction; growth hormone deficiency and acromegaly.   
 
1.3.1 Growth Hormone Deficiency 
Growth hormone deficiency (GHD) arises as a result of the lack of secretion of GH. 
A variety of aetiological factors may be responsible including pituitary tumours, 
pituitary surgery, congenital GH deficiency and CNS irradiation The physical 
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consequences of GHD vary according to the context in which it develops; children 
experience stunted growth whereas in adulthood, after fusion of epiphyseal plates, 
the main consequences of GHD are more subtle physical and metabolic effects.  
 
GHD in childhood  
Although there is an extensive list of potential causes of childhood GHD, the 
majority of cases are idiopathic, although there is an association with perinatal 
trauma. The prevalence is reported to be approximately 1:3500 children and it may 
present as an isolated or multiple pituitary hormone deficiency, most commonly 
associated with TSH deficiency. In isolated GHD, impairment of linear growth tends 
to occur in the first 2 years of life; this is usually preceded by normal birth weight 
and length. Early childhood may be associated with the development of a classical 
phenotype of growth failure, protrusion of the frontal bones, poor development of the 
bridge of the nose and delayed closure of the anterior fontanelle. Stimulation tests 
are required to confirm the diagnosis; clonidine or glucagon is more commonly used 
in the paediatric population rather than insulin due to the risk of hypoglycaemia. 
Genetic testing of the GH and other candidate genes should also be considered in 
the assessment of these patients. The main therapeutic aim of GH treatment in 
children with GHD is to normalise height during childhood, aiming for normal adult 
height.  
 
Treatment of GHD in childhood  
Recombinant human GH is used for the following conditions in childhood:  
 Growth hormone deficiency 
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 Turner syndrome 
 Prader–Willi syndrome 
 chronic renal insufficiency 
 born small for gestational age with subsequent growth failure at 4 years of age 
or later (SGA defined as either height at birth 2 standard deviations or more 
below the population average, weight at birth 2 standard deviations or more 
below the population average or weight at birth below the 10th percentile). 
 short stature homeobox-containing gene (SHOX) deficiency. 
According to NICE guidance, rhGH treatment should be discontinued in the 
following situations:  
 Growth velocity increases less than 50% from baseline in the first year of 
treatment 
 Final height is approached and growth velocity is less than 2 cm total growth 
in 1 year 
 Insurmountable problems with adherence 
 Final height is attained 
Doses vary according to underlying condition; for GHD children receive 23–
39 microgram/kg per day.  
 
GHD in adulthood 
In adulthood, GH deficiency most commonly occurs as a result of pituitary tumours 
and/ or treatment of such tumours. Rather than the obvious and easily measurable 
effect on linear growth, adult GHD presents itself in a more subtle, insidious manner 
with a range of symptoms such as reduced energy, lack of motivation and a greater 
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sense of social isolation. There are also clearly defined physical and in particular 
metabolic effects of GHD including increased central visceral adiposity, reduced 
lean body mass, reduced exercise capacity, diminished bone mass and altered 
lipoprotein metabolism resulting in raised LDL, triglycerides and low HDL levels. 
There is an increase in cardiovascular morbidity and mortality in GHD patients, 
resulting from the changes in body composition and metabolism.  
The extent of the effects of GHD have only been fully appreciated over recent years 
and use of recombinant GH still varies worldwide; this is due to variability in clinical 
practice, availability of rhGH and in particular the financial aspect of such treatment. 
In the UK the National Institute for Health and Clinical Excellence (NICE) created 
guidelines for the use of rhGH in adults with severe GHD. The following three 
criteria must be met to qualify for treatment: 
 Severe GH deficiency, defined as a peak GH response of less than 9 
mU/litre (3 ng/ml) during an insulin tolerance test or a cross-validated GH 
threshold in an equivalent test. 
 A perceived impairment of quality of life (QoL), as demonstrated by a 
reported score of at least 11 in the disease-specific ‘Quality of life 
assessment of growth hormone deficiency in adults’ (QoL-AGHDA) 
questionnaire. 
 They are already receiving treatment for any other pituitary hormone 
deficiencies as required. 
  
 
Treatment of GHD in adulthood  
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Standardised protocols exist to guide rhGH dosing using serum IGF-I levels as a 
guide to rhGH dose titration, aiming to maximise clinical benefit of treatment but 
minimise the potential risks of prolonged exposure to excess GH. GH replacement 
is monitored according to a combination of clinical response (well-being, body 
composition) and measurement of insulin-like growth factor I (IGF-I), aiming to avoid 
levels of this GH-dependent peptide above the upper limit of the age-adjusted 
normal range.  
Using such protocols for dose titration, it is apparent that individual requirements for 
GH vary considerably between patients. For example, in the original St 
Bartholomew’s report of 50 consecutive patients treated with an identical protocol of 
dose adjustment, with a target IGF-I between the median and upper end of the age-
related reference range, median (range) dose requirements for males and females 
respectively were 0.8 (0.4-1.6) and 1.2 (0.8-2) (Drake, Coyte et al. 1998). Although 
oestrogen, which attenuates IGF-I production, may partially explain the variability 
between genders, this does not explain why dose requirements vary 4- and 2.5-fold 
in male and female groups respectively. Pituitary irradiation is also associated with a 
low- normal serum IGF-I from retained low-amplitude GH secretion (Toogood, Nass 
et al. 1997) however GH/IGF-I discordance is evident in non-irradiated patients. A 
greater understanding of the mechanisms underlying the variability in GH response 
would allow a more accurate, individual titration of rhGH replacement.  
 
1.3.2 Growth Hormone Excess: Acromegaly 
The first medical description of GH excess was in 1567 by Johannes Wierus in 
France. In his first case collection Medicarum observationum raraum he wrote about 
a female giant who made her fortune travelling and charging an entry fee. Over 25 
years, having grown proportionally and uniformly and with the development of 
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secondary amenorrhoea at 14, she was slow moving and had coarse facial 
features. 
However the first detailed description along with the naming of the condition of 
acromegaly, using the Greek words akron - extremities and megas – large, was 
provided by the French neurologist Pierre Marie in 1886. Enlargement of the 
pituitary was noted in his original description but was thought to be a secondary 
phenomenon rather than the cause. The link between GH excess and pituitary 
tumours was first made during autopsies in 1892 (Massalongo R, 1892).  
Acromegaly is a rare condition affecting 60 people per million. It is most commonly 
due to GH hypersecretion from a pituitary adenoma but can rarely be due to 
excessive GHRH secretion from the hypothalamus or ectopic secretion from a 
neuroendocrine tumour. Chronic excessive GH secretion can lead to a range of 
effects on soft and bony tissue, most characteristically causing a change in 
appearance with coarsening of the facial features, broadening of the nose and 
prominent supra-orbital ridges. There is usually an increase in the soft tissues such 
as in the hands causing dough-like enlargement and ring and shoe size often 
increase. Elongation of the jaw leads to dental malocclusion and increased inter-
dental spacing. Excessive GH secretion prior to the fusion of bony epiphyses results 
in gigantism. Accelerated degenerative changes affecting the joints are a common 
occurrence and major cause of morbidity and although there is an increase in lean 
body mass and muscle hypertrophy, muscles are weaker (Nagulesparen, Trickey et 
al. 1976). Carpal tunnel syndrome affects approximately 60% of patients and is 
believed to be largely due to swelling of the median nerve itself rather than extrinsic 
compression from increased volume within the carpal tunnel (Jenkins, Sohaib et al. 
2000). Hypertrophy of the soft tissues of the upper airway can result in obstructive 
sleep apnoea. Other common and clinically significant findings include 
cardiomegaly, hypertension, an increased risk of type 2 diabetes mellitus secondary 
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to insulin resistance and an increased risk of neoplasia, particularly of the colon. 
Consequently it is associated with considerable morbidity and mortality; 
standardised mortality ratios are reported to be 1.3-1.8 with uncontrolled GH excess 
(Wright, Hill et al. 1970); (Alexander, Appleton et al. 1980); (Bates, Van't Hoff et al. 
1993).  
 
Diagnosis of acromegaly 
Diagnosis of acromegaly involves the measurement of serum GH, however due to 
the pulsatile nature of its secretion, a single GH measurement is insufficient. The 
most commonly used diagnostic test is the oral Glucose tolerance test (OGTT) in 
which abnormal GH levels fail to suppress following a 75g glucose load. In order to 
assess the overall GH burden, the mean of a series of 5 samples taken over several 
hours is calculated (GH day curve or GHDC).  
Although a linear correlation exists between log-transformed GH and serum IGF-I, 
up to one third of patients exhibit discordance between the two measures; a serum 
IGF-I level alone is therefore insufficient in order to confirm or refute the diagnosis. 
Assessment of pituitary function and neuro-ophthalmological testing are advisable 
at diagnosis due to the potential complications of a pituitary mass lesion.  
Pituitary MRI is the gold standard radiological investigation to identify the pituitary 
adenoma; at diagnosis 70% of patients have a macroadenoma measuring more 
than 10mm and these may invade the cavernous sinus or suprasellar region.   
1.3.3 Treatment of Acromegaly 
In view of the significant morbidity and mortality of this condition, treatment is 
needed for all patients. A range of options are available with varying levels of 
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response and side effects; many patients require more than one modality in order to 
achieve biochemical cure or control of GH excess.  
 
Pituitary surgery 
Trans-sphenoidal surgery is the initial treatment of choice for the majority of patients 
with cure rates of 70%-90% reported for microadenomas and 30%-50% for 
macroadenomas. The original trans-sphenoidal operation was performed by Harvey 
Cushing in 1910 but routine use of this technique only occurred since the mid-1970s 
when better visualisation techniques became available. In experienced hands the 
rates of complication are low with mortality reported as less than 0.5%. More 
recently endoscopic trans-sphenoidal surgery has become a more established 
technique, associated with improved clearance, less discomfort and fewer 
complications. The majority of pituitary tumours can be removed via this route, even 
with extension into the cavernous sinus, thus avoiding the need for the more 
invasive trans-cranial approaches.  
 
Pituitary Irradiation 
Pituitary irradiation is often used as an adjunctive treatment to non-curative pituitary 
surgery or in the primary treatment of patients unfit for surgery. Traditional external 
beam pituitary irradiation is focused on the pituitary fossa following accurate 
dosimetry planning. Most centres use a total dose 4500 cGy in 25 fractions via three 
fields (one frontal and two temporal). Care must be taken to avoid damage to the 
optic chiasm with the use of daily fractions of less than 200cGy. Response rates of 
50% fall in GH levels in the first two years post irradiation are reported, followed by 
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a continual exponential decline thereafter (Jenkins, Bates et al. 2006). The majority 
of patients achieve the target GH levels of less than 2ng/ml over time. 60% of 
patients are reported to normalise serum IGF-I levels after 10 years; this attenuated 
response may be due to the chronic low amplitude GH secretion known to generate 
low-normal IGF-I levels post pituitary irradiation (Toogood, Nass et al. 1997). The 
main complication of pituitary irradiation is hypopituitarism; at ten years 60% are 
hypogonadal, 50% ACTH deficient and 40% TSH deficient (Jenkins, Bates et al. 
2006).  
 
Stereotactic radiosurgery  
Stereotactic radiosurgery using gamma knife radiosurgery or stereotactic multiple 
arc radiotherapy (SMART) involves the delivery of a single high dose of irradiation, 
ensuring a rapid reduction in radiation exposure to the surrounding structures. 
Normalisation of IGF-I is reported to occur in up to 86% of patients at 10 years post 
GK with discontinuation of GH suppressive medication in 16/40 patients (Landolt, 
Haller et al. 1998); (Vik-Mo, Oksnes et al. 2007). 
 
Medical treatment for acromegaly 
There are three medical options in the treatment of acromegaly; dopamine agonists, 
somatostatin analogues and the GHR antagonist pegvisomant.  
Dopamine agonists 
Dopamine agonists (DAs) have been used for the treatment of acromegaly since the 
mid 1970s (Thorner, Chait et al. 1975). This class of drug causes stimulation of GH 
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release in normal individuals, but leads to paradoxical suppression of GH 
hypersecretion in a proportion of patients with acromegaly. Five subtypes of 
dopamine receptor exist which have specific tissue distribution; D2 receptors are 
expressed in the anterior and intermediate lobes of the pituitary gland and mediate 
inhibition of prolactin secretion. The effectiveness of DAs in the control of GH 
secretion appears to correlate with expression of D2 receptors within the tumour 
rather than the presence of prolactin (Colao, Ferone et al. 1997). Experience is 
greatest with bromocriptine; approximately 10% of patients achieve ‘safe’ GH and 
normal age-adjusted IGF-I levels using doses substantially higher than those 
required for the successful treatment of prolactin secreting tumours. Similarly 
disappointing data exist for pergolide and lysuride, although up to 1/3 of patients 
achieved biochemical control with the non-ergot derived DA quinagolide at doses 2-
4 times those used in the treatment of prolactinomas (Ferrari, Abs et al. 1997). 
Cabergoline is an ergot derived DA, selective for the D2 receptor with a longer half-
life and improved tolerability compared to other DAs such as bromocriptine. In the 
largest study to date, a normal serum IGF-I was achieved in 39% of patients treated 
with up to 3.5mg per week (Abs, Verhelst et al. 1998). Prolactin co-secretion and 
milder disease activity were favourable predictors of a good response; 
approximately 50% of patients achieved a serum IGF-I within the age-related 
reference range with starting value <750 ng/ml. My previously published report 
(Moyes, Metcalfe et al. 2008), detailing the clinical experience in 15 consecutive 
patients in our centre, demonstrated complete biochemical control (judged by a 
mean serum GH <5 miu/L and a normal age-adjusted IGF-I level) in 28% of patients 
using a median weekly dose of cabergoline of 1.75mg (range 0.5-7mg).  When 
assessing serum IGF-I alone, substantial reductions were observed in the majority 
of patients with 5/15 (33%) achieving normality and a further five patients 
demonstrating a clinically useful reduction on treatment. Further reports indicate a 
role for cabergoline as an “add on” for patients partially resistant to somatostatin 
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analogues (Cozzi, Attanasio et al. 2004); (Selvarajah, Webster et al. 2005); (Gatta, 
Hau et al. 2005).  
 
Somatostatin analogues  
Synthetic somatostatin analogues are have provided an effective and well tolerated 
medical treatment for a range of neuroendocrine disorders and are particularly 
helpful in the management of acromegaly. Octreotide can produce suppression of 
GH for several hours with >90% of patients demonstrating a reduction and 50-60% 
achieving a GH level of <2ng/ml and normal serum IGF-I after 2 hours. Due to its 
pharmacokinetics, it requires thrice daily subcutaneous injections. Depot 
preparations of somatostatin analogues are now in widespread use. These consist 
of the active drug incorporated with microspheres of biodegradable polylactide and 
polyglycolide polymers; these allow the slow release of the analogue after 
intramuscular injection. Two preparations are available octreotide LAR (Sandostatin 
LAR, Novartis) and lanreotide (Somatuline autogel, Ipsen). Both achieve 
biochemical control of acromegaly, as evidenced by serum GH <2ngml and 
normalised IGF-I in approximately 60%-70% of patients (Jenkins, Akker et al. 2000); 
(Caron, Beckers et al. 2002). 
Efficacy of somatostatin analogues is linked to their affinity for somatostatin receptor 
subtype 2 and 5; these are the receptors through which endogenous suppression of 
GH occurs and are the predominant receptors found in GH secreting tumours. A 
significant percentage are resistant to SSA treatment however; this is presumed to 
be due to reduced receptor subtype 2 or 5 expression in these tumours. In addition 
to its effects on GH secretion, SSA’s have the added benefit of achieving tumour 
shrinkage in up to 50% of patients; this has led to an increase in its use pre-
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operatively to shrink tumour size and potentially improve rates of surgical cure 
(Carlsen, Lund-Johansen et al. 2008).  
Side effects include local inflammation at the site of injection, gastrointestinal 
symptoms, development of gallstones and although they can improve insulin 
sensitivity by lowering GH levels, they also exert direct inhibitory effects on 
pancreatic insulin secretion.   
 
1.3.4 Pegvisomant  
Pegvisomant is a genetically engineered analogue of growth hormone (GH), with 
enhanced affinity for one GHR binding site and reduced affinity to the second GHR 
binding site, thereby preventing functional dimerization of the GHR (Figure 1.2). 
Pegylation of this compound, to yield a stable 42-46kDa molecule, results in 
prolongation of the half-life and reduces immunogenicity (Okada and Kopchick 
2001). By blocking effective dimerisation of the GHR, it prevents activation and 
thereby reduces the production of serum IGF-I. Through this mechanism it has been 
shown to be extremely effective in the management of acromegaly, with 
normalisation of serum IGF-I levels reported to occur in 75-97% of patients in a 
dose dependent manner (Trainer, Drake et al. 2000). It is important to note however 
that pegvisomant’s effect is purely on IGF-I generation due to blockade of the GHR; 
it has no effect on the tumour itself. Furthermore, there are concerns about the 
potential for tumour growth due to the lack of negative feedback at the pituitary; two 
cases have so far been reported. It is difficult however to determine whether this 
was due to the pegvisomant or whether it is due to the natural history of the tumours 
themselves; pegvisomant tends to be reserved for patients resistant to other 
treatment modalities and thus with the potential to be more aggressive.   
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Increasing clinical experience with pegvisomant has demonstrated a degree of 
variability in clinical response that is currently unexplained. Doses vary from 10mg 
to greater than 40mg per day, with marked variation in the IGF-I responses seen. 
Whilst patient compliance and administration of the subcutaneous injection may 
influence clinical efficacy, even in the context of standardised clinical trial protocols, 
variability in response is evident and the underlying reasons are unclear.  
One limitation to the effectiveness of pegvisomant is the lack of accurate targets for 
the monitoring of treatment. As pegvisomant is structurally similar to GH, standard 
laboratory assays are unable to distinguish between the two peptides, thereby 
precluding accurate measurement of GH. Furthermore by blocking activation of the 
GHR, GH secretion increases with pegvisomant use; serum IGF-I is therefore the 
only available biochemical marker for GH activity.  
For the optimisation of pegvisomant treatment protocols, two questions need to be 
clarified; what are the underlying reasons for variability in pegvisomant 
responsiveness and how might we overcome them, Secondly, with pegvisomant 
use, what should our target serum IGF-I level be to ensure optimise control of GH 
activity without causing inadvertent GH deficiency.  
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Figure 1.2 Mechanism of action of Pegvisomant  
Taken from Muller et al, Journal of Clinical Endocrinology & Metabolism April 1, 
2004 vol. 89 no. 4 1503-1511 
This schematic demonstrates the mechanism of action of pegvisomant; A 
demonstrates the normal binding of GH to the GHR with the following dimerisation 
and signal transduction. Diagram B represents the binding of Pegvisomant to the 
GHR, preventing dimerisation and thus signal transduction.  
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1.3.5 Target for Cure/ Monitoring of Treatment  
Several retrospective studies have demonstrated that in acromegaly, lowering of 
mean serum growth hormone (GH) levels to <5mU/L is associated with restoration 
of life expectancy to normal (Bates, Evans et al. 1995); (Rajasoorya, Holdaway et 
al. 1994); (Orme, McNally et al. 1998). Although fewer studies have correlated 
serum insulin-like growth factor-I (IGF-I) levels with mortality (Swearingen, Barker et 
al. 1998), measurement of this GH-dependent peptide is increasingly used as the 
sole marker of disease activity. Consensus guidelines suggest that the goals of 
treatment of acromegaly should include an epidemiologically ‘safe’ GH level and a 
normal age-adjusted serum IGF-I (excluding therapy with pegvisomant, where 
serum GH cannot meaningfully be measured). A strong linear correlation exists 
between log-transformed GH and serum IGF-I levels, but significant discordance 
exists in up to a third of patients; most commonly an elevated age-adjusted IGF-I 
level in the presence of ‘safe’ GH values (Freda, Wardlaw et al. 1998).  For such 
patients demonstrating GH/IGF-I ‘discordance’ clinical decision making is 
problematic. Evidence exists that higher IGF-I values in the presence of 
unequivocally ‘safe’ GH levels are associated with adverse changes in insulin 
sensitivity (Freda, Wardlaw et al. 1998) but clinical symptoms and signs in this 
patient group may be absent or subtle and long-term, costly therapy difficult to 
justify. Understanding the factors that determine this GH/IGF-I discordance could, 
potentially, facilitate more refined clinical decision making.  
 
1.4 Potential Factors Influencing GH Responsiveness 
What factors determine an individual’s GH responsiveness in conditions of GH 
deficiency and excess and also in an individual’s response to pegvisomant? A 
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number of hypotheses exist to explain this variability; one likely factor is variability in 
the GHR.   
 
1.4.1 Exon 3 deletion of GHR  
An obvious candidate for variability in GH responsiveness is the GH receptor 
(GHR). A genetic polymorphism exists in the GHR resulting in the deletion of exon 3 
(d3-GHR) and has been linked to enhanced GH responsiveness in children (Dos 
Santos C 2004). This is a common polymorphism with an overall prevalence of 25–
32% and a homozygosity rate of 9-14% (Pantel, Machinis et al. 2000); (Dos Santos 
C 2004). It results in the loss of amino acid residues 7-28; the effects of this loss are 
unknown. Modelling of the residues by crystallography has so far been unsuccessful 
(Urbanek, Russell et al. 1993); (Sobrier, Duquesnoy et al. 1993) but the peptide is 
located away from the binding surface of the receptor and does not directly 
influence the binding of GH to the GHR. It has been speculated that this region may 
play a role in the conformational changes during activation of the GHR dimer by GH 
(Dos Santos C 2004).  
 
The d3-GHR polymorphism was first linked to enhanced GH responsiveness in the 
paediatric population in 2004. GHR signal transduction in transfected cell lines was 
demonstrated to be 30% higher in d3 homo or heterodimers compared to full length 
homodimers (Dos Santos C 2004). Furthermore in a cohort of children short for 
gestational age (SGA) or with idiopathic short stature (ISS) treated with rhGH, 1.7 to 
2 times growth acceleration was demonstrated in those possessing one or more d3-
GHR allele compared to the full length homozygotes (Dos Santos C 2004). The 
majority of subsequent studies have been confined to children but data are 
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conflicting; enhanced linear growth responses to injected GH observed in some, but 
not all, patients with ISS, SGA, GHD and Turner syndrome (Blum, Machinis et al. 
2006); (Binder, Baur et al. 2006); (Carrascosa, Audi et al. 2008); (Jorge, Marchisotti 
et al. 2006); (Tauber, Ester et al. 2007); (Pilotta, Mella et al. 2006). 
Recent studies of adult GHD patients have shown similarly conflicting results. 
Enhanced IGF-generation was demonstrated after 1 but not 5 years therapy with 
GH in d3-GHR homo- and heterozygotes, in conjunction with changes in fasting lipid 
profile (van der Klaauw, van der Straaten et al. 2008). However a more recent study 
has demonstrated no differences in IGF-I response or reductions in body fat 
between d3 genotype groups after 1 year of rhGH treatment(Barbosa, Palming et al. 
2009) . Data in acromegalic subjects are similarly conflicting; improved efficiency of 
GH signal transduction into IGF-I production was suggested by one study where 
lower serum GH levels were detected in the combined d3-GHR group with 
comparable serum IGF-I levels (Schmid, Krayenbuehl et al. 2007). A subsequent 
study detected no difference in serum GH or IGF-I between genotype groups at 
diagnosis, but significantly higher post treatment IGF-I levels were seen in the d3-
GHR group compared to fl-GHR, with comparable serum GH levels (Mercado, 
Gonzalez et al. 2008). More recently, a study of 105 patients with acromegaly 
demonstrated no difference in serum GH or IGF-I levels between the three 
genotype groups (fl/fl, fl/d3 and d3/d3) and comparable linear correlation between 
GH and IGF-I between all 3 groups (Kamenicky, Dos Santos et al. 2009). A 
summary of the studies of the d3-GHR polymorphism in adult GH and acromegaly 
populations is shown in table 1.1. 
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Table 1.1 Summary Table of Previous Studies of the role of d3-GHR in 
determining an individual’s GH responsiveness in Adult Growth Hormone 
Deficiency 
This table summarises previously published studies investigating the role of the d3-
GHR polymorphism on GH responsiveness in adult GH deficient patients. Studies 
varied according to whether they combined the d3-homo and heterozygotes or 
analysed them separately. Data summarised include the % of each genotype, IGF-I 
response to GH and any clinical measures used. Clinical results are reported as 
mean(+/- SD)  
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Table 1.1 
Author/ 
Year 
Cohort  Genotype ΔIGF-I SDS rhGH dose 
(mg/day) 
Other clinical 
measures  
Van der 
Klaauw 
2008 
(van der 
Klaauw, 
van der 
Straaten 
et al. 
2008) 
n= 99 at 
1 year 
n=53 at 
5 years 
56% fl/fl 
38% fl/d3 
6% d3/d3 
fl/fl vs combined d3  
At 1 year 2.1(+/-
0.2) vs 3.2(+/-0.3) 
p=0.010 
 
At 5 years: 2.6(+/- 
0.4) vs 2.9(+/-0.4) 
p=NS 
1 year:  
fl/fl:0.4(0.02),  
d3/d3&fl/d3: 
0.4 (0.03) 
p=NS 
 
5 years:  
fl/fl: 
0.5(0.04),  
d3/d3 &fl/d3: 
0.5 (0.05) 
p=NS 
Cholesterol:  
1 yr fl/fl: -0.5(+/- 
0.1); d3/d3 
&fl/d3: -0.08(+/- 
0.1) p=0.01 
5 yrs: fl/fl: -0.(+/- 
0.3); d3/d3 
&fl/d3: -0.4(+/- 
0.2) p=NS 
WH Ratio 
1 yr fl/fl: -
0.004(+/- 
0.0008) d3/d3 
&fl/d3: -0.02(+/- 
0.009) p=NS 
5 yrs fl/fl: -
0.02(+/- 0.01) 
d3/d3&fl/d3: -
0.03(+/- 0.2) 
p=0.03 
Barbosa  
2008 
(Barbosa, 
Palming 
et al. 
2008) 
n=124 
at 1 
year 
58% fl/fl 
42% fl/d3 
and d3/d3 
fl/fl:  
M: 3.2(-0.7-7.7) 
F: 2.1 (0.5-8.8) 
 
 
d3/d3& fl/d3  
M: 3.9(0.8-9.1)  
F: 2.3(-0.6-4.2)   
fl/fl  
M: 0.3 
(0.1-0.7) 
F: 0.5 
(0.3-0.9) 
d3/d3 &fl/d3:  
M: 0.4(0.3-
0.8), F: 0.4 
(0.3-0.8) 
 
ΔBody fat: 
fl/fl: M -3.5 
(-15 to -10)  
F: -1/4 (-14 to 
3.8) 
d3/d3&fl/d3  
M: -2.4 (-11 to 
7.8) F: -3.4 
(-7.6 to 8.7)  
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Table 1.2 Summary of Previous Studies the role of d3-GHR in determining an 
individual’s GH responsiveness in Acromegaly 
This table summarises previously published studies investigating the role of the d3-
GHR polymorphism on GH responsiveness in adult patients with acromegaly. 
Studies varied according to whether they combined the d3-homo and heterozygotes 
or analysed them separately. Data summarised include the % of each genotype, 
IGF-I response to GH and any clinical measures used. Clinical results are reported 
as mean(+/- SD)  
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Table 1.2 
Author/ 
Year 
Cohort  Genotype 
% 
IGFI GH 
Schmid  
2007 
n=44  fl/fl 50 
d3/d3 
&fl/d3 50  
fl/fl 670g/l (447-1443) 
d3 group 840(342-
1494)   
p=0.85 
fl/fl 29.7 g/l (3.8-159)  
d3 group 8.4 (2.6-74)  
p=0.002 
Mercado 
2008 
n=152 fl/fl 45 
fl/d3 32 
d3/d3 22 
Diagnosis:  
fl/fl 617ng/ml (SD 151) 
fl/d3 615 (150) 
d3/d3 678 (202)  
p=0.2 
Post Rx 
fl/fl 367ng/ml (204) 
fl/d3 497 (212) 
d3/d3 678 (202)  
p=0.008 
Diagnosis 
fl/fl 26ng/ml (44.3) 
fl/d3 24.2 (24.3) 
d3/d3 41.6 (128) 
p=0.1 
Post Rx  
fl/fl 6.8 (24.5)  
fl/d3 8 (15) 
d3/d3 6.8 (15.8) 
p=0.5 
Bianchi  
2009 
n= 84  52.4 fl/fl 
29.7 fl/d3 
17.8 d3/d3 
No difference at 
diagnosis.  
Post surgery: no 
difference in IGF-I 
between genotype 
groups  
No difference at 
diagnosis 
Post surgery: 
fl/d3&d3/d3 
significantly lower 
compared to fl/fl 
(p=0.22) 
Significantly higher IGF-I GH discordance 
rates in combined d3 group compared to fl/fl 
(p=0.03) 
Kamenicky  
2009 
n=105 fl/fl 51 
fl/d3 30 
d3/d3 19 
No difference at 
diagnosis between 
fl/fl, fl/d3 and d3/d3 
No difference at 
diagnosis between 
fl/fl, fl/d3 and d3/d3 
Similar linear correlation between GH and IGF-
I between genotype groups (fl/fl: IGFI =377 
log10 GH+411, R=0.50, P<0.0001; d3/fl: 
IGFI=365 log10 GH=391, R=0.53, P<0.001; 
d3/d3: IGF1=346 log10 GH=448, R=0.46, 
P<0.05) 
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Potential Reasons for Discrepant Results  
One possible reason for the discrepancy in findings is variability in the methods 
used. Carrascosa et al demonstrated that 20% of d3 heterozygotes are 
misclassified as homozygotes using the standard 3 primer PCR technique 
(Carrascosa, Esteban et al. 2006); (Carrascosa, Audi et al. 2008) a second 2 primer 
PCR is required to avoid the preferential production of smaller amplification 
products. It is also possible that by combining d3 homo and heterozygous groups 
for analysis, the full effect of the d3-GHR may be wholly or partially concealed.  
 
Potential Therapeutic effect of d3-GHR polymorphism 
If the hypothesis that the d3-GHR polymorphism augments GH responsiveness is 
correct, this may lead to a more personal rhGH dose titration regime with pre-
therapeutic genotyping.  Possession of the d3-GHR allele/ alleles could potentially 
require less rhGH to yield the same IGF-I response and require a modified titration 
regime compared to fl/fl genotypes in GH deficient individuals. Furthermore in the 
acromegalic population, knowledge of an individual’s d3-GHR status could 
potentially influence how we diagnose and manage such patients. If more IGF-I is 
generated for the same amount of GH, those possessing the d3-GHR polymorphism 
could be expected to have more severe IGF-I mediated symptoms of acromegaly 
compared to the fl/fl population and may require more active treatment in order to 
lower the IGF-I level.  
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Other Genetic polymorphisms that may influence GH responsiveness 
More recently a further study by Glad et al has investigated the role of six SNPS in 
the GH receptor and the GH signaling pathway (JAK2, STAT5B, SOCS2 and 
PIK3CB) in conjunction with the effect of the d3-GHR polymorphism (Glad, Barbosa 
et al 2013). This demonstrated that after 1 week of GH replacement, fl/fl 
homozygotes demonstrated a better IGF-I response compared to the combined d3-
GHR group (p=0.016). Homozygotes of the minor allele of PIK3CB SNP rs361072 
responded better than carriers of the major allele (p=0.025) and both SNPs 
demonstrated an augmented IGF-I response at 6 months (p=0.041 and p=0.047, 
respectively) compared to baseline. SNP rs6873545 was associated with an 
enhanced IGF-I response at 1 year (p=0.041)(Glad, Barbosa et al. 2013). 
No other genetic polymorphisms of the GH receptor have been identified which 
influence GH response, instead focus in the paediatric population has turned to a 
polymorphism within the IGF-binding protein 3 (IGFBP-3) promoter region (-
202 A/C). A study investigating the effect of this polymorphism on circulating 
IGFBP-3 levels and response to rhGH therapy in pre-pubertal children with GH 
deficiency, showed that despite similar rhGH doses A allele homozygotes presented 
higher IGFBP-3 score levels and a higher mean growth velocity in the first year of 
rhGH treatment compared to A allele heterozygotes and wild type homozygotes 
(Costalonga, Antonini et al. 2009). No studies of this polymorphism within adult 
populations have yet been published.  
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1.4.2 Oestrogen and Pituitary Irradiation 
Potential confounders in any analysis of GH responsiveness are the presence of 
oestrogen and previous pituitary irradiation. Oestrogen is known to attenuate IGF-I 
production whereas there is evidence from ultrasensitive chemiluminescence 
assays that patients who have received external pituitary irradiation may generate a 
low-normal IGF-I level from retained low amplitude GH secretion. Such factors must 
therefore be accounted for in any statistical analyses.   
 
1.5 Aims of this work 
For the two clinical conditions of GH deficiency and acromegaly, there remain a 
number of unresolved questions; the aim of this thesis is to investigate the following: 
1. Is the d3-GHR polymorphism important in determining an individual’s GH 
responsiveness in conditions of GH excess and GH deficiency? 
2. Can we tailor the treatment of GH excess and GHD but pre-therapeutically 
genotyping patients for the d3 polymorphism?  
3. For patients treated with Pegvisomant for GH excess, can we optimise the 
use of serum IGF-I as a marker of disease control? 
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Chapter 2  
 
Materials and Methods 
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2.1 Laboratory 
2.1.1 DNA Extraction 
Genomic DNA was extracted from peripheral blood leucocytes using standard 
methods (BACC2 DNA extraction kit, GE Healthcare, UK).  
 3mls whole blood mixed with 4x volume reagent A 
 Centrifuged at 2500rpm for 5 mins; supernatant discarded.  
 Pellet mixed with 2 µl reagent B and vortexed. 
 500 µl sodium perchlorate added and mixed gently 
 2ml chloroform added and mixed gently 
 300 µl resin added and sample centrifuged at 2500rpm for 5 mins 
 Supernatant removed and 3x volume cold absolute ethanol added 
 DNA strands removed and reconstituted in DNAse free water 
 Sample centrifuged for 10 mins at 4000rpm 
 Supernatant discarded and pellet washed in 70% ethanol 
 Centrifuged for 10 mins at 4000rpm 
 Pellet reconstituted in DNAse free water.  
 
2.1.2 Oligonucleotides (Promega)  
The following oligonucleotides were used: 
Forward: 5’ TGTGCTGGTCTGTTGGTCTG 3’ 
Reverse full length: 5’ GGATGCTATGTCAGAGTCAG 3’ 
Reverse d3: 5’ GGTAAGTCACATAGATACTG 3’ 
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How primers were developed 
After establishing the gene sequence of interest using internet databases NCBI and 
ENSEMBL, primer pairs were designed according to the basic principles listed 
below: 
• Primers should ideally be 17-25 bp in length 
• Sequences should be non-repetitive and non-palindromic 
• G/C content should designed to be 40-60% 
• Forward and reverse primers should anneal at approximately the same 
temperature 
• Tm should be between 58 and 68°C and is calculated (approximately) as 
follows: 
 Melting temperature (°C) = (number of C/G bases) x 4 + (number of A/T 
bases)x 2 
• Primers should not form secondary structures 
 
2.1.3 Polymerase Chain Reaction (PCR)  
PCR was performed to amplify the region of interest. The basic principle involves 
denaturing double stranded DNA at high temperatures, ~95°C. This is followed by 
annealing of sequence-specific oligonucleotide primers typically at temperatures 50- 
60°C before synthesis of complementary DNA strands from 5’ to 3’ by a 
thermostable polymerase. Repeated cycles allow exponential multiplication of a 
specific portion of DNA. 
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A PCR reaction mixture, typically in a total volume of 25 μl was as follows: 
10x reaction Buffer (Promega, UK)   2.5 µl 
10mM dNTPs (Promega, UK)   1 µl 
Oligonucleotide (sense) 50 µM   1 µl 
Oligonucleotide full length (antisense) 50 µM 0.5 µl 
Oligonucleotide d3 (antisense) 50 µM  0.5 µl 
Double distilled water     18.8 µl 
Taq DNA polymerase (Promega, UK)  0.2 µl 
DNA template      1 µl 
 
PCR automated cycling was typically carried out as follows. After the initial 
denaturation at 95°C for 5 min, followed by 16 cycles of 94°C for 30 seconds, 60°C 
for 30 seconds and 72°C for 30 seconds. This was followed by 25 cycles of 94°C for 
30 sec, 45°C for 30 sec and 72°C for 1 min, with a final extension step at 72°C for 5 
min. 
 
2.1.4 Agarose Gel electrophoresis 
All PCR products were run on 1-2% (w/v) agarose gel made in 1X TAE (40 mM 
Trisacetate, 2 mM disodium ethylenediaminetetraacetate (Na2EDTA), pH 8.3; 
National Diagnostics, UK), and visualised along side DNA markers (GeneRulerTM 
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DNA Ladder Mix, 0.5 mg DNA/ml, Fermentas) with ethidium bromide (0.2 μg/ml) 
staining. Usually 5 μl of each reaction was mixed with loading dye solution (40% w/v 
sucrose, 0.25%w/v bromophenol blue or Orange G, DEPC water) at a 1:5 ratio prior 
to loading the wells of a 1% (w/v) agarose gel. Electrophoresis was typically carried 
out at 120V for 30 min or until clear separation of bands was achieved. Ethidium 
bromide intercalated into DNA will fluoresce under UV light at 300 nm, allowing the 
DNA to be visualised. An Uvitec transluminator was used to visualise bands, and 
capture an image of the resultant gel. 
The fl allele is represented by a 521 bp fragment and the d3 allele by a 470 bp 
fragment.  
 
Repeat PCR  
A second PCR reaction was performed on all d3/d3 samples using forward and full 
length reverse oligonucleotides to confirm homozygosity. 
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2.2 Biochemical Assays 
2.2.1 IGF-I 
Between 1997 and 2005 an RIA kit (Diagnostic System laboratories Inc, Webster, 
TX, USA) with mean intra and inter-assay coefficients of variation (CVs) of 7.2 and 
10.4% respectively was used. From 2005- present, serum IGF-I was measured by 
an automated solid-phase, enzyme-labelled chemiluminescent immunometric assay 
(Siemens Medical Solutions Diagnostics, Gwynedd, Wales, UK), with intra- and 
inter-assay CVs of less than 11% and 8% respectively. For each individual patient, 
baseline, 6 and 12 month IGF-I measurements were performed using the same 
assay. In order to take into account the change in assay during the time in which 
these patients were assessed and treated, data in this study have been analysed 
using standard deviation scores (SDS), calculated as n-mean/SD using age and 
gender related normative data obtained from our laboratory for each respective 
assay. 
2.2.2 Serum GH 
GH was quantitated by an immunoradiometric assay using Immulite 2000 (Siemen's 
Medical Solutions Diagnostics, Gwynedd, Wales, UK), with inter- and intra-assay 
CVs of 5%. 
2.2.3 Insulin 
Immunoradiometric assay using Immulite 2500 (Siemen's Medical Solutions 
Diagnostics, Gwynedd, Wales, UK) with inter- and intra-assay CVs of 5%. 
2.2.4 Glucose 
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Enzymatic (hexokinase) assay using Roche Modular (Roche Diagnostics GmbH, 
Mannheim, Germany) with inter- and intra-assay CVs of 2%. 
2.2.5 Fibrinogen 
Clotting based Claus assay using Sysmex CS2100i (Siemen's Medical Solutions 
Diagnostics, Gwynedd, Wales, UK) with inter- and intra-assay CVs of 5%. 
2.2.6 CRP 
 Particle-enhanced immunometric assay using Roche Modular (Roche Diagnostics 
GmbH, Mannheim, Germany) with inter- and intra-assay CVs of 5%. 
2.2.7 Lipid Profile  
Cholesterol: Enzymatic (cholesterol esterase and cholesterol oxidase) colorimetric 
assay using Roche Modular (Roche Diagnostics GmbH, Mannheim, Germany) with 
inter- and intra-assay CVs of 3%. 
Triglycerides: Enzymatic (lipoprotein lipase) colourimetric (Trinder endpoint) assay 
using Roche Modular (Roche Diagnostics GmbH, Mannheim, Germany) with inter- 
and intra-assay CVs of 3%. 
HDL: PEG-modified enzymatic (cholesterol esterase and cholesterol oxidase) 
colourmetric assay using Roche Modular (Roche Diagnostics GmbH, Mannheim, 
Germany) with inter- and intra-assay CVs of 2%. 
2.2.8 Lipoprotein A 
Immunoturbidimetric Assay with intra-assay CV <3% and inter-assay CV <4% 
(Diazyme, San Diego, USA). 
57 
2.3 Clinical Definitions 
2.3.1 Severe Growth Hormone Deficiency  
The following criteria are used in the diagnosis of severe GHD; all three must be 
fulfilled to meet the NICE criteria for use of recombinant GH (rhGH).  
 Peak growth hormone response of less than 9 mU/litre or 3g/l on an ‘insulin 
tolerance test’ for growth hormone deficiency (or similar validated test such 
as glucagon stimulation test)  
 Demonstrate an impaired quality of life using the validated AGHDA 
questionnaire, scoring >11/25 
 To already be receiving replacement for other deficient hormones if he or 
she has one or more pituitary hormone deficiencies 
 
2.3.2 Acromegaly  
Acromegaly is a condition of uncontrolled growth hormone excess. The gold 
standard test is the oral glucose tolerance test; confirmation of the diagnosis is 
made by the failure to suppress serum GH levels to <2mu/l after a 75g glucose 
load.  
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2.4 Patient Recruitment  
Patients diagnosed and treated for disorders of GH secretion at the department of 
Endocrinology at St Bartholomew’s hospital were invited to participate in these 
studies; inclusion criteria are listed for each study.  
All studies were approved by the local ethics committee and written informed 
consent was obtained from each patient. 
 
2.4.1 Exclusion Criteria 
Patients with identifiable reasons for altered IGF-I production were excluded from 
analyses. These include the following criteria: 
 Renal failure 
 Liver failure 
 Anorexia 
 Opiates 
 Levodopa  
 DHEA  
 Active Cushing’s syndrome 
 
59 
2.5 Clinical Measurements 
2.5.1 AGHDA 
Quality of Life-Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA) 
is a validated quality of life measure used to assess the severity of symptoms of 
severe GHD. These encompass questions regarding symptoms of physical and 
psychological well being including effects on memory, energy levels and social life. 
A score of >11/25 is needed to fulfil NICE criteria for severe GHD and for the use of 
exogenous GH. The AGHDA is reassessed after 9 months rhGH replacement to 
determine response to treatment; rhGH may be withdrawn unless the AGHDA score 
has improved by 7 points. 
2.5.2 AcroQoL 
AcroQoL questionnaire is a disease specific quality of life tool comprising 22 
questions on symptoms of physical and psychological well-being in relation to their 
growth hormone excess. 
2.5.3 EuroQoL 
EuroQoL is a standardised measure of health status. The visual analogue score 
comprises a scale of 1-100; the patient marks the level on the scale that 
corresponds to how well they are feeling. 
2.5.4 Waist: Hip Ratio 
Waist hip measurements were taken pre-commencement of rhGH and at 6 and 12 
month intervals after treatment as a measure of physiological response to rhGH. 
These measurements were consistently made by the same GH specialist nurse 
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using the department tape measure, using the narrowest measurement of the waist 
and the widest hip measurement.  
2.5.5 Body fat measurement   
Body fat was measured using Dual energy X ray Absorbtiometry (DEXA) and is 
reported as % body fat. 
2.6 Statistics 
Expert statistical advice was obtained from Mrs Enid Hennessy, Wolfson Institute, 
Queen Mary, University of London. All results are reported as mean value ± 
standard deviation (SD). Statistical significance was accepted at a p value <0.05. All 
analyses were performed using SPSS (version 11.01; SPSS Inc, Chicago, IL) for 
Windows XP (Microsoft Corp) and Excel 2007 (Microsoft Corp).  
Details regarding the statistical tests used for each study are listed in the relevant 
chapter.  
2.6.1 Standard Deviation Scores (SDS) 
Standard deviation scores were calculated to allow direct comparison of IGF-I 
results obtained from different IGF-I assays. These were calculated as N – mean / 
SD using age and gender related normative data obtained from our laboratory for 
each respective assay. 
2.6.2 %ULN 
Where normative assay data were not available, thereby preventing the calculation 
of SDS, IGF-I results were reported and analysed as % of the upper limit of the 
normal age and gender related reference range (%ULN).  
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Chapter 3  
 
Effect of the d3-GHR polymorphism 
on rhGH responsiveness in adults 
with severe growth hormone 
deficiency
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3.1 Introduction 
Since the original double-blind placebo-controlled studies of recombinant human 
growth hormone (rhGH) treatment for adult growth hormone deficiency 
(GHD)(Jorgensen, Pedersen et al. 1989, Salomon, Cuneo et al. 1989, Binnerts, 
Swart et al. 1992, Whitehead, Boreham et al. 1992, Bengtsson, Eden et al. 1993), it 
has become apparent that doses of rhGH need to be individually tailored to patients 
in order to maximise clinical benefit and minimise the possible risks of prolonged 
excess GH exposure (Drake, Howell et al. 2001). Most physicians experienced in 
the management of hypopituitary patients employ a strategy of dose titration, with 
monitoring of serum insulin-like growth factor-I (IGF-I), a GH dependent peptide, as 
the main marker of excess dosing. Using such protocols, it is apparent that 
individual requirements for rhGH vary considerably between patients.  For example, 
in a report of 50 consecutive patients treated with an identical dosing protocol that 
aims to maintain serum IGF-I between the median and upper end of the age-related 
reference range, median dose requirements for males and females respectively 
were 0.8 IU (range 0.4-1.6) and 1.2 IU (0.8-2)Drake, Coyte et al. (1998). Oestrogen 
is known to attenuate IGF-I production and may partially explain the variability 
between genders, but this does not explain why dose requirements vary 4- and 2.5-
fold in male and female groups respectively (Drake, Coyte et al. 1998). 
 
The factors responsible for determining individual GH responsiveness are currently 
unknown but an obvious candidate is the GH receptor (GHR). The GHR gene is 
located on the short arm of chromosome 5 (p13.1-p12) and contains nine coding 
exons, with exons 3-7 encoding the extracellular ligand binding domain (Leung, 
Spencer et al. 1987, Godowski, Leung et al. 1989). A genetic polymorphism exists 
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in the GHR resulting in the deletion of exon 3 and loss of amino acid residues 7-28; 
the overall prevalence is 25–32% with a homozygosity rate of 9-14% (Pantel, 
Machinis et al. 2000, Dos Santos, Essioux et al. 2004). The effects of the loss of 
these amino acids are unknown; modelling of the residues by crystallography has 
been unsuccessful but it appears not to influence the binding of GH to the GHR in 
vitro (Sobrier, Duquesnoy et al. 1993, Urbanek, Russell et al. 1993). It has been 
speculated that this region may play a role in the conformational changes during 
activation of the GHR dimer by GH (Dos Santos, Essioux et al. 2004).  
The presence of one or more d3-GHR alleles has been shown to accelerate linear 
growth in children short for gestational age (SGA) or with idiopathic short stature 
(ISS) treated with rhGH (Dos Santos, Essioux et al. 2004), although subsequent 
data have been conflicting (Blum, Machinis et al. 2006, Jorge, Marchisotti et al. 
2006, Carrascosa, Audi et al. 2008, Carrascosa, Audi et al. 2008). In adults with 
GHD, similarly conflicting results exist. In one study of 99 patients, a greater IGF-I 
response was demonstrated in subjects carrying at least one d3 allele after 1 but 
not 5 years of rhGH treatment (van der Klaauw, van der Straaten et al. 2008). 
However, in a separate, recent report no difference in rhGH responsiveness was 
demonstrated between d3+ or – genotypes in 124 patients treated for 1 
year(Barbosa, Palming et al. 2008). The reasons for these discordant results in 
adults and children are not clear, although one possibility is that by combining d3 
homo and heterozygous groups for analysis the full effect of the d3-GHR may be 
wholly or partially concealed. The aim of this study was to investigate whether, in 
the clinical setting, the d3-GHR polymorphism is an important contributor to variable 
GH responsiveness in adult hypopituitary patients treated with an identical dosing 
regimen of rhGH. In particular, we were interested to investigate differences in GH 
responsiveness between d3-GHR homo and heterozygotes as this has not been 
explored in previous studies.  
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3.1.1 Aim of this section 
 To establish the percentage of patients in our cohort carrying each of the 
GHR genotypes; fl homozygotes, d3 heterozygotes and d3 homozygotes 
 To investigate whether d3- homo or heterozygosity enhances the IGF-I 
response to rhGH 
 To investigate whether rhGH dose requirements decrease due to 
possession of one or more d3-GHR allele. 
 To investigate whether the physiological effects of rhGH vary according to 
possession of one or more d3-GHR allele. 
 To investigate how d3-GHR genotype and potential confounding factors 
such as pituitary irradiation, influence GH response individually and 
cumulatively with stepwise regression analyses.  
 
3.2 Study Design 
3.2.1 Patient Selection  
All patients treated with rhGH for severe GHD within the department of 
endocrinology at St Bartholomew’s Hospital were invited to participate. This study 
was approved by a local ethics committee (Reference 07/H0701/55) and all patients 
provided informed, written consent to allow the use of their clinical and biochemical 
records and all patients provided a 10ml EDTA blood sample to allow GHR 
genotyping. Details regarding GHR genotyping are given in Methods section 2.1. 
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194 patients with confirmed severe GHD were recruited. All fulfilled the criteria for 
the diagnosis of GHD, as per the Growth Hormone Research Society Committee 
consensus guidelines (Carroll et al, JCEM 1998). The biochemical diagnosis was 
confirmed by a failure to achieve a peak GH of >9mu/l (3g/l) during insulin induced 
hypoglycaemia (nadir glucose ≤2.2mmol/l) or on a glucagon stimulation test.  
All had commenced rhGH fulfilling criteria subsequently implemented by NICE (see 
methods section 2.31) and followed an identical dose titration protocol (Drake et al 
1998, J Clin Endocrinol Metab 83, 3913-3919) aiming to achieve and maintain a 
serum IGF-I between the median and upper end of the age related reference range.  
No patients had any identifiable reasons for altered IGF-I production e.g. anorexia 
nervosa, renal failure, liver failure or concomitant use of opiates, DHEA 
supplements or levodopa.  None had active Cushing’s syndrome at commencement 
of GH; those patients with a diagnosis of Cushing’s were 3-22 years post 
cure/successful control of cortisol excess.  
 
3.2.2 Data Collation 
As per the rhGH treatment protocol, after titration of rhGH dose, all patients were 
routinely assessed clinically and biochemically at 3, 6, 9 and 12 months and 
annually thereafter. For the purposes of this study, 6 and 12 month clinical data 
(waist:hip ratio, fasting lipid profile and quality of life AGHDA questionnaire); 
biochemical response to rhGH treatment (ΔIGF-I SDS) and maintenance dose of 
rhGH required were all analysed with respect to GHR genotype. To remove the 
potential confounding effect of rhGH dose, analyses were repeated using the ratio 
of IGF-I change to rhGH dose (delta IGF-I/ rhGH dose) at 6 and 12 months. 
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3.2.3 Assays 
Please see methods section 2.2 
3.2.4 GHR Genotyping 
Please see methods section 2.1 
 
3.2.5 Statistical Analyses 
Results are reported as mean value ± standard deviation (SD). Statistical 
significance was accepted at a p value <0.05. One way ANOVA with Fisher LSD 
post hoc analysis was performed to compare rhGH response at 6 and 12 months 
and the doses of rhGH required between the 3 genotype groups; fl/fl, fl/d3 and 
d3/d3. Comparison was also made of the change in biological parameters of GH 
activity; waist:hip ratio, quality of life (AGHDA) score and fasting lipid profile.  
A stepwise multiple regression model was created to assess the individual and 
cumulative effect of genotype on GH response in conjunction with other potentially 
contributory factors; GH dose, oestrogen and external pituitary irradiation. To 
exclude the confounding effect of GH dose, analyses (ANOVA and multiple 
regression analysis) were performed using the ratio of delta IGF-I/ GH dose at 6 and 
12 months. Analysis was performed using SPSS (version 11.01; SPSS Inc, 
Chicago, IL) for Windows XP (Microsoft Corp). 
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3.3 Results  
3.3.1 Cohort Details  
Details regarding the patient cohort and are shown in table 3.1. Out of 194 patients, 
81 were male and 113 female, of whom 88 were pre-menopausal or were receiving 
oestrogen replacement (subcutaneous or oral preparations; numbers were 
insufficient to allow subgroup analysis). At diagnosis the cohorts were between 8-81 
years old. Causes of GHD include pituitary tumours, other intra-cranial tumours 
such as craniopharyngiomas, pituitary apoplexy, trauma and inflammatory 
conditions such as lymphocytic hypophysitis. 89% of the cohort had multiple 
pituitary hormone deficiencies and 11% isolated GHD. 64% had received pituitary 
irradiation (external beam or gamma knife) as treatment for their underlying 
condition. The cohort had been treated with rhGH for a mean 91 months, range 12-
276 months.  
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 Table 3.1 Clinical features and Demographics of the Cohort studied 
This table demonstrates the characteristics of the entire cohort studied, detailing the 
male to female ratio, including the presence or absence of oestrogen. Further 
details are given regarding the cause of growth hormone deficiency, the age at 
diagnosis and whether pituitary irradiation was administered. The confirmation of 
GHD was made following insulin induced stress test (ITT) and the last row details 
the duration of rhGH replacement.  
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Table 3.1 
 
   n= 194 
N % 
Gender  Male  81 41.8% 
 Female 
 
Total 
-Oestrogen replete 
-Oestrogen deficient 
113 
88 
25 
58.2% 
45.3% 
12.8% 
Age at Diagnosis  <20 10 5.1% 
  21-30 15 7.7% 
  31-40 41 21.1% 
  41-50 56 28.8% 
  51-60 42 21.6% 
  >60 30 15.5% 
Pituitary 
Hormone 
Deficiency 
Isolated Growth Hormone Deficiency 20 10.3% 
Multiple Pituitary Hormone Deficiency 174 89.6% 
Cause of  
Growth Hormone 
Deficiency  
Pituitary tumour/ 
treatment 
Total 
-Non functioning 
-Prolactinoma 
-Acromegaly 
-ACTH secreting  
137 70.6% 
58 29.8% 
34 17.5% 
9 4.6% 
36 18.5% 
 Pituitary apoplexy 9 4.5% 
 Inflammatory/Infective 9 4.5% 
 Trauma 3 1.5% 
 Congenital  2 1.0% 
 Other CNS tumours 25 12.9% 
 Other 8 4.1% 
Radiotherapy  Yes Total 124 63.9% 
  External Beam 
Radiotherapy 
122 62.9% 
  Gamma Knife Radiosurgery 5 2.6% 
 No  69 35.6% 
Peak GH on ITT (miu/l)  Mean (SD) 2.36 (2.65) 
Duration of rhGH Treatment 
Mean (months) 
Range (months) 
91 
12-276 
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3.3.2 GHR Genotyping: To determine the percentage of patients in the cohort 
carrying each of the genotypes; fl/fl, fl/d3 and d3/d3 
194 patients were prospectively genotyped to determine the frequency of the d3-
GHR polymorphism (see methods section 2.1). DNA was extracted from whole 
blood and using established oligonucleotides (forward, full length reverse and 
reverse d3 primers) to identify the region of interest, a PCR reaction was performed 
and the PCR products identified on agarose gel electrophoresis. The fl allele is 
represented by a 521 bp fragment and the d3 allele by a 470 bp fragment (figure 
3.1a).   
A previous study reported an over-estimation of the d3 homozygotes by 20% 
(Carrascosa, Esteban et al. 2006) due to the misclassification of heterozygotes. 
This is presumably due to the fact that smaller PCR products are preferentially 
formed in a competitive reaction. To exclude d3 heterozygosity in d3/d3 
homozygotes, the PCR was repeated in all d3/d3 homozygotes using forward and 
reverse full length oligonucleotides (Figure 3.1b). 
The frequencies of the 3 genotypes (fl/fl, fl/d3 and d3/d3) were 52% (n=101), 38.7% 
(n=75) and 9.3% (n=18) respectively and were in Hardy-Weinberg equilibrium. 
These frequencies are in accordance with previously published data. Repeat PCR 
of d3/d3 patients using forward and full length reverse primers resulted in 
reclassification of 2/20 (9%) patients as heterozygotes. Proportions of male and 
female subjects were comparable between genotype groups. 
The cohort was divided into 3 genotype groups for further analyses; full length 
homozygotes fl/fl, d3 heterozygotes fl/d3 and d3 homozygotes d3/d3 (Figure 3.1).  
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Figure 3.1  Amplification products of multiplex PCR 
Products are shown on agarose gel stained with ethidium bromide.  
The fl allele is represented by a 521 bp fragment and the d3 allele by a 470 bp 
fragment. 
3.1a Lane 1 represents a genomic DNA ladder; lane 2 represents fl/fl homozgote; 
lane 3 represents d3/d3 homozygote and lane 4 represents fl/d3 heterozygote. 
3.1b Result of second PCR to confirm d3-GHR heterozygosity.  
This figure shows a comparison of PCR results for the same patient. To avoid the 
mis-classification of d3 heterozygotes as homozygotes a second PCR reaction was 
performed using only forward and full length reverse primers.  
Lane 1 is a genomic DNA ladder; lane 2 represents the results of a 3 primer PCR 
demonstrating a single 470bp band (d3/d3); lane 3 represents the same patient’s 
result from a repeat PCR using only forward and full length reverse primers with a 
521bp band is visible confirming heterozygosity. 
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Figure 3.1a 
 
 
Figure 3.1b 
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3.3.3 Analyses of IGF-I response in relation to d3-GHR genotype 
The working hypothesis for this study was that the presence of one or more d3 
allele enhances an individual’s response to GH as demonstrated by the amount of 
IGF-I generated. If correct, one would expect increased IGF-I production for a given 
level of GH in those patients carrying one or more d3-GHR allele. 
3.3.3.1 Baseline Serum IGF-I SDS 
To test this hypothesis, a comparison of the baseline IGF-I levels produced by the 3 
genotype groups was made using ANOVA with post hoc analyses. This 
demonstrated that the baseline serum IGF-I SDS results for the 3 genotype groups 
were comparable; fl/fl mean -1.03 (SD 1.36), fl/d3 -1.14 (SD 1.25) and d3/d3 -1.17 
(SD 1.19). No statistically significant difference detected between groups; fl/fl vs 
fl/d3 p=0.610, fl/fl vs d3/d3 p=0.675 and fl/d3 vs d3/d3 p=0.910 (Table 3.2).   
3.3.3.2 Response to rhGH at 6 months  
The effect of GHR genotype on the early phase response to rhGH was measured at 
6 months. Analyses of the IGF-I SDS at 6 months revealed no statistically significant 
difference between the three genotype groups (Table 3.2). Analyses of the change 
in IGF-I (IGF-I) between baseline and 6 months rhGH replacement also 
demonstrated no statistically significant difference between genotype groups (table 
3.2, figure 3.2). 
The change in IGF-I per unit rhGH dose was also analysed (IGF-I/rhGH dose) and 
a comparison of the three genotype groups made; this confirmed a lack of any 
statistically significant difference in IGF-I/rhGH dose between genotypes with one 
or more d3 allele and full length homozygotes (Table 3.2, figure 3.3)  
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Table 3.2 Comparison of the three GHR genotypes for GH responsiveness 
after 6 months rhGH replacement 
This table demonstrates the numbers of patients and the male to female distribution 
within each genotype cohort; full length homozygote fl/fl, d3 heterozygote fl/d3 and 
d3 homozygote d3/d3. The left half of the table details the results for each genotype 
group for IGF-I SDS at baseline and after 6 months rhGH replacement, reporting the 
mean and (standard deviation) for each cohort. GH responsiveness is reported as 
IGF-I and IGF-I per rhGH dose (IGF-I/rhGH dose) achieved after 6 months 
rhGH replacement.  
The right hand side of the table shows the results for the comparison between the 
genotype groups for the above measures using ANOVA with Fisher LSD post hoc 
analyses. Statistical significance is taken at p≤0.05. Significant results are 
highlighted in bold.  
 
Abbreviations: fl/fl: full length homozygotes; fl/d3: d3 heterozygotes; d3/d3: d3 
homozygotes; rhGH: recombinant growth hormone 
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Table 3.2 
 
 
 
fl/fl 
n=101 
fl/d3 
n=75 
d3/d3 
n=18 
 
 
 
ANOVA 
p values 
Male 43 32 6 fl/fl 
vs 
fl/d3 
fl/fl 
vs 
d3/d3 
fl/d3 
vs 
d3/d3 
Female 
58 43 12 
IGF-I 
SDS 
Baseline  
-1.03 
(1.36) 
-1.14 
(1.25) 
-1.17 
(1.19) 
0.610 0.675 0.910 
6 months  
0.82 
(1.68) 
0.78 
(1.60) 
0.52 
(1.55) 
0.883 0.478 0.545 
IGF-I  
at 6 months 
1.85 
(1.88) 
1.91 
(1.49) 
1.69 
(1.63) 
0.805 0.721 0.623 
IGF-I/rhGH 
dose  
at 6 months  
4.98 
(11.1) 
5.89 
(6.89) 
5.20 
(5.03) 
0.784 0.786 0.671 
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Figure 3.2 Box Plots to compare the three genotype groups for ΔIGF-I 
between baseline and 6 months rhGH replacement  
This box plot represents the results for IGF-I achieved after 6 months rhGH 
replacement for the three genotype groups; fl/fl, fl/d3 and d3/d3. The box shows the 
distribution from the 25th to 75 centile, the line within the box denotes the median 
with the range demonstrated by the “whiskers”. Occasional outliers are shown as 
triangles.  
Comparison of the three genotype groups were performed using ANOVA with 
Fisher LSD post hoc analyses and the results are shown above the box plots; NS 
denotes no statistically significant difference was found.  
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Figure 3.2 
 
 
 
NS 
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Figure 3.3 Box Plots to compare the three genotype groups for ΔIGF-I/rhGH 
dose achieved between baseline and 6 months  
This box plot demonstrates the change in IGF-I per unit rhGH dose (IGF-I/rhGH 
dose) at six months for the three genotypes; fl/fl, fl/d3 and d3/d3. The box shows the 
distribution from the 25th to 75 centile, the line within the box denotes the median 
with the range demonstrated by the “whiskers” and occasional outliers are shown as 
triangles.  
A comparison between the full length homozygous group (fl/fl) and the d3 homo and 
heterozygotes (d3/d3 and fl/d3) for IGF-I/rhGH dose was performed using ANOVA 
with post hoc analyses. No statistically significant difference was detected in these 
comparisons; NS denotes non-significance.  
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Figure 3.3 
 
NS 
NS 
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3.3.4 Response to rhGH at 12 months  
The longer term response to rhGH was measured at 12 months and results 
compared between the three genotype groups. The working hypothesis for this 
section was that the genotype groups possessing one or more d3 allele would 
confer a greater IGF-I response to rhGH.  
A significantly greater IGF-I SDS level at 12 months was achieved in the d3 
homozygous group compared to the full length homozygous group using ANOVA 
with post hoc analyses; (Table 3.3). There was no detectable difference however 
between the full length homozygous group and the d3 heterozygous group. 
Furthermore no statistically significant difference was found comparing the d3 homo 
and heterozygous groups (p=0.066) (Table 3.3). 
Similarly, there was a statistically significant difference in IGF-I achieved after 
12months rhGH in the d3 homozygous group compared to the full length 
homozygotes (table 3.3, figure 3.4). No difference was detected between the d3 
heterozygotes and full length homozygotes, or between the two d3 possessing 
groups.  
In accordance with the results for IGF-I results achieved after 12 months, a 
significant difference in IGF-I/rhGH dose was detected in the d3 homozygous 
group (p=0.004) compared to the full length homozygous group. However a 
significant difference was also detected in the comparison of the d3 homo and 
heterozygous groups (p=0.007). There was no detectable difference in IGF-I 
response comparing the full length homozygotes to the d3 heterozygotes (p=0.882) 
(Table 3.3, figure 3.5).  
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Table 3.3 GH Responsiveness after12 months rhGH Replacement 
This table demonstrates the numbers of patients and the male to female distribution 
within each genotype cohort; full length homozygote fl/fl, d3 heterozygote fl/d3 and 
d3 homozygote d3/d3.  
The left half of the table details the results for each genotype group for IGF-I SDS at 
baseline and after 12 months rhGH replacement, reporting the mean and (standard 
deviation) for each cohort. GH responsiveness is reported as IGF-I and IGF-I per 
rhGH dose (IGF-I/rhGH dose) achieved after 12 months rhGH replacement.  
The right hand side of the table shows the results for the comparison between the 
genotype groups for the above measures using ANOVA with Fisher LSD post hoc 
analyses. Statistical significance is taken at p≤0.05. Significant results are 
highlighted in bold.  
 
Abbreviations: fl/fl: full length homozygotes; fl/d3: d3 heterozygotes; d3/d3: d3 
homozygotes; rhGH: recombinant growth hormone 
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Table 3.3 
 
 
fl/fl 
n=101 
fl/d3 
n=75 
d3/d3 
n=18 
 
 
 
ANOVA 
p values 
Male 43 32 6 fl/fl 
vs 
fl/d3 
fl/fl 
vs 
d3/d3 
fl/d3 
vs 
d3/d3 
Female 
58 43 12 
IGF-I 
SDS 
Baseline  
-1.03 
(1.36) 
-1.14 
(1.25) 
-1.17 
(1.19) 
0.610 0.675 0.910 
12 
months  
0.96 
(1.49) 
1.01 
(1.61) 
1.76 
(1.52) 
0.843 0.046 0.066 
IGF-I  
at 12 months  
1.99 
(1.49) 
2.15 
(1.74) 
2.93 
(1.29) 
0.556 0.028 0.070 
IGF-I/rhGH 
dose  
at 12 months  
5.80 
(5.58) 
5.93 
(5.65) 
10.2 
(8.68) 
0.882 0.004 0.007 
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Figure 3.4  Box Plots to compare the ΔIGF-I achieved between baseline and 12 
months rhGH for the three genotype groups 
This box plot demonstrates the change in IGF-I achieved after 12 months rhGH 
replacement for the three genotype groups; fl/lf, fl/d3 and d3/d3. The box shows the 
distribution from the 25th to 75 centile, the line within the box denotes the median 
with the range demonstrated by the “whiskers”. Occasional outliers are shown as 
triangles. Comparison of these results was performed using ANOVA with post hoc 
analyses.  
A significant difference was detected comparing the d3/d3 to the fl/fl group. No 
significant difference was detected for the d3 heterozygous group compared to the 
full length homozygous group. No difference was detected between the d3 homo 
and heterozygous groups. 
*denotes statistical significance (p <0.05); NS denotes no statistical significance. 
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Figure 3.4 
 
 
 
NS 
*  
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Figure 3.5 Box Plots to compare the three genotype groups for ΔIGF-I/rhGH 
dose achieved between baseline and 12 months.  
This box plot demonstrates the change in IGF-I per unit rhGH dose (IGF-I/rhGH 
dose) at twelve months for the three genotypes; fl/fl, fl/d3 and d3/d3. The box shows 
the distribution from the 25th to 75 centile, the line within the box denotes the 
median with the range demonstrated by the “whiskers” and occasional outliers are 
shown as triangles and diamonds.  The results of the ANOVA analyses comparing 
the fl/fl group with the d3 homo and heterozygous groups are shown; * denotes a 
statistically significant difference detected between the d3/d3 and fl/fl group and also 
between the d3/d3 and fl/d3 group. NS denotes no statistical significance detected 
between the fl/fl and fl/d3 groups.  
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Figure 3.5 
 
 
* 
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3.3.5 Comparison of rhGH Dose Requirements between GHR genotype groups  
The working hypothesis for this section is that subjects possessing one or more d3 
alleles require a lower dose of rhGH to achieve and maintain a serum IGF-I level 
within the target range. Analyses were performed of the rhGH doses used at 6 and 
12 months for the three genotype groups.  
The rhGH doses required to maintain a serum IGF-I between the median and upper 
limit of the normal reference range at 6 months were comparable between genotype 
groups; mean 0.37mg, 0.38mg and 0.37mg for fl/fl, fl/d3 and d3/d3 respectively 
(table 3.4). ANOVA with post hoc analyses confirmed that there was no statistically 
significant difference between the groups; p=0.802 comparing fl/fl to fl/d3, 0.953 
comparing fl/fl to d3/d3 and 0.903 comparing fl/d3 to d3/d3 (table 3.4, figure 3.6). 
Furthermore, the doses of rhGH were comparable between genotype groups at 12 
months; mean 0.41mg for fl/fl, 0.41mg for fl/d3 and 0.43mg for d3/d3. No statistically 
significant difference was detected between genotype groups (table 3.4, figure 3.7). 
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Table 3.4 Comparison of rhGH Dose Requirements between GHR genotype 
groups 
This table demonstrates the mean, (standard deviation) and range of rhGH doses 
used by each genotype at 6 and 12 months. The right half of the table shows the 
results of the ANOVA analyses comparing the three genotypes. Statistical 
significance is taken as p≤0.05.  
 
 
 
fl/fl 
n=101 
fl/d3 
n=75 
d3/d3 
n=18 
 
ANOVA 
p values 
Gender      
 
Male 43 32 6 
 
fl/fl 
vs 
fl/d3 
fl/fl 
vs 
d3/d3 
fl/d3 
vs 
d3/d3 Female 
58 43 12 
rhGH  
Dose 
(mg) 
6 months 
 
Range  
0.37 
(0.17) 
0.1-1.0 
0.38 
(0.16) 
0.1-0.9 
0.37 
(0.13) 
0.1-0.7 
 
0.802 0.953 0.933 
12 
months 
 
Range 
0.41 
(0.22) 
0.1-1.2 
0.41 
(0.23) 
0.1-1.3 
0.43 
(0.33) 
0.1-1.5 
0.906 0.701 0.658 
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Figure 3.6 Box Plots to compare the three genotype groups rhGH dose at 6 
months 
This box plot demonstrates the rhGH doses required by the three genotype groups 
(fl/fl, fl/d3 and d3/d3) at 6 months. The box shows the distribution from the 25th to 75 
centile, the line within the box denotes the median with the range demonstrated by 
the “whiskers” and occasional outliers are shown as triangles.  
The rhGH doses required by d3 homo and heterozygotes were compared to the full 
length homozygous rhGH dose requirements using ANOVA with Fisher LSD post 
hoc analyses. No statistically significant difference was detected in these 
comparisons; NS denotes non-significance.  
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Figure 3.6 
 
 
NS 
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Figure 3.7  Box Plot to compare the rhGH dose requirements for the three 
genotype groups at 12 months 
This box plot demonstrates the rhGH results at 12 months for the three genotype 
groups; fl/fl, fl/d3 and d3/d3. The box shows the distribution from the 25th to 75 
centile, the line within the box denotes the median (the median in this case is at the 
same level as the lower end of the range) with the range demonstrated by the 
“whiskers” and occasional outliers are shown as triangles. The results of ANOVA 
analyses are shown above the diagram; comparison between the fl/fl group and the 
d3 homo and heterozygotes yielded non-significant results.  
NS denotes no statistical significance. 
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Figure 3.7 
 
 
NS 
NS 
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3.3.6 The effect of d3-GHR genotype on clinical markers of rhGH 
responsiveness 
By analogy with the measurement of linear growth in children, certain clinical 
markers of GH activity are used in the investigation of GH responsiveness in adults. 
These include quality of life scores, waist: hip ratio and fasting lipid profile.  
The hypothesis of this part of the study is that possession of one or more d3 allele 
conferred an augmented GH response, as demonstrated by the clinical 
measurements.  
3.3.6.1 QoL-AGHDA  
For the purposes of this study, AGHDA results were collated after 12 months rhGH 
treatment and the change in AGHDA (AGHDA) between baseline and 12 months 
was calculated. The hypothesis for this section is that d3 homo or heterozygosity 
enhances the clinical response to rhGH replacement, thereby resulting in a greater 
change in AGHDA score.   
The mean AGHDA was 10.3 (SD 6.66) for the fl/fl group, 9.35 (SD 6.00) for fl/d3 
and 11.3 (SD 5.75) for the d3/d3 group. Comparison between the three genotype 
groups for AGHDA using ANOVA yielded no significant difference; p=0.533 for fl/fl 
vs fl/d3, p=0.472 for fl/fl vs d3/d3 and p=0.296 for fl/d3 vs d3/d3 (Table 3.5, Figure 
3.8). 
3.3.6.2 Waist: Hip ratio 
The hypothesis for this section is that possessing one or more d3 allele enhances 
the physical response to GH, as demonstrated by an augmented change in waist: 
hip ratio measurements. For the purposes of this study, the difference in waist: hip 
94 
ratio taken at baseline and after 12 months rhGH replacement was calculated. The 
results were as follows: fl/fl mean (SD) 0.02 (0.16), fl/d3 0.57 (0.16) and d3/d3 0.03 
(0.08).  
Using ANOVA with post hoc analyses, no statistically significant difference was 
detected between genotype groups for Δwaist:hip ratio; fl/lf vs fl/d3 p= 0.116, fl/fl vs 
d3/d3 p= 0.749 and fl/d3 vs d3/d3 p=0.547 (Table 3.5, Figure 3.9). 
 
3.3.6.3 Fasting Lipid Profile  
Monitoring of fasting lipid profile occurs routinely as part of the rhGH replacement 
protocol. The change in total cholesterol (ΔChol) and triglyceride levels (Trig) that 
occurred between baseline and 12 months rhGH replacement were calculated for 
the three genotype groups and compared using ANOVA with post hoc analyses. 
The hypothesis for this section is that d3 homo or heterozygosity enhances the 
change in cholesterol level in response to rhGH replacement.   
The mean ΔChol was 0.42 (SD 1.26) for fl/fl, 0.605 (SD 1.17) for fl/d3 and 0.64 (SD 
1.44) for d3/d3. ANOVA statistical analyses however, did not detect a significant 
difference between genotype groups; p=0.124 for fl/fl vs fl/d3, p=0.290for fl/fl vs 
d3/d3, p= 0.901 fl/d3 vs d3/d3 (Table 3.5, Figure 3.10). Similarly, analyses of the 
triglyceride results, found no statistically significant difference; p=0.993 fl/fl vs fl/d3, 
p=0.267 for fl/fl vs d3/d3 and p=0.279 for fl/d3 vs d3/d3 (Table 3.5, figure 3.11).   
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Table 3.5  Results of the Clinical Markers of GH activity  
This table demonstrates the response of clinical markers of GH activity resulting 
from rhGH replacement and measured as part of the rhGH replacement protocol. 
Results are reported as mean (SD) for each of the threee genotype groups; fl/fl, 
fl/d3 and d3/d3.  
The clinical markers are the change in QoL-AGHDA score (AGHDA), the change 
in waist: hip ratio (waist:hip) and the change in fasting lipids, in particular total 
cholesterol and triglycerides (Chol and Trig) achieved after 12 months rhGH 
replacement. The right side of the table details the results of the comparison of the 
three genotype groups for these clinical markers using ANOVA with post hoc 
analyses; significance is taken at p≤0.05.  
 
Abbreviations: fl/fl: full length homozygotes; fl/d3: d3 heterozygotes; d3/d3: d3 
homozygotes; rhGH: recombinant growth hormone; AGHDA: QoL-AGHDA 
questionnaire score out of a maximum of 25; Chol: cholesterol; Trig: triglycerides 
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Table 3.5 
 
 
 
fl/fl 
n=101 
fl/d3 
n=75 
d3/d3 
n=18 
 
ANOVA p values 
Gender 
 
Male 43 32 6 fl/fl 
vs 
fl/d3 
fl/fl 
vs 
d3/d3 
fl/d3 
vs 
d3/d3 
Female 58 43 12 
AGHDA 
10.3 
(6.65) 
9.35 
(6.00) 
11.3 
(5.75) 
 
0.533 0.473 0.296  
 
Waist:Hip Ratio 
0.02 
(0.16) 
0.57 
(0.16) 
0.03 
(0.08) 
 
0.116 0.749 0.547  
 
Cholesterol 
mmol/l 
0.42 
(1.26) 
0.605 
(1.17) 
0.64 
(1.44) 
 
0.124 0.290 0.901  
 
Triglycerides 
mmol/l 
0.18 
(1.13) 
0.14 
(0.95) 
0.38 
(0.86) 
 
0.993 0.267 0.279  
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Figure 3.8  Comparison of the Three Genotype Groups For ΔWaist: Hip Ratio 
This box plot demonstrates the difference between the genotype groups in the 
change in waist hip ratio (WH) achieved after 12 months rhGH replacement.  
The box shows the distribution from the 25th to 75 centile, the line within the box 
denotes the median with the range demonstrated by the “whiskers”. Occasional 
outliers are shown as triangles and diamonds.   
Using ANOVA with post hoc analyses, no statistical difference was detected 
between the three genotype groups.  
NS denotes no statistical significance. 
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Figure 3.8 
 
 
 
 
 
NS 
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Figure 3.9  Comparison of the Three Genotype Groups For ΔAGHDA Score  
AGHDA scores were calculated at baseline and after 12 months rhGH replacement 
and the change in AGHDA (AGHDA) achieved after 12 months was taken as a 
measure of GH responsiveness. This box plot demonstrates the AGHDA results 
for the three genotype groups. The box shows the distribution from the 25th to 75 
centile, the line within the box denotes the median with the range demonstrated by 
the “whiskers”. Occasional outliers are shown as triangles. The results of ANOVA 
comparison of the three genotypes are shown; NS denotes no statistical 
significance. 
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Figure 3.9 
 
  
 
 
 
NS 
NS 
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Figure 3.10  Comparison of the Three Genotype Groups for Change in total 
Cholesterol after 12 months rhGH 
This box plot demonstrates the change in total cholesterol (Cholesterol) achieved 
after 12 months rhGH replacement by the three genotype groups; fl/fl, fl/d3 and 
d3/d3. The box shows the distribution from the 25th to 75 centile, the line within the 
box denotes the median with the range demonstrated by the “whiskers”. Occasional 
outliers are shown as triangles and diamonds. The results of ANOVA with post hoc 
analyses comparing the fl/fl to the d3 homo and heterozygotes are shown above the 
diagram; NS denotes no statistical significance.  
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Figure 3.10 
 
 
 
 
 
 
 
NS 
NS 
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Figure 3.11  Box plot to demonstrate the change in fasting triglyceride level in 
the three genotype groups. 
This box plot demonstrates the change in total triglyceride (triglyceride) achieved 
after 12 months rhGH replacement by the three genotype groups; fl/fl, fl/d3 and 
d3/d3.  
The box shows the distribution from the 25th to 75 centile, the line within the box 
denotes the median with the range demonstrated by the “whiskers”. Occasional 
outliers are shown as triangles and diamonds. The results of ANOVA with post hoc 
analyses comparing the fl/fl to the d3 homo and heterozygotes are shown above the 
diagram; NS denotes no statistical significance.  
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Figure 3.11 
 
 
 
NS 
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3.3.7 Multiple Regression Analyses for IGF-I Response  
The purpose of this section was to individually and cumulatively investigate the 
factors affecting GH response as measured by IGF-I response over 6 and 12 
months. Using stepwise, multiple regression analyses, known potential confounding 
variables such as presence of oestrogen and previous pituitary irradiation would be 
rigorously assessed.  
3.3.7.1 IGF-I at 6 months  
Neither d3 homo nor d3 heterozygosity conferred an augmented IGF-I response to 
rhGH between baseline and 6 months when investigated individually or 
cumulatively; p=0.799 for fl/d3, p=0.755 for d3/d3 on cumulative analyses (table 
3.4). There was no significant contribution from rhGH dose (p=0.203) and neither of 
the potential confounders had a significant effect on IGF-I response at 6 months 
(p= 0.432 for oestrogen, p=0.231 for pituitary irradiation).  
3.3.7.2 IGF-I/rhGH dose at 6 months 
To ensure that any potential variations in rhGH dose between genotypes, 
regression analyses were performed of IGF-I/rhGH dose. Again, these 
demonstrated no significant relationship of d3 homo or heterozygosity on IGF-
I/rhGH dose response between baseline and 6 months (p=0.770 for fl/d3 and 
p=0.835 for d3/d3). Furthermore, there was no significant effect of either oestrogen 
or pituitary irradiation; p=0.197 for oestrogen, p=0.144 for pituitary irradiation (Table 
3.4).  
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Table 3.6 Results of Multiple Regression analyses investigating factors 
influencing GH responsiveness comparing to full length homozygotes (fl/fl) 
between baseline and 6 months 
This table demonstrates the cumulative results of the multiple regression analyses 
of GH responsiveness as shown by ΔIGF-I and ΔIGF-I per unit dose (ΔIGF-I/rhGH 
dose). d3-GHR homo and heterozygosity were included in the analyses along with 
rhGH dose and the potential confounders oestrogen and previous pituitary 
irradiation.  
Statistical significance was taken as p≤0.05. 
 
 
Baseline - 6 months 
ΔIGF-I ΔIGF-I/Dose 
β-Coeff p value β-Coeff p value 
fl/d3 0.019 0.799 0.022 0.770 
d3/d3 -0.023 0.755 -0.016 0.835 
Oestrogen 
(excluding RT) 
0.088 
 
0.432 
(0.473) 
-0.094 
 
0.197 
(0.136) 
Pituitary 
Irradiation 
0.094 0.231 0.107 0.144 
GH Dose -0.059 0.203 N/A N/A 
R Squared 0.020 0.024 
3.3.7.3 Multiple regression results for ΔIGF-I response at 12 months  
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Regression analyses have shown that d3-GHR homozygosity confers a positive, 
significant effect of IGF-I response at 12 months; -coefficient 0.161, p=0.02. d3-
GHR heterozygosity however, did not demonstrate any significant effect on IGF-I 
response;  coefficient 0.053, p=0.477. Further analyses of rhGH dose yielded non-
significant results, as did oestrogen and pituitary irradiation (table 3.5).  
 
3.3.7.4 Multiple regression results for IGF-I/rhGH dose response at 12 
months 
The positive, significant effect of d3 homozygosity was confirmed with analyses of 
IGF-I per rhGH dose;   coefficient 0.214, p=0.004 (Table 3.5), whereas d3 
heterozygosity was again shown to have no significant effect;  coefficient 0.006, 
p=0.940. Oestrogen appeared to be nearing significance on cumulative analyses 
with a potential negative effect; - coefficient -0.122, p=0.089. Further stepwise 
analyses were performed to determine whether the inclusion or omission of factors 
such as pituitary irradiation had an effect on the oestrogen analysis result; these 
confirmed a non-significant result (p=0.072).  
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Table 3.7 Results of Multiple Regression analyses investigating factors 
influencing GH responsiveness comparing to full length homozygotes (fl/fl) 
between baseline and 12 months.  
This table demonstrates the cumulative results of the multiple regression analyses 
of GH responsiveness as shown by ΔIGF-I and ΔIGF-I per unit dose (ΔIGF-I/rhGH 
dose). d3-GHR homo and heterozygosity were included in the analyses along with 
rhGH dose and the potential confounders oestrogen and previous pituitary 
irradiation.  
Statistical significance was taken as p≤0.05 and significant results are shown in 
bold.  
 
Baseline - 12 months 
ΔIGF-I ΔIGF-I/Dose 
β-Coeff p value β-Coeff p value 
fl/d3 0.053 0.477 0.006 0.940 
d3/d3 0.161 0.029 0.214 0.004 
Oestrogen 
(excluding RT) 
0.06 
 
0.422 
(0.171) 
-0.122 
 
0.089 
(0.072) 
Pituitary  
Irradiation 
0.046 0.528 0.043 0.549 
GH Dose 0.142 0.059 N/A N/A 
R Squared 0.054 0.061 
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3.3.8 Results of IGF-I comparing the two IGF-I assays used; pre and post 
2005 
As two IGF-I assays were used during the course of this study, further analyses 
were performed of the results taken on each assay in order to investigate whether 
the change in assay was responsible for the results. Table 3.6 shows the results of 
the IGF-I results obtained on each assay and for each genotype, and the 
percentage change in IGF-I was calculated between baseline and 6 months, and 
baseline and 12 months. Following subdivision of the cohort, numbers were too 
small for statistical analyses.   
 
3.3.9 Overall Summary of Results 
A summary of all of the results for this chapter is given in table 3.7; each of the 
different measures of GH response are shown and whether d3 homo or 
heterozygosity significantly influenced GH responsiveness. 
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Table 3.8 Comparison of the two IGF-I assays used  
This table demonstrates the IGF-I response (reported as ng/ml) between baseline 
and 6 and 12 months respectively, for the two assays used; pre-2005 and post 
2005. The left side of the table shows the results for each genotype analysed on 
each assay demonstrating the IGF-I response between baseline and 6 and 12 
months respectively; these are reported as the mean and (SD). The numbers within 
the subgroups were too small to allow statistical analyses.
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Table 3.6 
 ΔIGF-I (ng/ml)  
Assay 1 (pre 2005) Assay 2 (post 2005) 
N 0-6 
months 
0-12 
months 
N 0-6 
months 
0-12 
months 
fl/fl 79 88.8 
(71.0) 
82.9 
(67.5) 
22 82.8 
(43.3) 
89.9 
(65.1) 
fl/d3 59 106.0 
(54.0) 
108 
(80.0) 
16 79.0 
(44.1) 
93.0 
(63.4) 
d3/d3 15 85.7 
(81.4) 
110.3 
(69.2) 
3 100.0 
(30.8) 
83.0 
(25.9) 
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Table 3.7 Summary Table of Results for the Effect of d3-GHR on GH 
responsiveness in GHD cohort 
This table summarises all of the results of the statistical analyses performed for 
each of the measures of GH responsiveness, demonstrating whether there was a 
detectable difference in the d3-heterozygous and d3-homozygous groups compared 
to the full length homozygous group.  
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Table 3.7 
Measure 
Difference detected 
d3 Heterozygotes 
(fl/d3) 
Difference detected 
d3 Homozygotes 
(d3/d3) 
IGF-I SDS Baseline No No 
IGF-I SDS 6 months No No 
IGF-I SDS 12 months No No 
rhGH Dose 6 months No No 
rhGH Dose 12 months No No 
IGF-I 0-6 months No No 
IGF-I 0-12 months No Yes 
IGF-I/rhGH dose 6 months No No 
IGF-I/rhGH dose 12 months No Yes 
AGHDA No No 
Waist: Hip ratio No No 
Cholesterol No No 
Triglycerides No No 
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3.4 Discussion  
Variability in GH responsiveness is well recognised and has been investigated more 
extensively in children in whom pre-pubescent linear growth provides an accurate, 
reliable measure of GH actions. rhGH is frequently used in children with short 
stature, in particular those short for gestational age (SGA), idiopathic short stature 
(ISS) and with GH deficiency. The exon 3 deletion of the GHR was originally 
identified as a potential factor influencing GH responsiveness in the study by Dos 
Santos et al in 2004 (Dos Santos, Essioux et al. 2004). A 1.7-2 fold growth 
acceleration was observed in children possessing one or more d3 allele compared 
to full length homozygotes when treated with rhGH for SGA or ISS. Furthermore, 
they demonstrated ~30% increased GHR signal transduction in d3 homo or 
heterodimers compared to full length homodimers (Dos Santos, Essioux et al. 
2004). Subsequent studies in paediatric populations have yielded conflicting data 
and the importance of this polymorphism remains unclear.  
GH responsiveness in adult populations is more difficult to establish due to the lack 
of linear growth as a clinical marker; surrogate markers of GH responsiveness are 
used instead, such as IGF-I response. Observations from clinical studies and 
practice suggest there is considerable variability in GH responsiveness in adults; for 
example rhGH dose requirements vary by 2.5 and 4 fold in male and female 
populations respectively. If we were able to identify the factors responsible for 
determining an individual’s response to GH, we could tailor rhGH replacement more 
appropriately and avoid situations of under or over replacement which are 
associated with morbidity. The purpose of this study was to investigate in detail the 
role of the exon 3-GHR polymorphism in determining response to rhGH in an adult 
population with GHD.  
Summary of Results  
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GHR Genotyping  
The genotyping of 194 patients with severe GHD from a single centre yielded similar 
results to those published previously. 52% of the population were full length 
homozygotes, approximately 38% were d3 heterozygotes and approximately 10% 
were d3 homozygotes. As previously described, misclassification of d3 
heterozygotes as homozygotes was evident in 2 out of 20 subjects; a second PCR 
was necessary to confirm these results. A 20% misclassification rate was previously 
demonstrated (Carrascosa, Esteban et al. 2006) and this may be in part responsible 
for the variability in results published by previous authors.   
 
Analyses of IGF-I response in relation to d3-GHR genotype 
There was no detectable difference in ΔIGF-I response achieved by the d3 homo or 
heterozygotes compared to the full length homozygotes for the early, titration phase 
of rhGH replacement, as shown by the change over 6 months. Furthermore, 
correcting for the potential confounding effect of rhGH dose using ΔIGF-I/rhGH 
dose, also yielded non- significant results. Similarly analyses of the clinical markers 
of GH activity such as Δwaist hip ratio, also failed to detect a significant difference in 
response between the d3 possessing genotypes and the full length homozygotes.  
These negative findings would indicate that during this early, titration phase of rhGH 
replacement, there is no difference in GH responsiveness between d3 + or – 
groups.  
Analyses of the results after 12 months rhGH replacement however did reveal a 
difference in IGF-I response but only in the d3 homozygotes compared to fl/fl; no 
difference was detected comparing the d3 heterozygotes to fl/fl. Unexpectedly, 
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analyses of IGF-I per unit rhGH dose demonstrated not only a difference between 
d3/d3 and fl/fl, but also a significant difference between the d3 homo- and d3 
heterozygotes. Many of the previously published studies combined the two groups 
for analyses, stating that only one d3 allele was sufficient to augment response. 
These results would suggest otherwise; not only is there are two d3-GHR alleles 
needed to augment the response, but the behaviour of the d3 homo and 
heterozygotes are significantly different and should not be combined for analysis.  
 
rhGH Dose  
If prior knowledge of an individual’s GHR genotype is to be of clinical use, a 
detectable difference in maintenance rhGH dose requirements would be required; 
this was not evident on statistical analyses at either 6 or 12 months. The lack of 
statistical difference in maintenance rhGH dose requirements may be due to the 
dosing regimen.  Patients commenced 0.8IU (more recently 0.3mg) daily, with 
regular measurement of serum IGF-I and dose adjustments as required, aiming to 
maintain a value between the median and upper end of the age-adjusted normal 
range. For the vast majority of male patients, this starting dose resulted in a serum 
IGF-I within the ‘target range’, with no requirement for subsequent dose increments. 
The ‘target range’ for this dose titration protocol is wide; for example, the normal 
range for a patient aged 21-30 is 117-358 ng/ml, with a median of 176, thereby 
giving a ‘target range’ of 182 ng/ml. Although no increments in dose were needed 
for the majority of patients above 0.8 or 1.2 IU for males and females respectively, 
statistically significant differences in IGF-I values at 12 months were noted between 
genotype groups, but within the target range. This would suggest that, although 
heterogeneity in GH responsiveness between genotype groups is evident at 12 
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months, this is not of particular clinical relevance and does not explain the marked 
variation in rhGH doses observed in clinical practice.   
 
Clinical Markers of GH activity 
Although a detectable difference in IGF-I response was noted at 12 months, 
analyses of the clinical markers of GH activity failed to identify a difference in 
response between the d3+ and d3- groups.  
There are a number of potential explanations for this. In the absence of an easily 
measurable and reproducible measure such as linear growth, the clinical effects of 
GH in adults are difficult to accurately and measure and are subject to bias.  
For example measurement of the waist: hip ratio is dependent on the same person 
measuring the same sites on two separate occasions with the same tape measure. 
Similarly the AGHDA questionnaire is a subjective quality of life questionnaire that 
may be influenced by other non GH related life events.  
These results may also be explained by the possibility that the small, albeit 
detectable, difference in IGF-I generation was insufficient to cause a significant 
difference in the clinical measures of GH activity; if all patients in the cohort have 
achieve a target IGF-I of between the median and upper limit of the normal 
reference range, then variations in serum IGF-I within the reference range may not 
be associated with observable differences in clinical parameters.  
Potential Confounders 
Previous studies have identified oestrogen and pituitary irradiation as confounders 
of any study of the GH/IGF-I axis; oestrogen attenuates the production of IGF-I for a 
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given level of GH whereas pituitary irradiation in the context of acromegaly is often 
associated, after many years, with low amplitude, but persistent, GH secretion. 
Detailed, stepwise regression analyses, however, did not detect a significant effect 
of either oestrogen or pituitary irradiation on ΔIGF-I at 6 or 12 months. The effect of 
persistent low grade GH secretion on GH responsiveness is unclear, however it is 
unlikely that any potential difference between with and without residual GH 
secretion could be detected in view of the insensitivity of ΔIGF-I and rhGH dose as 
markers of GH responsiveness.  
Subgroup analyses between the groups of women taking different preparations of 
oestrogen would also be preferable; patches provide a more stable release of 
oestrogen compared to the peaks and troughs of tablet use. Unfortunately numbers 
were insufficient to allow subgroup analysis. However, as the overall oestrogen 
effect was insignificant this issue regarding lack of numbers of a sub-analysis is 
unlikely to be a major drawback.  
In view of the suppressive effect of obesity on IGF-I production, it would also have 
been preferable to include BMI as a variable in the regression analyses; 
unfortunately as there was a lack of relevant retrospective data, this was not 
possible.  
Although there may be the possibility of variability in IGF-I response to different 
preparations of rhGH, we would not anticipate this in view of rhGH being genetically 
engineered, however this hypothesis was not specifically examined.  
In summary, in this study of 194 patients with GHD, which is the largest published to 
date, the only detectable difference was over 12 months rhGH replacement, and 
this was only observed in the d3-GHR homozygotes and not d3 heterozygotes. No 
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differences were found in dose requirements or of the clinical measures of GH 
activity, thus questioning the clinical relevance of such a finding.  
 
Critique of Work  
The strengths of this work lie in the number of subjects included in the analyses 
which was double that of previously published studies. Robust, methodical, detailed 
statistical analyses were also performed with input from an expert statistician to 
ensure the validity of these results. The two d3-GHR groups were analysed 
separately to ensure that the effect of one or two d3-GHR alleles was fully 
investigated, and certainly the results of this study would strongly favour the need 
for this, since a difference in GH response was detected between d3 homo and 
heterozygotes. Furthermore, following on from the findings of Carracosa et al, 
repeat PCRs were performed for all labelled d3 homozygotes initially due to the 
potential for a 20% misclassification rate. The repeat PCR yielded a 10% 
misclassification rate; considering the potential differences in behaviour of d3 homo 
and heterozygotes, it raises the question of whether the variability in previously 
published results are due in part to these misclassifications +/- the combination of 
the two d3 genotypes for analysis.  
One limitation of this work it its retrospective nature; a prospective study would 
preferable to minimise bias and ensure the validity of the findings however the sheer 
scale of this study with a cohort of 194 and the methodical way in which identical 
data sets were collected prospectively during the course of rhGH treatment does 
help to optimise the validity of the results. Another limitation is the lack of an easily 
measurable and reproducible physical marker of GH response; paediatric studies 
benefit from the availability of linear growth to allow robust clinical studies of the 
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variability in GH responsiveness. All physical measures used as part of the rhGH 
protocol and for the purposes of this study were subject to bias for example 
waist:hip ratio will be prone to measurement error even when performed by the 
same investigator. AGHDA questionnaires are commonly influenced by an 
individual’s personality and judgement of their own symptoms; a more stoic 
individual tends to score lower marks than a person with depression and yet there is 
no method for correcting for this when analysing results.  
Although changes in fasting lipid profiles can provide a helpful marker of GH activity, 
a multitude of other influencing factors such as BMI, dietary intake and exercise 
cannot be accounted for and minimised in a retrospective study. The concurrent use 
of lipid lowering therapy could also influence the reliability of any results of fasting 
lipid profile both within the cohort but also for each individual’s response. Due to the 
lack of available and accurate data regarding use of lipid lowering therapy over the 
study period, subgroup analysis was not possible.  
It would have been preferable to analyse the effects of varying levels of endogenous 
and exogenous oestrogen caused by different methods of administration, but the 
numbers were too small to allow sub-group analyses. One would hypothesise that 
differing IGF-I responses may occur in those receiving transdermal oestrogen who 
maintain consistent blood oestradiol levels as opposed to the peaks and troughs 
experienced with oral oestrogen. 
The change in IGF-I assay in 2005 also has the potential to influence results; 
although all patients used in this study had baseline, 6 month and 12 month IGF-I 
levels measured on the same assay. The difference between the two IGF-I assays 
in results and age and gender specified normative reference range precluded direct 
comparison of results and IGF-I SDS were used for the purposes of this study.   
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There was also potential for bias from the doses of rhGH used for each individual; to 
minimise the effect of any potential variability in rhGH prescribing, the change in 
IGF-I per unit dose was also used for analyses.  
 
Interpretation in the context of published data  
Previous studies of the effect of the d3-GHR on GH responsiveness have largely 
been confined to children. Data have been conflicting, with enhanced linear growth 
responses to injected GH observed in some, but not all, patients with ISS, SGA, 
GHD and Turner syndrome (Dos Santos, Essioux et al. 2004, Binder, Baur et al. 
2006, Blum, Machinis et al. 2006, Jorge, Marchisotti et al. 2006, Pilotta, Mella et al. 
2006, Tauber, Ester et al. 2007). Two recent studies of adult GHD patients have 
shown similarly conflicting results. Enhanced IGF-I generation was demonstrated 
after 1 but not 5 years therapy with GH in d3-GHR homo- and heterozygotes, in 
conjunction with changes in fasting lipid profile (van der Klaauw, van der Straaten et 
al. 2008) However a more recent study has demonstrated no differences in IGF-I 
response or reductions in body fat between d3 genotype groups after 1 year of 
rhGH treatment(Barbosa, Palming et al. 2008) (Barbosa 2008). Conflicting data 
regarding IGF-I levels in response to a GH stimulus have also been shown in adult 
acromegalic patients both pre and post-operatively (Schmid, Krayenbuehl et al. 
2007) (Mercado, Gonzalez et al. 2008) (Schmid 2007, Mercado 2008).  
 
There are 2 possible reasons for the lack of concordance between studies. First, it 
is possible that there is variability in the response of d3 homozygotes and 
heterozygotes; we postulate that this may be due to functional differences in the 
GHR formed. Assuming equivalent affinity of receptor dimers, only 25% of the 
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GHRs of heterozygous patients will be d3/d3 homodimers (Figure 3.12). If a d3/d3 
homodimer is required for augmented GH responsiveness, then a d3 heterozygote 
will exhibit only 25% of the ‘extra’ IGF-I generation capacity: an effect that may not 
be detected in smaller studies. More detailed studies of the transcriptional activity of 
hetero versus homodimers are needed to determine whether there is a difference in 
functional activity and thus whether there is a partial increase in GHR response in 
d3 heterozygotes in comparison to d3 homozygotes. Second, repetition of the PCR 
with two primers has ensured that our classification of subjects as d3 homo- or 
hetero-zygotes is robust; previous studies have shown that 20% of d3 
heterozygotes are misclassified as homozygotes without this additional step 
(Carrascosa, Esteban et al. 2006, Carrascosa, Audi et al. 2008, Carrascosa, Audi et 
al. 2008). As the majority of previous studies have not performed this second PCR, 
it is possible that a significant proportion of subjects have been mislabelled. If GH 
responsiveness varies between d3 homo- and heterozygotes, such genotype 
misclassifications may have contributed to the inconsistency of published clinical 
data.  
In conclusion this large scale extensive study of the effect of the d3-GHR genotype 
on rhGH responsiveness in adult hypopituitary patients, has demonstrated an 
increase in rhGH responsiveness at 12 months. However, given only 10% of the 
population are homozygous for d3-GHR and the marginal nature of the increased 
response, this is unlikely to explain the marked variability in rhGH dose 
requirements in this patient group and further studies are needed before more 
tailored approaches to rhGH dosing can be developed.  
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Figure 3.12 d3-GHR Homo- and Heterodimers  
Schematic diagram to demonstrate the influence of GHR genotype on the GHR 
formed. Black represents the full length (fl) and grey represents d3 transmembrane 
domains; two chains dimerise to form a functional GHR. The type of GHR formed 
depends on genotype; homozygous individuals for wild-type or d3 alleles form GHR 
homodimers (fl/fl or d3/d3 respectively). Heterozygous individuals possess a mixture 
of fl and d3 homo and heterodimers; assuming equal affinity of receptor dimers, only 
25% will be d3 homodimers.  
 
124 
Figure 3.12 
 
 
        fl/fl        d3/d3           fl/d3 
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Chapter 4  
 
 
Effect of the d3-GHR Polymorphism 
on rhGH Responsiveness in Adults 
with Acromegaly 
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4.1 Introduction 
Several retrospective studies have demonstrated that in patients with acromegaly, 
lowering of mean serum growth hormone (GH) levels to <5mU/L is associated with 
restoration of life expectancy to normal (Bates 1995, Rajasooriya 1994, Orme 
1998)(Rajasoorya, Holdaway et al. 1994, Bates, Evans et al. 1995, Orme, McNally 
et al. 1998). Although fewer studies have correlated serum insulin-like growth factor-
I (IGF-I) levels with mortality (Swearingen 1998), measurement of this GH-
dependent peptide is increasingly used by many physicians (particularly in North 
America) as the sole marker of disease activity. Consensus guidelines suggest that 
the goals of treatment of acromegaly should include an epidemiologically ‘safe’ GH 
level and a normal age-adjusted serum IGF-I (excepting therapy with pegvisomant, 
where serum GH cannot meaningfully be measured). A strong linear correlation 
exists between log-transformed GH and serum IGF-I levels, but significant 
discordance exists in up to a third of patients; most commonly an elevated age-
adjusted IGF-I level in the presence of ‘safe’ GH values(Freda, Wardlaw et al. 
1998).  For such patients demonstrating GH/IGF-I ‘discordance’ clinical decision 
making is problematic. Evidence exists that higher IGF-I values in the presence of 
unequivocally ‘safe’ GH levels are associated with adverse changes in insulin 
sensitivity (Freda 1998) but clinical symptoms and signs in this patient group may 
be absent or subtle and long-term costly therapy, difficult to justify. Understanding 
the factors that determine this GH/IGF-I discordance could, potentially, facilitate 
more refined clinical decision making.  
The deletion of exon 3 in the GHR (d3-GHR) has been linked to augmented growth 
velocity in GH deficient (GHD) children treated with GH. Data in acromegalic 
subjects are conflicting; this may be in part attributable to variations in methodology 
such as the grouping together of d3 homo and heterozygotes for analysis. The 
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purpose of this study was to investigate the effect of the d3-GHR on the IGF-I 
response to GH in a cohort of patients with acromegaly.  
 
Aim of this section 
 To establish the percentage of patients in our cohort carrying each of the 
GHR genotypes; fl homozygotes, d3 heterozygotes and d3 homozygotes 
 To investigate whether d3- homo or heterozygosity influences the IGF-I 
response to GH 
 
4.2 Study Design 
4.2.1 Patient Selection  
All patients with acromegaly within the department of endocrinology at St 
Bartholomew’s Hospital (approximately 400 in total) were invited to participate. This 
study was approved by a local ethics committee (Reference 07/H0701/55) and all 
patients provided informed, written consent to allow the use of their clinical and 
biochemical records and all patients provided a 10ml EDTA blood sample to allow 
GHR genotyping. Details regarding GHR genotyping are given in methods section 
2.1. 
79 adult patients with acromegaly from a single centre were studied with 
prospective genotyping of their growth hormone receptor (GHR) and collation of 
retrospective clinical data. All patients were in routine clinical follow-up and the 
diagnosis of acromegaly had been confirmed biochemically by a failure to suppress 
GH levels on a standard oral glucose tolerance test.  
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No patients had any identifiable reasons for altered IGF-I production e.g. anorexia 
nervosa, renal failure, liver failure or concomitant use of opiates, DHEA 
supplements or levodopa.   
 
4.2.2 Data Collation 
Data collation was limited by the lack of an available serum IGF-I assay pre-1994; 
using source data (hospital case notes) diagnostic IGF-I results were only available 
for 44 of the 79 patients with diagnostic GH results available in 70 out of 79 patients.   
Routine assessment of serum IGF-I and the mean of a five point GH “day curve” 
were performed at three months after the primary form of treatment (surgery, 
medical therapy, radiotherapy). These results were collated for all 79 patients within 
the study cohort and used for analysis. 
IGF-I levels were converted to % upper limit of the age related normal reference 
range (IGF-I%ULN) to aid comparison between results. Details regarding the IGF-I 
and GH assays are given in methods section 2.2. 
 
4.2.3 Statistical Analyses 
Expert statistical advice was obtained. Data were assessed for normal distribution; 
in view of the presence of skewed data, these are reported as median (range) and 
Kruskall-Wallis non-parametric testing were used for comparison of results.  
GH and IGF-I levels were converted to logeGH and logeIGF-I respectively to 
minimise the influence of outliers for the purposes of regression analyses.  
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 Statistical significance was accepted at a p value <0.05. All analyses were 
performed using SPSS (version 11.01; SPSS Inc, Chicago, IL) for Windows XP 
(Microsoft Corp) and Excel 2007 (Microsoft Corp). 
 
4.3 Results  
4.3.1 Cohort Details  
Details regarding the patient cohort are shown in table 4.1. The cohort were aged 
18-79 years old at diagnosis and consisted of 41 males and 38 females (Table 4.1). 
The mean GH level (taken from a 5 point day curve) at diagnosis ranged from 5.1-
527.6miu/l, with a mean of 68.3miu/l. Diagnostic IGF-I levels, reported as % upper 
limit of the normal reference range were 125-700.4% with a mean of 313.5% ULN 
(Table 4.1).  
Pituitary adenomata were evident on diagnostic imaging in 73 patients; 56 (76%) 
had macroadenomata and cavernous sinus involvement was evident in 11 patients. 
Four modalities of treatment were used as primary treatment for acromegaly; 49 
patients received trans-sphenoidal surgery (TSS), 16 had pituitary irradiation 
(EBRT), 11 received somatostatin analogues and 3 were treated with dopamine 
agonists. Using recently defined criteria for cure (mean GH <2miu/l and IGF-I within 
age-adjusted normal reference range) 20 out of 79 patients achieved remission after 
primary treatment.  
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Table 4.1 Clinical features and Demographics of the Cohort  
   n= 79 
N % 
Gender  Male  40 50.6% 
 
 Female 
 
Total 
-Oestrogen replete 
-Oestrogen deficient 
39 
20 
19 
49.3% 
25.3% 
24.0% 
Age at 
Diagnosis 
 <20 4 5.1% 
  21-30 7 8.8% 
  31-40 19 24.1% 
  41-50 26 32.9% 
  51-60 18 22.8% 
  >60 5 6.3% 
MRI Macroadenoma 56 70.9% 
Microadenoma 17 21.6% 
 Empty Sella 6 7.6% 
Surgery  62 78.5% 
Radiotherapy  Yes Total  48 60.8% 
-EBRT 47 59.5% 
-Gamma Knife  Radiosurgery 10 12.6% 
 No  31 39.2% 
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4.3.2 GHR Genotyping 
79 patients were prospectively genotyped to determine the frequency of the d3-
GHR polymorphism (see methods section 2.1). DNA was extracted from whole 
blood and using established oligonucleotides (forward, full length reverse and 
reverse d3 primers) to identify the region of interest, a PCR reaction was performed 
and the PCR products identified on agarose gel electrophoresis. The fl allele is 
represented by a 521 bp fragment and the d3 allele by a 470 bp fragment (figure 
4.1a).   
Repeat PCR were performed using only forward and reverse full length 
oligonucleotides (Figure 4.1b) to avoid the potential misclassification of the d3 
heterozygotes as homozygotes, as discussed in section 3.  
The frequencies of the 3 genotypes (fl/fl, fl/d3 and d3/d3) were 50.6% (n=40), 36.7% 
(n=29) and 12.6% (n=10) respectively and were in Hardy-Weinberg equilibrium. 
These frequencies are in accordance with previously published data. Repeat PCR 
of d3/d3 patients using forward and full length reverse primers resulted in 
reclassification of 2/12 (16.7%) patients as heterozygotes. Proportions of male and 
female subjects were comparable between genotype groups. 
The cohort was divided into 3 genotype groups for further analyses; full length 
homozygotes fl/fl, d3 heterozygotes fl/d3 and d3 homozygotes d3/d3.  
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Figure 4.1  Amplification products of multiplex PCR 
Products are shown on agarose gel stained with ethidium bromide.  
The fl allele is represented by a 521 bp fragment and the d3 allele by a 470 bp 
fragment. 
 
4.1a Lane 1 represents a genomic DNA ladder; lane 2 represents fl/fl homozgote; 
lane 3 represents d3/d3 homozygote and lane 4 represents fl/d3 heterozygote. 
 
4.1b Result of second PCR to confirm d3-GHR heterozygosity.  
This figure shows a comparison of PCR results for the same patient. To avoid the 
mis-classification of d3 heterozygotes as homozygotes a second PCR reaction was 
performed using only forward and full length reverse primers.  
Lane 1 is a genomic DNA ladder; lane 2 represents the results of a 3 primer PCR 
demonstrating a single 470bp band (d3/d3); lane 3 represents the same patient’s 
result from a repeat PCR using only forward and full length reverse primers with a 
521bp band is visible confirming heterozygosity. 
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Figure 4.1a  
                    
 
 
Figure 4.1b 
                    
500bp 
Lane      1    2        3       4 
1000bp 
1000bp 
Lane      1    2        3   
500bp 
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4.3.3 Comparison of IGF-I response in relation to d3-GHR genotype 
The working hypothesis for this study was that the presence of one or more d3 
allele enhances an individual’s response to GH as demonstrated by the amount of 
IGF-I generated. If correct, one would expect increased IGF-I production for a given 
level of GH in those patients carrying one or more d3-GHR allele at any given time. 
 
4.3.3.1 Whole Cohort analyses: Post Primary treatment  
To test this hypothesis, analyses of IGF-I %ULN and mean GH level (from a 5 point 
GH day curve) and IGF-I/GH were performed to compare the three genotype 
groups; fl/fl, fl/d3 and d3/d3. Results for the whole cohort (n=79) were taken from 
the standard three month post treatment assessment.  
As the distribution of GH and consequently IGF-I/GH were skewed, non-parametric 
tests were performed. IGF-I %ULN levels were 107.9 (19.1-478.5) for fl/fl, 
124.5(28.1-423.9) for fl/d3 and 146.8 (48.2-640.5) for d3/d3; no statistically 
significant difference was detected between genotype groups (p=0.806) (table 4.2a, 
figure 4.2a). GH levels were median 3.9 (range 0.5-167.4) for fl/fl, 3.16 (0.5-438) for 
fl/d3 and 8.37 (1.1-110) for d3/d3 (table 4.2a, figure 4.2b); no statistically significant 
difference was detected between genotype groups (p=0.906). IGF-I/GH were 25.2 
(1.6-101.1) for fl/fl, 28.5 (0.44-250.7) for fl/d3 and 23.2 (4.82-58.6) for d3/d3; no 
statistically significant difference was detected between genotypes (p=0.395) (table 
4.2a, figure 4.2c). 
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Table 4.2  Comparison of the three GHR genotypes for GH and IGF-I levels 
taken 3 months post primary treatment 
This table summarises the GH and IGF-I results for the cohort of 79 patients taken 
at 3 months after their primary treatment for acromegaly. The left half of the table 
demonstrates the numbers of patients and the male to female distribution within 
each genotype cohort; full length homozygote fl/fl, d3 heterozygote fl/d3 and d3 
homozygote d3/d3.  
The median and (range) for GH, IGF-I and GH/IGF-I are shown for each genotype 
group.  The right hand side of the table shows the results of the statistical analyses 
comparing the results for the genotype groups; Kruskall Wallis non-parametric 
analyses were used in view of the skewed data. Statistical significance is taken at 
p≤0.05.  
Abbreviations: fl/fl: full length homozygotes; fl/d3: d3 heterozygotes; d3/d3: d3 
homozygotes; IGF-I %ULN: % upper limit of normal reference range for IGF-I  
 
 
 
fl/fl 
 
fl/d3 
 
d3/d3 
 
p value 
Number (% Female) 40 (52.5%) 29 (44.8%) 10 (40%) 
IGF-I %ULN 107.9 
(19.9-478.5) 
124.5  
(28.2- 423.9) 
146.8  
(48.3-640.5) 
0.539 
Mean GH (miu/l) 3.9 
(0.5-167.4) 
3.16  
(0.5-438) 
8.4 
(1.1-110) 
0.523 
IGF-I/GH 25.2 
(1.62-101.1) 
28.5 
(0.44-250.7) 
23.2 
(4.82-58.6) 
0.641 
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Figure 4.2 Box Plots to compare the three genotype groups for IGF-I post 
primary treatment 
 This box plot represents the post treatment results for IGF-I for the three genotype 
groups; group 1= fl/fl, group 2= fl/d3 and group 3= d3/d3. The box shows the 
distribution from the 25th to 75 centile, the line within the box denotes the median 
with the range demonstrated by the “whiskers”. Occasional outliers are shown as 
circles and asterix.  
Comparison of the three genotype groups was performed using non-parametric 
testing; no statistically significant difference was detected between the genotype 
groups. 
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Figure 4.3 Box Plots to compare the three genotype groups for GH post 
primary treatment  
This box plot represents the post treatment results for GH for the three genotype 
groups; group 1= fl/fl, group 2= fl/d3 and group 3= d3/d3. The box shows the 
distribution from the 25th to 75 centile, the line within the box denotes the median 
with the range demonstrated by the “whiskers”. Occasional outliers are shown as 
circles and asterix.  
Comparison of the three genotype groups was performed using non-parametric 
testing; no statistically significant difference was detected between the genotype 
groups. 
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Figure 4.4  Box Plots to compare the three genotype groups for IGF-I/GH post 
primary treatment  
This box plot represents the post treatment results for IGF-I/GH for the three 
genotype groups; group 1= fl/fl, group 2= fl/d3 and group 3= d3/d3. The box shows 
the distribution from the 25th to 75 centile, the line within the box denotes the 
median with the range demonstrated by the “whiskers”. Occasional outliers are 
shown as circles and asterix.  
Comparison of the three genotype groups was performed using non-parametric 
testing; no statistically significant difference was detected between the genotype 
groups. 
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4.3.3.2 Diagnostic Data 
Further analyses were performed of the subgroup of 44 patients for whom 
diagnostic data were available. GH and thus IGF-I/GH results were again skewed 
and non-parametric analyses were performed.  
 
GH levels were median 39.2 (range 5.1-248.2) for fl/fl, 43.1 (6.8-527.6) for fl/d3 and 
45.4 (10.6-110.3) for d3/d3 at diagnosis; there was no statistically significant 
difference between genotype groups (p=0.968) (table 4.2b, figure 4.3b). IGF-I 
%ULN levels were 301.7 (125-545) for fl/fl, 316.9(134-483.1) for fl/d3 and 293 
(187.5-700.4) for d3/d3; there was no statistically significant difference between 
genotype groups (p=0.806) (table 4.2b, figure 4.3a). IGF-I/GH levels were 6.85 
(1.27-39.7) for fl/fl, 3.27 (0.41-30.8) for fl/d3 and 6.35 (4.31-36.6) for d3/d3; again 
there was no statistically significant difference between genotype groups (p=0.395) 
(table 4.2b, figure 4.3c). 
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Table 4.3  Comparison of the three GHR genotypes for GH and IGF-I levels 
taken at diagnosis  
This table summarises the GH and IGF-I results for the subgroup of 44 patients for 
whom diagnostic GH and IGF-I results were available; the top half details the 
diagnostic results and the bottom half of the table demonstrates the post primary 
treatment results for this subgroup of the cohort. The left half of the table 
demonstrates the numbers of patients and the male to female distribution within 
each genotype cohort; full length homozygote fl/fl, d3 heterozygote fl/d3 and d3 
homozygote d3/d3. 
The median and (range) for GH, IGF-I and GH/IGF-I are shown for each genotype 
group. The right hand side of the table shows the results for the comparison 
between the genotype groups for the above measures using Kruskall Wallis non-
parametric analyses in view of the skewed data. Statistical significance is taken at 
p≤0.05.  
Abbreviations: fl/fl: full length homozygotes; fl/d3: d3 heterozygotes; d3/d3: d3 
homozygotes; IGF-I %ULN: % upper limit of normal reference range for IGF-I  
 
 
 
fl/fl 
 
fl/d3 
 
d3/d3 
 
p value 
Number  
(% Female) 
24 (62.5) 14 (35.7) 7 (28.6) 
IGF-I %ULN 301.7  
(125-545) 
316.9  
(134.0-483.1) 
293.0  
(187.5-700.4) 
0.806 
Mean GH 
(miu/l) 
39.2  
(5.1-248.2) 
43.1  
(6.8-527.6) 
45.4  
(10.6-110.3) 
0.968 
IGF-I/GH 6.85  
(1.27-39.7) 
3.27  
(0.41-30.8) 
6.35  
(4.31-36.6) 
0.395 
141 
Figure 4.5 Box Plot to demonstrate Diagnostic IGF-I%ULN Results for the 
three genotype groups  
This box plot represents the results for IGF-I %ULN for the three genotype groups at 
diagnosis; group 1= fl/fl, group 2= fl/d3 and group 3= d3/d3. The box shows the 
distribution from the 25th to 75 centile, the line within the box denotes the median 
with the range demonstrated by the “whiskers”. Occasional outliers are shown as 
circles and asterix. Comparison of the three genotype groups was performed using 
non-parametric testing; no statistically significant difference was detected between 
the genotype groups. 
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Figure 4.6  Box Plot to demonstrate Diagnostic GH Results for the three 
genotype groups  
This box plot represents the results for the mean GH from a 5 point day curve for 
the three genotype groups at diagnosis; group 1= fl/fl, group 2= fl/d3 and group 3= 
d3/d3. The box shows the distribution from the 25th to 75 centile, the line within the 
box denotes the median with the range demonstrated by the “whiskers”. Occasional 
outliers are shown as circles and asterix.  
Comparison of the three genotype groups was performed using non-parametric 
testing; no statistically significant difference was detected between the genotype 
groups. 
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Figure 4.7  Box Plot to demonstrate Diagnostic IGF-I/GH Results for the three 
genotype groups  
This box plot represents the results for IGF-I/GH for the three genotype groups at 
diagnosis; group 1= fl/fl, group 2= fl/d3 and group 3= d3/d3. The box shows the 
distribution from the 25th to 75 centile, the line within the box denotes the median 
with the range demonstrated by the “whiskers”. Occasional outliers are shown as 
circles and asterix.  
Comparison of the three genotype groups was performed using non-parametric 
testing; no statistically significant difference was detected between the genotype 
groups. 
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4.3.4 Regression analyses of the effect of d3 homo and heterozygosity on 
loge(IGF-I%ULN) 
GH and IGF-I%ULN were converted to loge(GH) and loge(IGF-I%ULN) to minimise 
the impact of outliers; this yielded a linear relationship for both post treatment data 
(figure 4.4a) and diagnostic data (figure 4.4b). The slopes were greater for post 
treatment data with lower GH values, than for the pre-treatment values; this is 
consistent with individuals having a ceiling on IGF-I generation irrespective of 
further increases in GH. 
4.3.4.1 Post Primary Treatment 
Analysis of the post treatment data for the whole cohort confirmed a significant 
relationship between loge(GH) and loge(IGF-I%ULN) (figure 4.4a, table 4.3a). 
Neither d3 homo (d3/d3) or heterozygosity (fl/d3) were confirmed to have a 
significant effect on loge(IGF-I%ULN) measured 3 months post primary treatment 
(p=0.708 for d3/d3, p=0.560 for fl/d3) (table 4.3a). As both demonstrated positive, 
albeit non-significant results, further analyses of fl/fl were performed; this confirmed 
a non-significant effect on loge(IGF-I%ULN) (p=0.533) (table 4.3a). 
28 of the 79 patients achieved biochemically normal GH and IGF-I levels post 
primary treatment; to ensure that these “normal” results have not masked the effect 
of the d3-GHR polymorphism on GH responsiveness, analyses were repeated 
excluding these patients from the analyses. Repeat regression of this subgroup 
confirmed that there was no statistically significant effect of either fl/d3 (p=0.172) or 
d3/d3 (p=0.752) (table 4.3b). 
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4.3.4.2 Diagnostic Data  
Analysis of the subgroup for whom diagnostic data were available confirmed a linear 
relationship between loge(GH) and loge(IGF-I%ULN) (figure 4.4c) with a significant 
relationship between loge(GH) and loge(IGF-I%ULN); p=0.032 (table 4.3c). 
Possession of one or more d3 allele did not have a significant effect on loge(IGF-
I%ULN); p=0.2 for fl/d3 and 0.801 for d3/d3 (table 4.3c).  
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Figure 4.8  Graph to demonstrate the relationship between loge(GH) and 
loge(IGF-I%ULN) measured at 3 months post primary treatment 
This plot demonstrates the distribution of post primary treatment GH and IGF-
I%ULN results for the cohort studied. A linear relationship is demonstrated between 
GH and IGF-I; loge(GH) and loge(IGF-I%ULN) were used to minimise the impact of 
outliers. Regression analyses confirmed a statistically significant relationship 
between loge(GH) and loge(IGF-I%ULN) (p=0.00).  
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Table 4.4  Multiple Regression analyses investigating factors influencing GH 
responsiveness: Post Primary Treatment 
The main question is the relationship between GH and IGF-I and how variations in 
GHR genotype may influence the IGF-I response. Regression analyses were 
performed to investigate the relationship between GH and IGF-I as demonstrated by 
loge(IGF-I %ULN) and loge(GH) and the effect of d3 homo (d3/d3) and 
heterozygosity (fl/d3) on IGF-I levels. This table demonstrates the results of these 
analyses in conjunction with analyses of the potential confounders, oestrogen and 
pituitary irradiation on IGF-I levels taken at a single, comparative time point of 3 
months post primary treatment. Results for the whole cohort of 79 patients were 
used for these analyses. As both fl/d3 and d3/d3 yielded positive but non-significant 
results, further analysis of fl/fl was performed to investigate whether these results 
were different; this is shown at the bottom of the table and confirms a non-significant 
result. 
Statistical significance is taken at ≤0.05.  
 
 
loge(IGF-I %ULN) 
β-Coeff p value 
loge(GH) 0.746 0.00 
fl/d3 0.049 0.560 
d3/d3 0.032 0.708 
Oestrogen -0.47 0.643 
Pituitary irradiation -0.60 0.481 
R squared  0.548 
 
fl/fl -0.050 0.533 
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Figure 4.5 Graph of the relationship between loge(GH) and loge(IGF-I%ULN) 
measured at 3 months post primary treatment: non-cured subgroup 
This plot demonstrates the distribution of post primary treatment GH and IGF-
I%ULN results for the subgroup within the cohort who did not achieve a GH <5miu/l 
and an IGF-I within the normal age related reference range post primary treatment. 
Regression analyses of this subgroup confirmed a statistically significant 
relationship between loge(GH) and loge(IGF-I%ULN) (p=0.00) but d3-GHR 
genotypes had no effect on loge(IGF-I%ULN).  
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Table 4.6 Multiple Regression analyses: Post Primary Treatment Subgroup 
analysis 
This table summarises the results of the regression analyses of the subgroup who 
failed to achieve a normal GH and IGF-I level post primary treatment; this was 
performed to ensure that “normal” GH and IGF-I results were not masking the effect 
of the d3-GHR polymorphism. Neither d3/d3 or fl/d3 genotypes were found to have 
a significant effect on IGF-I level (loge IGF-I %ULN).  
 
 
 
loge(IGF-I %ULN) 
β-Coeff p value 
loge(GH) 0.369 0.041 
fl/d3 -0.251 0.172 
d3/d3 0.057 0.752 
Oestrogen -0.219 0.320 
Pituitary irradiation 0.152 0.400 
R squared  0.362 
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Figure 4.9  Graph to demonstrate the relationship between loge(GH) and 
loge(IGF-I%ULN) measured at diagnosis  
This plot demonstrates the relationship between loge(GH) and loge(IGF-I%ULN) in 
the cohort for whom diagnostic data were available (n=44). A linear relationship 
between loge(GH) and loge(IGF-I%ULN) was confirmed and was statistically 
significant (p=0.032).  
 
151 
 
Table 4.7 Multiple Regression analyses investigating factors influencing GH 
responsiveness: Diagnostic data 
This table summarises the results of the analyses of the subgroup for whom 
diagnostic data were available. A multiple regression model was developed to 
investigate the effect of d3-GHR genotype and other factors on IGF-I levels 
(loge(IGF-I %ULN) used for analyses). A statistically significant effect of loge(GH) is 
seen. Neither d3 homo or heterozygosity were found to have a significant effect on 
loge(IGF-I%ULN) at diagnosis. The presence of oestrogen as a potential confounder 
was included in the analyses and confirmed to not have a significant effect on the 
diagnostic data.  
 
 
 
loge(IGF-I %ULN) 
β-Coeff p value 
loge(GH) 0.239 0.032 
fl/d3 -0.146 0.200 
d3/d3 0.29 0.801 
Oestrogen -0.117 0.398 
R squared  0.174  
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4.4 Discussion 
Discordance in the relationship between GH and IGF-I remains poorly understood. 
Data in children has largely demonstrated an augmented linear growth response in 
those in possession of one or more d3-GHR allele. Data in adult studies of GH 
deficiency and excess have yielded conflicting results(Mercado, DaVila et al. 1994, 
Schmid, Krayenbuehl et al. 2007, Barbosa, Palming et al. 2008, van der Klaauw, 
van der Straaten et al. 2008, Kamenicky, Dos Santos et al. 2009)  and the question 
arises as to whether the d3-GHR polymorphism has a significant effect on GH 
response or whether the lack of an easily measureable and reproducible marker of 
GH activity in adults is masking its effect. The aim of this study was to investigate 
the effect of the d3-GHR polymorphism on GH responsiveness in a cohort of 
patients with acromegaly.  
 
Summary of Results  
GHR Genotyping  
The genotyping of 79 patients with acromegaly from a single centre yielded similar 
results to those published previously. 50.6% of the population were full length 
homozygotes, 36.7% were d3 heterozygotes and 12.6% were d3 homozygotes. As 
previously described, misclassification of d3 heterozygotes as homozygotes was 
evident in 2 out of 12 subjects; a second PCR was necessary to confirm these 
results. A 20% misclassification rate was previously demonstrated (Carrascosa, 
Esteban et al. 2006) and this may be in part responsible for the variability in results 
published by previous authors.   
Analysis of GH responsiveness between genotype groups 
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The study hypothesis was that possession of one or more d3 allele enhances GH 
responsiveness as shown by an augmented IGF-I response to a given level of GH 
in patients with acromegaly. A cohort of 79 patients was studied; these 
demonstrated a wide range of ages, disease severity and duration since diagnosis 
from weeks to decades. Paired GH and IGF-I results were used for analysis; due to 
the wide variability in the time of diagnoses and the lack of IGF-I assay pre-1994, 
diagnostic data were not available for the whole cohort. Instead a time point of three 
months post primary treatment was used to allow standardisation of results for 
comparison with a subgroup analysis of those patients with diagnostic results; using 
this time point, data were available for analysis in all patients. Response to 
treatment or the effect of different treatment types was not analysed as the 
hypothesis specifically relates to the relationship between GH and IGF-I; the only 
treatment that would have an effect on this relationship is pegvisomant which was 
not used as primary therapy in any of the cohort studied.  
Non parametric tests were used in the comparison of GH, IGF-I (reported as % 
upper limit of normal) and IGF-I/GH for the three genotype groups fl/fl, fl/d3 and 
d3/d3, in view of the skewed data. No significant difference was detected between 
the three genotypes for either GH, IGF-I or IGF-I/GH in the analyses of post 
treatment results and diagnostic data.  
More detailed analyses of the relationship between GH and IGF-I were performed 
using regression analyses. As expected, the plot of loge GH and loge IGF-I %ULN 
yielded a linear relationship between GH and IGF-I. A steeper slope was evident 
with the post treatment data in relation to the diagnostic data; this suggests that 
above a certain level of GH there may be saturation of the GHR and consequently 
further IGF-I may not be generated.  
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Multiple regression analyses confirmed the positive, linear relationship between GH 
and IGF-I; analyses of d3 homo- and heterozygotes however failed to demonstrate 
a significant effect on IGF-I level. As both groups showed non-significant but 
positive effects in the post treatment cohort, further analyses of the fl/fl group were 
performed; this excluded a significant negative effect. In order to ensure that the 
inclusion of patients with “normal” GH and IGF-I levels in the post treatment analysis 
were not influencing results, repeat analyses of the subgroup of patients with 
persistently abnormal GH and IGF-I results post treatment. This repeat analysis did 
not demonstrate a statistically significant effect of the d3-GHR polymorphism on GH 
responsiveness in the post treatment group. Further analyses were also performed 
of the 44 patients for whom diagnostic GH and IGF-I results were available; again, 
no statistically significant effect of d3 homo or heterozygosity on GH responsiveness 
was observed.  
In summary, despite robust statistical analyses of a large cohort of patients with 
acromegaly, there was no evidence of an enhanced IGF-I response to GH in either 
the d3-GHR homozygous or d3-GHR heterozygous groups. 
 
Critique of Work 
The strengths of this study are in the methodology. Detailed, robust statistical 
analyses were performed with input from an expert statistician to ensure validity of 
the results and conclusions. In order to avoid masking any subtle effects of the 
polymorphism, d3 homo and heterozygosity were analysed separately. 
Furthermore, a second PCR was performed for all labelled d3 homozygotes to avoid 
the potential for misclassification as reported by Carrascosa et al (Carrascosa, 
Esteban et al. 2006); consequently 2 out of 12 patients were reclassified as d3 
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heterozygotes. Despite detailed analyses, there was no evidence of an augmented 
IGF-I response to GH in those possessing one or more d3 allele; as such our 
original hypothesis was not supported by these data.  
This study was however limited by the availability of data; although the original 
cohort was 79 patients, diagnostic IGF-I levels were only available for 44 patients. 
Although in theory, paired GH and IGF-I levels could be analysed from any time 
point, analysing raw data from diagnosis would be preferable in order to standardise 
results for comparison.  
Analysis of the whole cohort for post treatment results showed no statistically 
significant effect of the d3-GHR polymorphism on IGF-I generation for given GH 
stimulus. It should however be noted that 28 of the 79 patients achieved GH levels 
of <5miu/l and an IGF-I within normal reference range after the primary treatment. 
This raises the question of whether any change in GH responsiveness due to the 
d3-GHR polymorphism would be present or detectable when GH levels are normal. 
Further analyses excluding those who achieved “normal” GH levels within this 
cohort did not detect any difference in IGF-I response in the d3-GHR genotype 
groups; it would however be preferable to have a larger cohort with abnormal GH 
and IGF-I results to maximise statistical power. In contrast to the study presented 
within this thesis from patients with GHD, it proved more problematic to recruit 
patients with acromegaly into this study. The 79 patients recruited represent 
approximately 20% of the department’s acromegaly caseload. The most likely 
explanation for the discrepancy in recruitment rates relates to the close clinical 
relationship with GHD patients and the department’s hypopituitary/GH clinical nurse 
specialist, whose help in recruiting GHD patients was invaluable. 
 
156 
Consideration of these data in the context of the Published Literature 
This data has added to the confusion over whether the d3-GHR polymorphism has 
a significant role in determining an individual’s response to GH. Several studies in a 
range of adult and children patient cohorts have yielded conflicting results; either 
demonstrating a pronounced augmentation of GH response or negative or equivocal 
GH responses. 
In adults with acromegaly, four other studies have preceded this one and even in 
spite of the predominantly positive results, the inconsistent effect of d3-GHR is 
apparent and does raise the question of how clinically relevant this polymorphism is. 
Mercado et al demonstrated no significant difference in IGF-I levels at baseline but 
higher IGF-I levels in the combined d3-GHR group post treatment and a higher 
prevalence of diabetes(Mercado, Gonzalez et al. 2008). Schmid et al demonstrated 
higher serum GH levels at diagnosis in the fl/fl group compared to the combined d3 
group with comparable IGF-I levels, thereby suggesting more IGF-I is generated for 
a given level of GH, however no association with clinical end points such as 
diabetes was detected(Schmid, Krayenbuehl et al. 2007). Bianchi et al also 
demonstrated a difference only after treatment (surgery or SA) but without any 
detectable difference at diagnosis(Bianchi, Giustina et al. 2009). A Dutch study of 
80 patients (Wassenaar, Dekkers et al. 2009) demonstrated an increase in the 
irreversible complications of acromegaly (osteoarthritis and colonic polyps) in the 
combined d3 group but in the absence of a detectable difference in IGF-I levels 
between d3+ and - groups. Since the majority of the effects of GH are mediated 
through IGF-I and the effect of the d3-GHR is purported to be to enhance the IGF-I 
response, it is unclear how or why this polymorphism has resulted in such a 
significant increase in complications. Rather than demonstrating a clear effect of the 
d3-GHR in enhancing GH response, it suggests that there must be another factor 
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that is augmenting the response to IGF-I, such as variability in the IGF-I receptor. 
Most recently, a study of 105 acromegalic patients failed to show any difference in 
GH or IGF-I levels between genotype groups and furthermore failed to show any 
difference in correlation (Kamenicky, Dos Santos et al. 2009). Cumulatively the lack 
of a conclusive, significant result from these studies does suggest that there must 
be other more relevant GH responsiveness factors other than the d3-GHR 
polymorphism. 
 
Future Work  
The absence of a conclusive result from this or other published studies suggests 
that the d3-GHR polymorphism is not a major factor in determining an individual’s 
response to GH. Whilst it may be that the lack of an easily measurable and 
reproducible marker of GH activity in adults is influencing results, other potential GH 
responsiveness factors must now be given more consideration.  
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Chapter 5  
 
Study to determine the optimum 
serum IGF-I range in patients with 
acromegaly treated with 
Pegvisomant 
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5.1 Introduction 
Pegvisomant, a GH receptor antagonist, is a highly effective treatment for 
acromegaly with clinical and biochemical response rates of up to 97% reported (van 
der Lely, Hutson et al. 2001). Monitoring of treatment can be difficult; the similarity 
of pegvisomant to GH dictates that, for many assays, serum GH levels cannot be 
used to guide treatment (Veldhuis, Bidlingmaier et al. 2001) leaving serum IGF-I as 
the sole marker of disease activity. There are a number of problems with this 
(unavoidable) approach. First, IGF-I has a wide normal reference range and, without 
knowledge of an individual patient’s GH/IGF-I physiology prior to the development of 
acromegaly, it is not clear where, within that reference range, GH activity is at its 
most “normal.” Second, variations in IGF-I assay quality are well recognised 
(Pokrajac, Wark et al. 2007) and many do not take account of the known gender 
difference in IGF-I generation for a given excess GH stimulus (Parkinson, Ryder et 
al. 2001). Third, as discussed earlier in this thesis, there is a known 30% 
discordance rate between GH and IGF-I for unknown reasons. Characteristic 
physiological and metabolic changes occur in relation to both GH deficiency and 
excess. For example, active acromegaly is associated with increased lean body 
mass, decreased fat mass, redued C-reactive protein (CRP) levels, sodium and 
water retention and accelerated lipolysis. ln contrast, untreated severe adult-onset 
GHD is characterised by decreased muscle mass, visceral adiposity, elevated CRP, 
a reduction in totally body sodium and fasting hyperlipidaemia. The aim of this 
study, therefore, was to document changes in GH-dependent metabolic parameters 
with pegvisomant treatment, in order to determine where within the reference range 
of IGF-I ‘optimum’ biochemical control of acromegaly lies (thereby acting as a guide 
for pegvisomant treatment) and to explore whether it is possible that a state of 
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‘functional/pharmacological’ GHD may be induced by excessive pegvisomant 
dosing in this condition. 
 
5.1.1 Aim of this section 
 To induce a metabolic syndrome similar to GH deficiency with the use of 
supra-physiological doses of pegvisomant to allow the identification of an 
‘optimum’ range of serum IGF-I to guide pegvisomant dosing. 
 
5.2 Study Design 
This clinical trial was approved by a central ethics committee (Reference 
07/H0703/126) and by the Medicines Healthcare Regulatory Agency (EudraCT No: 
2007-003741-33). 
  
A cohort of 10 patients currently receiving pegvisomant treatment for active 
acromegaly was prospectively recruited; 1 patient subsequently withdrew from the 
study due to personal reasons. All patients were already taking pegvisomant for 
acromegaly that was refractory to other treatment (i.e previous non curative surgery, 
radiotherapy or failure to achieve remission with somatostatin analogues). The 
following inclusion and exclusion criteria were applied:  
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5.2.1 Inclusion criteria: 
 Active acromegaly on pegvisomant monotherapy at a stable dose with a 
normal age-adjusted serum IGF-I for at least 3 months 
 Over 18 years of age 
 Willing to provide informed consent 
 
5.2.2 Exclusion criteria:  
 Unwilling or unable to provide informed consent 
 Other conditions known to alter IGF-I levels (severe hepatic disease, severe 
renal disease, malnutrition, ethanol and drug abuse) 
 Abnormal liver enzymes  
 Pregnancy/lactation 
 
All had achieved biochemical control of acromegaly, as evidenced by a normal 
serum IGF-I level on their maintenance dose of pegvisomant. All study participants 
provided informed, written consent.  
 
5.2.3 Clinical Assessment 
The following markers of GH activity were taken at baseline whilst on their 
maintenance dose of pegvisomant: 
 Body Composition: DXA % Body fat and waist: hip ratio 
 Glycaemic control and insulin resistance: fasting insulin and glucose and 
HOMA2 IR analysis 
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 Cardiovascular risk: Lipoprotein (a), fibrinogen, CRP 
 Quality of life: AcroQoL, EuroQoL, AGHDA questionnaires (Appendix ) 
All patients then followed a dose titration of pegvisomant, with monitoring of serum 
IGF-I levels on a 2 weekly basis, aiming for just below the lower limit of the age 
adjusted reference range. Once target IGF-I was achieved, the dose of pegvisomant 
was continued for a 12 week period and the above measurements were reassessed 
at the end of the trial period.  
 
5.2.4 Statistical model 
The proposed statistical model to identify the optimal IGF-I range from the 
distribution of results of the physiological markers of GH activity was as follows: 
perform a regression of IGF-I against physiological marker to form regression line 
IGF-1 = α + β × M   , where α is the value of IGF-1 at M=0 and β is the slope of the 
line. The range of IGF-I values that correspond to the ‘safe’ range of the metabolic 
marker are:  α + β × m1 and α + β × m2. The range can then be narrowed by adding 
and subtracting 1.96 times the within-person standard deviation of paired 
measurements of IGF-1from the same sample from the lower and upper intervals of 
the range (figure 5.1). The proposed model requires a full set of data of IGF-I levels 
with paired physiological markers taken at baseline and with a subnormal IGF-I 
induced by over treatment with pegvisomant.  
In order to investigate for differences in the physiological markers between baseline 
and after 12 weeks at an increased dose of pegvisomant, non-parametric tests were 
performed due to the small sample size. Results are reported as median (range) 
due to the small sample size. Statistical significance was accepted at a p value 
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<0.05. Analysis was performed using SPSS (version 11.01; SPSS Inc, Chicago, IL) 
for Windows XP (Microsoft Corp). 
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Figure 5.1  Statistical model to identify the range of IGF-I which corresponds 
to normalisation of physiological markers of GH activity 
This graph demonstrates the proposed model for calculation of the optimal range of 
IGF-I in pegvisomant treatment. A regression line of IGF-I against physiological 
marker; IGF-1 = α + β × M, where α is the value of IGF-1 at M=0 and β is the slope 
of the line. The range of IGF-I values that correspond to the ‘safe’ range of the 
physiological marker are:  α + β × m1 and α + β × m2. To further narrow the ‘safe’ 
range, add and subtract 1.96 times the within-person standard deviation of paired 
measurements of IGF-1from the same sample from the lower and upper intervals of 
the range.  
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Figure 5.1 Statistical model to identify the range of IGF-I which corresponds to 
normalisation of physiological markers of GH activity 
 
 
 
Metabolic marker 
m1 m2 
α + (β × m2) 
IGF-1 
α + (β × m1) + (1.96 ×sw) 
α + (β × m2) - (1.96 ×sw) 
α + (β × m1) 
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5.3 Pegvisomant Dose Titration 
All patients followed the dosing regimen shown below with the aim of achieving an 
IGF-I just below the normal reference range. The section in italics was included as 
an amendment to the original protocol to allow an increase of the maximum dose to 
50mg od; this is the maximum daily dose used in the original pegvisomant 
publications. Response to an increased pegvisomant dose was assessed by IGF-I 
measured two weeks post increase and subsequent changes were made as per 
protocol. Weekly doses were calculated as an equivalent daily dose (weekly dose 
divided by 7) and the above protocol was followed accordingly. Any increases in 
dose were administered as a single weekly dose, for example an additional dose of 
10mg per day was administered as additional 70mg per week in addition to the 
usual maintenance dose.  
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Table 5.1.1  Pegvisomant Dosing regime  
This table summarises the pegvisomant dosing schedule used in this study. The 
target for treatment was a serum IGF-I level below the normal reference range. IGF-
I levels were rechecked two weeks after an increase in dose and further increases 
made as necessary. The doses in italics were an amendment to the original protocol 
in view of the difficulty experienced in achieving target IGF-I.  
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Table 5.1 Pegvisomant Dosing regime  
Dose of pegvisomant Increase by Dose 
5 mg od 5 mg 10mg 
10mg 
IGF-I below 
median 
5mg 15 mg od 
IGF-I above 
median 
10mg 20 mg od 
15 mg 
od 
IGF-I below 
median 
5mg 20 mg od 
IGF-I above 
median 
10mg 25 mg od 
20 mg 
od 
IGF-I below 
median 
10mg 30 mg od 
IGF-I above 
median 
15mg 35 mg od 
25 mg 
od 
IGF-I below 
median 
10mg 35 mg od 
IGF-I above 
median 
15mg 40 mg od 
30 mg 
od 
IGF-I below 
median 
10mg 40 mg od 
IGF-I above 
median 
15mg 45 mg od 
 
35mg 
od 
 
IGF-I below 
median 
10mg 45mg 
IGF-I above 
median 
15mg 50mg 
40mg 
od 
IGF-I below 
median 
10mg 50mg 
IGF-I above 
median 
10mg 50mg 
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5.4 Results  
5.4.1 Patient Cohort  
10 patients with active acromegaly treated with pegvisomant for acromegaly and 
refractory to standard medical treatments (in accordance with clinical guidelines) 
were originally recruited. The cohort consisted of five male and five female patients 
aged between 32 and 74 years of age; one female patient subsequently withdrew 
from the study for personal reasons. All nine of the cohort had received prior 
pituitary surgery and/or external pituitary irradiation and/or medical therapy (Table 
5.2). All had been treated with a stable dose of pegvisomant for a minimum of 3 
months and had a normal age-adjusted serum IGF-I level prior to commencement of 
the study.   
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Table 5.1.2 Cohort Details 
This table summarises the clinical details for the study cohort including diagnostic 
clinical and biochemical data and previous treatment received for acromegaly. The 
IGF-I levels taken prior to commencing pegvisomant as part of their clinical care is 
also stated; this demonstrates the severity of their GH excess despite previous 
treatment with surgery, radiotherapy and medical treatments.   
 IGF-I levels are reported as % upper limit of normal; this allows direct comparison 
of results measured on different assays.  
Key: Diag: diagnosis, TSS: trans-sphenoidal surgery, RT: external beam 
radiotherapy, RS: radiosurgery, DA: dopamine agonists, SA: somatostatin analogs, 
%ULN: IGF-I level reported as % upper limit of normal reference range, * data not 
available, IGF-I Pre Pegv: IGF-I level taken prior to commencing pegvisomant. 
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Table 5.2 Cohort Details  
Pt Age 
M/F 
IGF-I 
Diag 
ng/ml 
(%ULN) 
Mean 
GH 
Diag 
miu/l  
Tumour 
size at 
diagnosis 
Previous Treatment Pre-Pegv 
IGF-I 
ng/ml 
(%ULN) 
TSS RT RS DA SA 
1 74 F *not 
available 
200 “enlarged 
fossa” 
N N Y Y Y 452 
(226%) 
2 48 
M 
86.8 
(139.5%) 
43.1 Macro Y x2 Y Y Y Y 478 
(189.7%) 
3 59 F 120 
(187.5%) 
26.3 Macro Y Y N Y Y 416 
(184.8%) 
4 64 
M 
1022 
(454.2%) 
130.4 macro  Y Y  N N Y 703 
(312.4%) 
5 56 
M 
1205 
(535.5%) 
71.4 macro  Y Y Fail Y Y 556 
(247%) 
6 69 
M 
* not 
available 
106.3 Macro Y Y Y Y Y 365 on 
SA 
(182.5%) 
7 48 F * not 
available 
88.0 Macro Y Y N Y Y 407 
(161.5%) 
8 46 
M 
988 
(392%) 
199 Macro Y N  N Y Y 678 
(269%) 
9 32 F 1001 
(280.4%) 
197 Macro Y 
 
Y N Y Y 732 
(204%) 
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5.4.2 Response to Pegvisomant dose titration  
Pegvisomant doses were increased as detailed in section 5.3 with the aim of 
achieving a serum IGF-I just below the normal age-adjusted reference range. The 
summary of the dosing schedule and IGF-I levels for all nine subjects are shown in 
table 5.3. IGF-I levels were converted to standard deviation scores using N – mean / 
SD using age and gender related normative data for the assay used; these data are 
shown in table 5.4. At baseline IGF-I SDS were median 2.08 (range -0.77 to 3.55) 
and on the maximum trial dose IGF-I SDS were median -1.43 (range -3.09 to 0.20) 
(Figure 5.2). One of the cohort had a high IGF-I SDS of 3.55; at the time of 
recruitment he satisfied inclusion criteria with a stable IGF-I level but was 
unexpectedly found to have a high IGF-I at his initial visit. In view of the limited 
number of patients on pegvisomant, he was included in the study.  
There is no prior intellectual knowledge regarding the use of supra-physiological 
doses of pegvisomant; all previous clinical trials used clinically effective doses only 
aiming for normalisation of IGF-I rather than mild GH deficiency. Although 
reductions in IGF-I were seen in all patients (figure 5.2) with a decrease in IGF-I of 
median 54.7% (range 26.6-66.4%) (Table 5.3), only three patients achieved a target 
IGF-I of below the age and gender defined normal reference range (table 5.3). Of 
the six patients who failed to achieve the target IGF-I, four were on the maximum 
dose of pegvisomant (50mg). Due to a limitation of time caused by a prolonged 
titration phase, two patients were unable to increase to the maximum 50mg and 
completed the study on 40mg per day. The three patients who achieved a sub-
normal IGF-I were all female; two were post menopausal and thus oestrogen 
deficient.  
The inability to achieve target IGF-I in the whole cohort prevented completion of the 
full statistical analysis as per the original protocol; from the data available it was not 
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possible to determine the optimal range of IGF-I for monitoring of pegvisomant 
using the proposed statistical model. The data does however provide interesting 
information regarding the unexpected difficulty in inducing a subnormal serum IGF-I 
even with very high doses of pegvisomant.  
174 
Table 5.1.3  Summary of IGF-I levels at baseline and following increased 
doses of pegvisomant  
This table summarises the IGF-I levels taken at baseline on the usual maintenance 
pegvisomant dose and subsequent changes to IGF-I (numbered 1 to 5) in response 
to the increased pegvisomant doses (numbered 1 to 5) for the study cohort of 9 
subjects. Doses of pegvisomant were increased aiming for a target IGF-I level of 
below the lower limit of age and gender defined reference range as shown in italics.  
Dose of pegvisomant is reported as mg per day (mg per week stated in brackets for 
those patients on a weekly dose). A maximum dose of pegvisomant of 50mg per 
day was stipulated based on data from previous clinical trials. The lowest IGF-I level 
achieved is shown in bold; six out of the nine patients failed to achieve target IGF-I 
despite the use of high dose pegvisomant.  
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Table 5.3 Summary of IGF-I levels at baseline and following increased doses of pegvisomant  
Pt Baseline 
dose  
mg/day 
(mg/wk) 
Baseline 
IGF-I 
Target 
IGF-I 
Dose  
(1) 
IGF-I 
(1) 
Dose 
(2) 
IGF-I 
(2) 
Dose 
(3) 
IGF-I 
(3) 
Dose 
(4) 
IGF-I 
(4) 
Dose 
(5) 
IGF-I 
(5) 
Trial 
dose 
Weight 
kg 
Target  
IGF-I 
achieved 
1 10 90 69 15 140 20 115 25 102 30 87 35 66 35 59 Yes 
2 15 250 94 15 214 25 147 30 147 35 118 40 105 40 92 No 
3 10 182 81 20 104 25 64       25 65 Yes 
4 8.6 (60) 250 81 15 
(105) 
174 25 
(175) 
123 35 
(245) 
106 40 
(280) 
91   40 101 No 
5 20 285 81 35 241 50 158       50 105 No 
6 20 223 69 35 149 50 123       50 95 No 
7 10 130 94 15 104 20 68       20 68 Yes 
8 14.3 (100) 248 94 20 
(140) 
227 30 
(210) 
228 40 
(280) 
175 50 
(350) 
95   50 86 No 
9 30 243 109 45 188 50 129       50 82 No 
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Figure 5.2 Difference in IGF-I levels between baseline and trial end 
This graph demonstrates the fall in serum IGF-I in response to the increased dose 
of pegvisomant. IGF-I levels are reported as standard deviation scores; -2 to +2 are 
considered normal. Each line represents an individual patient’s IGF-I results at 
baseline and on the trial dose of pegvisomant. The aim was to increase the dose to 
lower the IGF-I level to below the normal reference range; although all IGF-I levels 
decreased in response to the increased dose only three patients achieved a level 
below the normal reference range.  
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Figure 5.2 Difference in IGF-I levels between Baseline and Trial end 
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5.4.3 Change in IGF-I  
Although the majority of patients failed to achieve target IGF-I, all subjects 
experienced a reduction in IGF-I in response to the increased dose of between 26.7 
and 66.4%. Figure 5.3 demonstrates the plot of change in IGF-I against change in 
pegvisomant dose for the cohort; it is apparent that although there appears to be a 
linear relationship, there are a number of outliers which suggests that an individual 
patient’s biochemical response to pegvisomant is multi-factorial. To investigate this 
further, a regression analysis was performed to investigate the individual and 
cumulative effects of pegvisomant dose, gender and body weight on ΔIGF-I. Results 
are shown in table 5.4; none of the factors were found to have a statistically 
significant effect on ΔIGF-I. 
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Figure 5.3 Plot of ΔIGF-I against ΔPegvisomant Dose  
This graph represents the plot of ΔIGF-I against ΔPegvisomant Dose for the cohort 
studied. Only three out of the nine patients studied achieved a target sub-normal 
IGF-I which suggests there is some variability in response to pegvisomant. This 
variability is further demonstrated in this plot; although the relationship of ΔIGF-I 
against ΔPegvisomant Dose is mostly linear, a number of outliers are present. 
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Figure 5.3 Plot of ΔIGF-I against ΔPegvisomant Dose  
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Table 5.1.4  Factors affecting IGF-I response to Increased Dose Pegvisomant  
A linear regression model of ΔIGF-I SDS against change in dose, body weight, 
gender and maintenance pegvisomant dose was performed to investigate the 
individual and cumulative effects on ΔIGF-I SDS; none were found to have a 
statistically significant effect on ΔIGF-I.  
  
 
ΔIGF-I 
β-Coeff p value 
Change in Pegvisomant Dose -0.453 0.561 
Maintenance Pegvisomant Dose  -0.81 0.902 
Gender -0.576 0.680 
Body weight  0.377 0.749 
R Squared 0.388 
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5.4.4 Effect of Pegvisomant on Physiological Markers of GH activity  
Characteristic physiological changes are expected in relation to GH activity levels; 
the most directly measurable relate to changes in body composition, insulin 
resistance, markers of cardiovascular risk and quality of life. These were assessed 
at baseline on the patient’s maintenance pegvisomant dose and at the end of the 
trial period on the increased dose.  
Fasting plasma glucose at baseline was median 5.0mmol/l (range 4.5-6.5) and at 
trial end median 4.9mmol/l (3.9-7.5); no statistically significant difference was 
detected (p= 0.373) using non parametric tests in view of the small sample size 
(Table 5.5). Repeat testing with removal of the outlier (figure 5.4a) confirmed no 
statistically significant difference (p=0.091).  Fasting insulin levels were median 
7.5miu/l (range 2.0-26.0) at baseline and 4.2miu/l (2.0-9.0) at the end of the trial; 
again no statistically significant difference detected (p=0.069) (figure 5.4b). There 
was also no significant difference in HOMA2-IR Insulin resistance scores; median 
1.1 (0.4-3.5) at baseline and median 0.6 (0.4-1.3) on increased dose pegvisomant 
(p=0.075) (figure 5.4c).  
Assessment of body composition revealed a significant difference in percentage 
body fat as measured by DXA; median 25.4% (19.4-36.5) at baseline and 26.5% 
(18.6.0-37.6) final result, p=0.036 (figure 5.5a). No difference was detected with 
waist:hip ratio however; median 0.87 (0.83-1.03) at baseline compared to 0.90 
(0.83-0.98) on high dose pegvisomant (p=0.528) (figure 5.5b). Cardiovascular risk 
factors were assessed; a significant response to pegvisomant was seen with 
fibrinogen, baseline median 3.13g/l (2.31-3.92) compared to 2.86g/l (1.99-3.45) at 
trial end (p=0.012) (figure 5.6b). There was however no detectable difference with 
lipoprotein A; median 135mg/l (24-806) at baseline and 82mg/l (24-679) at trial end 
(p=0.345) (figure 5.6a). 
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 No statistically significant differences were detected in the quality of life 
assessments. The Adult Growth Hormone Deficiency Assessment (AGHDA) score 
was median 3 (range 0-23) at baseline and median 5 (2 to 23) at trial end; this was 
not statistically significant p=0.102 (figure 5.7a). 
AcroQol; a specific acromegaly related questionnaire of physical and psychological 
wellbeing, also showed no statistically significant difference between baseline 
(median 86.4, range 29.5 to 109.1) and trial end (median 80.7, range 15.9-98.9) 
p=0.173 (figure 5.7b). The visual analog scale of EuroQoL, a non disease specific 
QoL questionnaire, also demonstrated no statistically significant difference; median 
75 (50-95) at baseline and median 80(50-95) on high dose pegvisomant, p=0.344 
(table 5.5, figure 5.7c).  
The aim of the study was to induce ‘functional/pharmacological’ GHD; due to the 
inability to achieve target IGF-I in the majority of the cohort, it was not possible to 
perform the statistical analyses initially planned due to the overlap of results. Figure 
5.8 uses fasting plasma glucose as an example to demonstrate this overlap of 
results; it is not possible to calculate the difference between mean + and - 1.96SD 
for the two sets of results. Similar plots were evident for all markers of GH activity 
assessed. 
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Table 5.1.5 Response of Physiological Markers of GH to Increased 
Pegvisomant Dose 
This table summarises the results taken at baseline on maintenance pegvisomant 
dose in comparison to measurements taken after 3 months of overtreatment, with a 
serum IGF-I below or close to the lower limit of the normal reference range. 
Measurements were made of characteristic markers of GH activity; body 
composition, insulin resistance, cardiovascular risk and quality of life scores. Non-
parametric tests (Wilcoxon signed rank) were performed in view of the small sample 
size; significance is taken at p≤0.05.  
 
 
 
Baseline 
Median (Range) 
Final 
Median (Range) 
p value 
Fasting Plasma Glucose 5.0 (4.5-6.5) 4.9 (3.9-7.9) 0.373 
Fasting Insulin 7.5 (2.0-26.0) 4.2 (2.0-9.0) 0.069 
HOMA2-IR 1.1 (0.4-3.5) 0.6 (0.4-1.3) 0.075 
Fibrinogen 3.13 (2.31-3.92) 2.86 (1.99-3.45) 0.012 
Lipoprotein A 135 (24-806) 82 (24-679) 0.345 
% Body Fat 25.4 (19.4-36.5) 25.4 (21.0-37.2) 0.028 
Waist:Hip Ratio 0.87 (0.83-1.03) 0.91 (0.86-0.97) 0.398 
AGHDA (Max 25) 3 (0-23) 6 (2-23) 0.194 
ACROQOL (Max 110) 84.1 (29.5-109.1) 78.4 (15.9-98.9) 0.310 
EUROQOL 75 (50-95) 76 (50-95) 0.465 
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Figure 5.4 Change in Fasting Plasma Glucose in Response to Increased 
Pegvisomant Dosing 
This graph represents the changes in fasting glucose in relation to a change in GH 
activity caused by the increase in pegvisomant dose. Each line corresponds to an 
individual patient’s data; the baseline level was taken on the maintenance dose 
pegvisomant and the final level was taken on the increased pegvisomant dose used 
for the trial period. No statistically significant difference was seen with any 
parameter in this cohort; this is likely to reflect a combination of the difficulty in 
achieving the target sub-normal IGF-I levels and the modest numbers of patients 
available to recruit into such studies, even in tertiary centres.  
One outlier is noted for the fasting glucose measurements; levels increased from 
5.6mmol/l to 7.9mmol/l in this patient. Repeat analysis of the results excluding the 
outlier confirmed a lack of a statistically significance (p=0.091). 
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Figure 5.4 Fasting Plasma Glucose in Response to Increased dose of 
Pegvisomant  
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Figure 5.5 Change in Fasting Insulin levels in Response to Increased dose of 
Pegvisomant 
This graph represents the changes in fasting insulin in relation to a change in GH 
activity caused by the increase in pegvisomant dose. Each line corresponds to an 
individual patient’s data; the baseline level was taken on the maintenance dose 
pegvisomant and the final level was taken on the increased pegvisomant dose used 
for the trial period. No statistically significant difference was seen with any 
parameter in this cohort; this is likely to reflect a combination of the difficulty in 
achieving the target sub-normal IGF-I levels and the modest numbers of patients 
available to recruit into such studies, even in tertiary centres.  
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Figure 5.5 
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Figure 5.6 HOMA2-IR insulin resistance  
This graph represents the changes in HOMA2 insulin resistance in relation to a 
change in GH activity caused by the increase in pegvisomant dose. Each line 
corresponds to an individual patient’s data; the baseline level was taken on the 
maintenance dose pegvisomant and the final level was taken on the increased 
pegvisomant dose used for the trial period. No statistically significant difference was 
seen with any parameter in this cohort; this is likely to reflect a combination of the 
difficulty in achieving the target sub-normal IGF-I levels and the modest numbers of 
patients available to recruit into such studies, even in tertiary centres.  
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Figure 5.6 
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Figure 5.7 Change In Body Composition In Response To Increased Dose 
Pegvisomant 
The following graph reflects the changes in body composition in response to the 
increased pegvisomant dose. %body fat was measured for each patient at baseline 
on their usual maintenance pegvisomant dose and again after 12 weeks on the 
increased trial dose; each line on the graph corresponds to an individual patient’s 
data. 
A statistically significant difference was detected for %body fat  
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Figure 5.7 Change in %Body Fat in Response to Increased Dose Pegvisomant 
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Figure 5.8 Change in Waist Hip Ratio in Response to Increased Dose 
Pegvisomant 
The following graph reflects the changes waist:hip ratio in response to the increased 
pegvisomant dose; this was measured for each patient at baseline on their usual 
maintenance pegvisomant dose and again after 12 weeks on the increased trial 
dose; each line on the graph corresponds to an individual patient’s data. 
No statistically significant difference was detected. 
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Figure 5.8 
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Figure 5.9 Change in Lipoprotein A levels in Response To Increased Dose 
Pegvisomant 
The following graph reflects the changes in the cardiovascular risk marker 
lipoprotein A in response to the increased pegvisomant dose. These were 
measured for each patient at baseline on maintenance dose pegvisomant and again 
after 12 weeks on the increased trial dose; each line on the graph corresponds to an 
individual patient’s data. No statistically significant difference was detected for 
lipoprotein a.  
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Figure 5.9 Change in Lipoprotein A levels in Response To Increased Dose 
Pegvisomant 
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Figure 5.10 Change in Fibrinogen levels in Response To Increased Dose 
Pegvisomant 
The following graph reflects the changes in the cardiovascular risk marker 
fibrinogen in response to the increased pegvisomant dose. These were measured 
for each patient at baseline on maintenance dose pegvisomant and again after 12 
weeks on the increased trial dose; each line on the graph corresponds to an 
individual patient’s data. A statistically significant difference was detected for 
fibrinogen.  
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Figure 5.11 Changes in Adult Growth Hormone Deficiency Assessment 
(AGHDA) In Response To Increased Dose Pegvisomant 
The following graph reflects the change in the AGHDA quality of life questionnaire 
score in response to the increased pegvisomant dose and consequent reduction in 
GH activity. These were measured for each patient at baseline on maintenance 
dose pegvisomant and again after 12 weeks on the increased trial dose; each line 
on the graph corresponds to an individual patient’s data. 
No statistically significant difference was detected between baseline and on the trial 
dose of pegvisomant.  
199 
Figure 5.11 Changes in Adult Growth Hormone Deficiency Assessment 
(AGHDA) In Response To Increased Dose Pegvisomant 
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Figure 5.12 Changes in AcroQoL In Response To Increased Dose 
Pegvisomant 
The following graph reflects the change in the AcroQoL quality of life questionnaire 
score in response to the increased pegvisomant dose and consequent reduction in 
GH activity. These were measured for each patient at baseline on maintenance 
dose pegvisomant and again after 12 weeks on the increased trial dose; each line 
on the graph corresponds to an individual patient’s data. 
No statistically significant difference was detected between baseline and on the trial 
dose of pegvisomant.  
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Figure 5.12 
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Figure 5.13 Change in EuroQoL Visual Analogue score In Response To 
Increased Dose Pegvisomant 
The following graph reflects the change in the EuroQoL quality of life questionnaire 
score in response to the increased pegvisomant dose and consequent reduction in 
GH activity. These were measured for each patient at baseline on maintenance 
dose pegvisomant and again after 12 weeks on the increased trial dose; each line 
on the graph corresponds to an individual patient’s data. 
No statistically significant difference was detected between baseline and on the trial 
dose of pegvisomant.  
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Figure 5.13 
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Figure 5.14 Plot of the Results for Fasting plasma glucose against IGF-I  
This graph shows the plot of the log [fasting plasma glucose] results taken at the 
start of the trial on maintenance pegvisomant dose and at the end of the trial on an 
increased dose against log [IGF-I %ULN] . Log transformation was necessary to 
form a straight line relationship and the regression line is shown. The dotted lines(  ) 
demonstrate the mean +/- 1.96x SD for baseline FPG results. The dashed lines(    ) 
demonstrate the mean +/- 1.96x SD for the final FPG results.  
The intention of the study was to render patients mildly GH deficient in order to 
investigate the effect on metabolic markers such as FPG to try to narrow the range 
of IGF-I as a guide for treatment, by calculating the difference between mean +/- 
1.96 x standard deviation on the samples at baseline and at trial end. Unexpectedly 
even in spite of maximal doses of pegvisomant the majority of the cohort failed to 
lower their IGF-I levels sufficiently, thereby resulting in a significant overlap in 
metabolic marker results such as FPG. This overlap of results prevents the 
calculation of the “safe range” of IGF-I.  
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Figure 5.14 Plot of the Results for Fasting plasma glucose against IGF-I  
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5.5 Discussion 
Pegvisomant is well established as a medical therapy for patients with acromegaly 
whose disease is refractory to conventional therapies, but its clinical use is made 
difficult by the lack of a robust method for monitoring treatment. Although serum 
IGF-I serves as a marker of GH activity, variability in the assay and known 
discordance between GH and IGF-I levels limit its reliability. The original purpose of 
this study was to investigate, using biological parameters relevant to the GH/IGF-I 
system, whether there is an ‘optimum part of the age-adjusted IGF-I reference 
range within which clinicians can be confident that patients are not either over- or 
under-treated.  
The main conclusion of this study was the unexpected finding that even with 
maximal increases in pegvisomant dose it was difficult to reduce serum IGF-I to 
levels below the reference range. This observation hampered the planned statistical 
analyses but did provide an interesting insight into the pharmacological properties of 
pegvisomant.  
 
Summary of Results  
Response to Pegvisomant Dose Titration 
The cohort of nine patients underwent a scheduled dose titration whereby doses 
were increased by 2 to 4.6 fold. Only three patients achieved a target IGF-I of below 
the age-related reference range, all of whom were female and two of whom were 
postmenopausal, suggesting that this observation is unlikely to be an oestrogen 
effect. Previous data suggests that increased body mass is associated with 
increased pegvisomant clearance; to test this hypothesis a regression analysis of 
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ΔIGF-I was performed to investigate the effects of body weight, gender and 
pegvisomant dose. None of these factors were found to have a significant effect on 
ΔIGF-I.  
It should be noted that although six patients failed to achieve the target IGF-I of 
below the normal reference range, all patients achieved a reduction in serum IGF-I 
of between 26.7 and 66.4%. Those who failed to reach the target range had higher 
starting values and so had further to fall; it is possible that further increases in 
pegvisomant doses may have been able to achieve the desired subnormal serum 
IGF-I, but a lack of safety data regarding the use of higher daily doses constrained 
the protocol design. It should also be noted that although all patients prior to 
enrolment had serum IGF-I levels within the normal range, values at 
commencement of the dose titration protocol were actually above the normal 
reference range for three patients. Although they subsequently achieved between 
44 - 63% reductions in IGF-I, they required a far larger drop in order to achieve 
target IGF-I.  
 
Effect of Pegvisomant on Physiological Markers of GH activity  
Due to the lack of overt ‘pharmacological’ GH deficiency (arbitrarily defined as a 
subnormal serum IGF-I) in the majority of the cohort, the original statistical analyses 
of these results were not possible. All measures assessed are known to be markers 
of GH activity with distinct patterns in relation to both GH excess and deficiency. 
Non-parametric testing confirmed that there was not a statistically significant 
difference between baseline and final results for the majority of the physiological 
markers – presumably due, at least in part, to this difficulty in achieving a sufficiently 
low serum IGF-I.  
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On review of individual results, some marked improvements in metabolic markers 
occurred in response to the reduction in IGF-I. Patient no 6’s fasting insulin level 
decreased from 26miu/l to 9miu/l with a reduction in fasting glucose from 6.5 to 
5mmol/l as a result of reducing serum IGF-I from the upper limit of normal to the 
level of the median for his age related reference range. This emphasises the point 
that a clearer target for treatment is needed in order to minimise risk of excess GH; 
prior to the study he was considered to be on a satisfactory dose of pegvisomant 
but these results suggest it is entirely plausible that values of serum IGF-I that lie 
within a population reference may represent marginal GH excess for an individual 
patient.   
Such exuberant responses were not universal throughout the cohort for each 
measure however, thus accounting for the lack of statistical significance. The quality 
of life questionnaires in particular demonstrated a variety of responses which 
emphasise the potential for bias. It is not possible to remove the influence of an 
individual’s personality when using these quality of life scores. For example one 
patient scored 23/25 on AGHDA questionnaires both at baseline and at the end of 
the study; no change was evident despite the IGF-I level decreasing from above the 
median to a level of GHD (IGF-I 64ng/ml). 
Critique of Work  
The unexpected difficulty in achieving the target IGF-I is a major drawback of this 
study; as such the proposed statistical analyses were not possible. The protocol 
was written using all available pharmacological data from the original pegvisomant 
trials; however the previous studies had not intended to cause GH deficiency and 
therefore the relevant information regarding high dose pegvisomant was not 
available. The study was also limited by the lack of safety and pharmacokinetic data 
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above 50mg; without such data it was not possible to obtain the necessary approval 
to use higher doses for the purpose of a study.  
In order to fully answer the study question of identifying the optimum serum IGF-I 
range with pegvisomant use, a number of requirements exist. This study design 
largely focused on improving the accuracy of the lower end of the normal IGF-I 
reference range by inducing pharmacological GH deficiency. Ideally the baseline 
investigations would occur at a time of GH excess followed by a period of mild GH 
deficiency in order to narrow the IGF-I range from the top and the bottom. This 
however is not possible in view of the ethical implications of withholding necessary 
treatment for GH excess with the potential for causing significant morbidity. This 
study was also restricted by the limitations on pegvisomant dose; it is possible that 
with further increases in dose all patients may have achieved target IGF-I although 
the lack of safety and pharmacokinetic data in humans above 50mg per day 
precludes this. A larger cohort would also have been preferable although cohort size 
would always be limited by the comparatively small number of patients on 
pegvisomant.  
Other limitations of this work include the reproducibility of some measures. Waist 
hip ratio in particular is subject to error even when performed by the same 
investigator. Quality of life questionnaires are subject to influence by an individual’s 
personality and judgement of their own symptoms; a more stoic individual tends to 
score lower marks than a person with depression and yet there is no method for 
correcting for this when analysing results. The duration of this study also influenced 
results, particularly as the dose titration phase took considerably longer than 
expected, there was up to 22 weeks between baseline and final assessments which 
had potential implications for the results. One outlier is evident in the fasting plasma 
glucose levels; results increased from 5.6 to 7.9mmol/l despite the reduction in GH 
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activity; this suggests that lifestyle factors perhaps influenced by the duration of the 
study affected this individual’s insulin resistance.   
 
Consideration of these data in the context of the Published Literature 
No previous studies have sought to answer the question of identifying the optimal 
serum IGF-I for acromegalic patients treated with pegvisomant. Furthermore no 
previous studies have aimed to induce GH deficiency with pegvisomant or have 
used such high doses for an extended period of time.  
There is a report of an accidental pegvisomant overdose; 80mg daily was taken for 
seven days instead of 80mg per week. The only symptom reported was slight 
increase in fatigue and the serum IGF-I decreased from 940ng/m to 153ng/ml (this 
measurement was taken after 4 weeks on the increased dose) (Pegvisomant 
Investigator’s Brochure).  
 
Future work  
The experience gained from this study has given a further insight into the properties 
of pegvisomant that encourage further investigation. In order to further investigate 
the optimum IGF-I range ideally further studies would be undertaken using higher 
pegvisomant doses and in particular to perform more detailed pharmacokinetic 
studies of high dose pegvisomant. Previous data assumes a linear dose response 
relationship but this is based primarily on doses of 10-20mg per day.  
It would also be preferable to perform the study prospectively with the baseline data 
taken prior to the commencement of pegvisomant, when IGF-I levels for the whole 
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cohort were high. This would allow a more robust analysis of the data with a clearer 
identification of the optimum IGF-I range rather than focusing primarily on the lower 
end of the normal reference range. The feasibility of such a study would however be 
limited by ethical considerations and the necessary time to recruit patients at a time 
of GH excess prior to commencement of pegvisomant. 
The variability in achieving target IGF-I highlights the need for further studies into 
variability in pegvisomant responsiveness; factors such as heterogeneity in the GH 
receptor and variation in serum pegvisomant levels, in particular pegvisomant 
clearance in relation to body mass would be of interest.  
 
Summary and Conclusion 
Although the difficulty in achieving the target serum IGF-I in the cohort and to 
therefore perform the necessary statistical analyses was disappointing, this study 
has instead revealed the unpredicted difficulty in achieving sub-normal IGF-I levels 
with pegvisomant. Such information is of interest to the clinician; it does provide 
some reassurance that it is surprisingly difficult to over-treat a patient with 
pegvisomant. It has also highlighted the variability that is seen with pegvisomant 
levels and raises questions over what is underlying this variability in response. 
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Chapter 6  
 
Final Discussion 
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Clinical endocrine practice frequently involves ‘fine tuning’ therapy according to an 
individual patient’s needs. Hormonal assays can be useful in this regard. In primary 
and secondary adrenal failure, for example, measurements of serum cortisol (a 
reasonably robust assay in most hospital laboratories) may aid clinical decisions 
regarding glucocorticoid dosing. Similarly, measurements of serum testosterone are 
a useful adjunct to reported symptoms when deciding on a male patient’s 
replacement regimen for primary or secondary hypogonadism. In disorders of the 
GH/IGF-I axis, clinical decision making can sometimes be difficult. Clear 
epidemiological data exist that provide ‘target’ ranges for GH and IGF-I in the 
treatment of acromegaly, but what should the physician advise if the values in an 
individual are discordant? 
This thesis has attempted to explore various aspects of variability in GH signal 
transduction into IGF-I that remain poorly understood. An improved understanding 
of the underlying mechanisms may help with clinical decision making and has the 
potential for tailoring clinical treatment to the individual.  
The obvious candidate is variability in the GH receptor; the exon 3 deletion within 
the GHR has been extensively investigated in paediatric and adult populations but 
without conclusive evidence for or against a significant role in GH responsiveness. 
The majority of previously published studies combined d3-GHR homo and 
heterozygotes for analysis; it is possible that this was responsible for masking the 
true effect of this polymorphism. Furthermore, the majority of previously published 
studies did not perform the repeat PCR analysis to exclude the possible 
misclassification of d3-GHR heterozygotes as homozygotes. The studies of GHD 
and acromegalic patients within this thesis aimed to definitely answer the question 
of whether the d3-GHR polymorphism significantly influences GH signal 
transduction into IGF-I.  
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Detailed analyses of large cohorts of 194 GHD patients and 79 acromegalic patients 
were performed, separately analysing d3 homo- and heterozygotes and ensuring 
the extra PCR was performed. Despite these extra measures to improve the 
sensitivity of these studies to detect a difference in GH responsiveness, the 
possession of one or more d3-GHR allele was not found to significantly augment 
GH response. In the GHD population, only a marginal difference was detected in 
ΔIGF-I at 12 months, with no difference detected at 6 months or in rhGH dose used. 
The potential benefit of identifying GH responsiveness factors would be to provide a 
more tailored approach to treatment. These data suggest that it is not something 
that is of clinical relevance. 
In the acromegalic population, neither d3-GHR homo nor heterozygosity was found 
to have a significant effect on the relationship between GH and IGF-I. Again this 
would suggest that GHR variability is not something that needs to be factored into 
clinical assessment or decision making.  
Cumulatively, these results in conjunction with previously published data suggest 
that the d3-GHR polymorphism does not significantly affect GHR signal transduction 
and there is little therapeutic benefit in determining an individual’s d3-GHR status. 
Other factors relevant in determining GH signal transduction into IGF-I must exist 
and further work is needed to identify these. The need for sensitive and reproducible 
markers of GH activity, particularly for the adult population, to complement 
measurements of serum IGF-I is evident. 
The insensitivity of IGF-I as an accurate marker of GH activity is also of particular 
importance with pegvisomant use; this is the sole measure used to guide 
pegvisomant dose. The work within this thesis aimed to identify an optimum range 
of IGF-I within which metabolic parameters returned to normal and provide useful 
information for physicians regarding the avoidance of pharmacological GHD during 
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pegvisomant treatment. Unpredictably, it proved to be difficult to induce 
pharmacological GHD even with maximal doses of pegvisomant. Pegvisomant was 
presumed to have a linear dose response relationship based on original 
pharmacokinetic data using the standard lower therapeutic doses of between 10-
40mg per day. No previous study has ever aimed to induce pharmacological GHD 
or used doses of pegvisomant described here. This work has, for the first time, 
demonstrated the effects of high dose pegvisomant and has shown that there 
appears to be some variability in response to this drug. What is causing this 
variability in pegvisomant responsiveness is not clear; variability within the GH 
receptor is likely to play a part, along with variation in clearance rates related to 
body mass but other potential factors including the role of the growth hormone 
binding protein are of potential relevance. Further studies to determine the 
underlying reasons for variability in pegvisomant responsiveness are warranted.  
 
One of the major problems identified by this thesis is the use of IGF-I as the 
predominant marker of GH activity in the adult population; the wide normal 
reference range, variability in the assay and the impact of factors such as insulin 
resistance and oestrogen on IGF-I generation limit it’s sensitivity and usefulness. To 
allow full, detailed investigation of GH signal transduction of GH into IGF-I, the 
reliability of IGF-I assay needs to improve. This is however a chicken and egg 
situation; without identifying the reasons for the variability in GH signal transduction 
into IGF-I, the sensitivity of IGF-I as a research tool cannot improve. But until either 
the reliability of serum IGF-I improve or an alternate marker is found the variability in 
GH signal transduction into IGF-I cannot be fully and accurately investigated in the 
adult population. Despite massive improvements in assay technology and 
216 
availability, the practice of clinical endocrinology still requires a substantial amount 
of clinical judgement. 
 
Future Work  
The underlying reasons for variability in GH responsiveness remain unresolved and 
more work is needed to identify these in both adult and paediatric populations. The 
exon 3 deletion has been investigated extensively without a meaningful conclusion; 
this suggests that other, more important factors exist. It is likely that other 
polymorphisms within the GH receptor although, to the author’s knowledge, to date 
none have been discovered. Future work should initially focus on the -202 A 
polymorphism of IGFBP3; there is evidence within the paediatric population that this 
enhances IGFBP3 levels and growth velocity (Costalonga, Antonini et al. 2009). A 
more recent study however, has showed that there was no effect on final height 
achieved by 178 subjects with severe GH deficiency in childhood compared with a 
control group(Miletta, Scheidegger et al. 2012). The effect of this polymorphism 
within adult populations has not yet been investigated; this will form the focus of 
future studies into GH responsiveness. Although, as noted previously, further work 
on the sensitivity of the IGF-I assay is also needed to optimise our abilities to detect 
subtle changes in GH responsiveness.  
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Patient Information Sheet 
 
Effect of Growth Hormone Genotype on Growth Hormone responsiveness in 
patients with Growth Hormone Deficiency 
Lay Title: Why do some patients with growth hormone deficiency respond better 
than others to growth hormone replacement? 
 
You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully. Please ask us if 
there is anything that is not clear or if you would like more information. Take time to 
decide whether or not you wish to take part. 
 
Background: 
As you may know, growth hormone is important for adults as well as children as it 
has important effects on the body including cholesterol levels, sense of well-being 
and fat distribution. When patients are lacking in growth hormone we aim to replace 
it with daily injections of growth hormone. When we replace growth hormone it is 
important that we closely monitor treatment to ensure we achieve our target, but 
also to ensure we do not give too high a dose as this may cause different types of 
problems. We do this by checking the level of a hormone called IGF1; this is 
produced by the liver in response to growth hormone. When patients are deficient in 
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growth hormone their IGF1 levels are usually low and when patients have too much 
growth hormone their IGF1 levels are usually high.  
Our department has a lot of experience in treating patients with growth hormone 
and we have noticed that the doses required to achieve the target normal IGF1 level 
varies considerably between patients and we do not know why. We would like to 
investigate the possible reasons for this, so that we can learn how to select the best 
dose of growth hormone for each patient. We believe that the likely cause for this 
variability is the growth hormone receptor. A hormone acting through a receptor is 
rather like a key fitting into a lock: the key has to be a good fit for it to work. A recent 
study in children has suggested that different people may have slightly different 
growth hormone receptors on their cells. Growth hormone fits into these different 
receptors slightly differently and this appears to explain why some short children 
who are treated with growth hormone grow more than others.  It is possible that the 
same differences in the growth hormone receptor are the explanation for the 
differences in adult patients’ response to growth hormone.  
 
What it involves:  
When you have your next routine blood test on Francis Fraser ward, we would like 
to take an extra 10mls (1 tablespoon) of blood so that we can test it and see which 
type of growth hormone receptor you have. This is done by looking at the part of 
your DNA that is responsible for the growth hormone receptor. DNA is the genetic 
material within the cell and is divided into functional units called genes which carry 
the instructions for making up the body. Each gene relates to a specific part of the 
body and we are only interested in the genes responsible for the growth hormone 
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receptor, we will not be looking at the genes responsible for any other disease. This 
blood test is your only direct involvement in this study.  
We already have very clear records in your notes of the other information we need. 
In particular we will be looking at the dose of growth hormone you require and how 
your IGF1 level has changed on treatment. We will also be looking at the other 
measurements that we regularly record as part of the monitoring of your treatment; 
cholesterol levels, waist:hip ratio, and how your quality of life score has improved on 
treatment. We will also be looking at whether previous treatment such as pituitary 
radiotherapy and the presence or absence of oestrogen (i.e. whether you are male 
or female) has an effect on your results. All of this data is already in your notes and 
so will not be repeated for the study.  
 
Do I have to take part?  
Participation in the study is entirely voluntary; it is up to you to decide whether or not 
to take part.  If you do, you will be given this information sheet to keep and be asked 
to sign a consent form. You are still free to withdraw at any time and without giving a 
reason.  A decision to withdraw at any time, or a decision not to take part, will not 
affect the standard of care you receive. Any stored blood or tissue samples that can 
still be identified as yours will be destroyed on completion of the study. 
What will happen if you take part? 
We will need to arrange to meet in order for the consent form to be signed and any 
additional questions may be asked. We will then make arrangements for your blood 
test to be taken when you next attend our department. No further direct involvement 
is needed from you, all other results have already been documented in your notes 
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since you commenced on GH. Your clinical care will continue within the Department 
of Endocrinology at St. Bartholomew’s Hospital.  
What are the other possible disadvantages and risks of taking part? 
Other than the discomfort of having a blood test (which will be taken at the time of a 
routine blood test anyway) we do not perceive there to be any other risks or 
disadvantages to the participants. Genetic analysis for the DNA responsible for the 
GH receptor will not affect your ability to obtain life or medical insurance, but if you 
do experience any problems as a result of this study, the insurance company may 
contact the research team for verification.  
Possible benefits of participation 
We cannot promise the study will help you but the information we get might help 
improve the treatment of people with growth hormone deficiency in the future.  
Results 
We plan to publish the results of this study in a medical journal and as part of an MD 
thesis in due course. No identifiable patient details will be included in any 
publication (i.e. no names, date of birth etc) unless prior consent from each patient 
has been obtained.  
This study is being funded by Ipsen, a pharmaceutical company who make one 
particular brand of GH. They are interested in the results of this study as it will 
improve the general understanding of GH replacement. As a result of this 
sponsorship they will have access to our study data and results, but they will not 
have access to any of your personal details. The study has been designed and will 
be run entirely by doctors working in the Department of Endocrinology at Barts and 
the London Trust. 
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What happens to the blood samples?  
We will extract your DNA and analyse the part responsible for the GH receptor. If 
the results of the study do not explain why there is such variability in growth 
hormone response we may wish to test other genes that may provide the answer 
during the course of this study. No analysis of your DNA will take place that is not 
related to how growth hormone signals into IGF-I. Once the study has completed, 
we will destroy all samples. 
What happens to all data? 
The required clinical data (blood results etc) will be obtained from your hospital 
notes and all data will be stored in a file within a Barts and the London trust 
computer that will only be accessible by members of the research team.  
If you join the study, some parts of your medical records and the data collected for 
the study may be looked at by representatives of regulatory authorities and by 
authorised people from Barts and the London Trust, other NHS bodies to check that 
the study is being carried out correctly. All will have a duty of confidentiality to you 
as a research participant and nothing that could reveal your identity will be disclosed 
outside the research site.  
All information which is collected about you during the course of the research will be 
kept strictly confidential.  If you consent to take part in the research the people 
conducting the study will abide by the Data Protection Act 1998, and the rights you 
have under this Act.   
With your consent we will inform your GP of your participation in this study but 
specific details regarding your results will not be disclosed without your consent.  
What happens if there is a problem? 
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We would not expect you to suffer any harm or injury because of your participation 
in it.  If you are harmed by taking part in this study, there is no special compensation 
arrangement. If you are harmed due to someone’s negligence, then you may have 
grounds for legal action but you may have to pay your legal costs. Regardless of 
this, if you wish to complain or have any concerns about any aspect of the way you 
have been approached or treated during the course of this study, the normal 
National Health Service complaints mechanisms should be available to you.  
Please contact Patient Advisory Liaison Service (PALS) if you have 
any concerns regarding the care you have received, or as an initial point of 
contact if you have a complaint.  Please telephone 020 7377 6335, minicom 020 
7943 1350, or email pals@bartsandthelondon.nhs.uk, you can also visit PALS by 
asking at any hospital reception. 
What if relevant new information becomes available?   
Sometimes during the course of a research project, new information becomes 
available about the treatment/drug that is being studied.  If this happens, your 
research doctor will tell you about it and discuss whether you want to or should 
continue in the study.  If you decide not to carry on, your research doctor will make 
arrangements for your care to continue.  If you decide to continue in the study you 
will be asked to sign an updated consent form. Also, on receiving new information 
your research doctor might consider it to be in your best interests to withdraw you 
from the study.  He/she will explain the reasons and arrange for your care to 
continue. If the study is stopped for any other reason, you will be told why and your 
continuing care will be arranged. 
 
What happens when the research study stops? 
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You will continue to receive your usual care at the endocrinology department at St 
Bartholomew's Hospital throughout the course of this study and after it concludes.  
What if there is a problem and Contact Details for further information 
Further details can be obtained from: 
Dr V Moyes or Dr W Drake 
Department of Endocrinology 
St Bartholomew's Hospital 
West Smithfield 
London EC1A 7BE 
0207 601 8346 or via Barts and the London switchboard 0207 377 7000 
email: veronica.moyes@bartsandthelondon.nhs.uk 
Who is organising and funding the research and where was it reviewed?   
This project has been organised by Dr WM Drake with Ipsen Ltd and has been peer 
reviewed. This study was given a favourable ethical opinion for conduct in the NHS 
by the East London and City REC
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CONSENT FORM  (Version 3  Dated 18/10/2007) 
 
Effect of Growth Hormone Genotype on Growth Hormone responsiveness in patients 
with Growth Hormone Deficiency   
 
 
 
 
 
Investigator:  Dr WM Drake, Dr VJ Moyes 
Centre Number:     Patient Identification Number for this trial: 
 
                                                                 Please initial 
box to indicate agreement 
 
 
1. 
I confirm that I have read and understand the information sheet: Effect of 
Growth Hormone Genotype on Growth Hormone responsiveness in patients 
with Growth Hormone Deficiency, dated 18/10/7 (version 7) for the above 
study. I have had the opportunity to consider the information, ask questions 
and have had these answered satisfactorily. 
 
 
2. 
I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my medical care or legal rights  
being affected. 
 
 
3. 
I understand that relevant sections of any of my medical notes and data 
collected during the study may be looked at by responsible individuals from 
regulatory authorities or from the Barts and the London/ Queen Mary 
University of London, where it is relevant to my taking part in this research.  I 
give permission for these individuals to have access to my records.  
 
4. I agree to my GP being informed of my participation in the study. 
 
 
5. I agree to take part in the above study. 
 
 
6. I understand that my blood sample will be destroyed on completion of the 
study.  
 
 
 
________________________ ________________                _________________ 
Name of Patient Date Signature 
 
_________________________ ________________                _________________ 
Name of Person taking consent Date Signature 
(if different from Investigator) 
 
_________________________ ________________                _________________ 
Investigator Date  Signature 
 
 
1 copy for Patient, 1 for Investigator and original to be kept in medical notes
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Patient Information Sheet 
 
Effect of Growth Hormone Genotype on Growth Hormone responsiveness in 
patients with Acromegaly 
Lay Title: Why do some patients with growth hormone excess (acromegaly) need 
more therapy than others to achieve their target blood tests? 
 
You are being invited to take part in a research study.  Before you decide it is 
important for you to understand why the research is being done and what it will 
involve.  Please take time to read the following information carefully. Please ask us 
if there is anything that is not clear or if you would like more information.  Take time 
to decide whether or not you wish to take part. 
What is the purpose of our study? 
In adults, too much growth hormone causes a condition called acromegaly, which 
leads to unpleasant symptoms including sweating, joint pain and fatigue and 
overgrowth of soft tissues. When doctors are diagnosing and assessing 
acromegaly, they usually measure two blood tests: the level of growth hormone and 
also the level of insulin-like growth factor I (IGF-I). Growth hormone triggers the 
production of IGF-I and so in general the more growth hormone there is in the 
bloodstream the more IGF-I will be made and the worse a patient’s symptoms will 
be.  Previous studies have shown that for most patients there is a direct relationship 
between level of growth hormone and level of IGF1, however in about 1/3 of 
patients there is no clear correlation. This can work both ways, for some patients the 
IGF-I level is lower than expected for the amount of growth hormone whilst for other 
patients rather low growth hormone levels are associated with a high IGF-I. We 
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would like to understand why this happens as it will help us to be more accurate 
when we treat patients with acromegaly.  
Growth hormone, like all hormones, is a chemical messenger and it has its effect by 
fitting into the growth hormone receptor which is present on virtually all cells of the 
body. A hormone acting through a receptor is rather like a key fitting into a lock: the 
key has to be a good fit for it to work. A recent study in children has suggested that 
different people may have slightly different growth hormone receptors on their cells. 
Growth hormone fits into these different receptors slightly differently and this 
appears to explain why some short children who are treated with growth hormone, 
grow more than others.  It is possible that the same differences in the growth 
hormone receptor form part of the explanation as to the discrepancy between 
growth hormone and IGF1 levels in some patients with acromegaly.  
What it involves:  
When you have your next routine blood test on Francis Fraser ward, we would like 
to take an extra 10mls (1 tablespoon) of blood so that we can test it and see which 
type of growth hormone receptor you have. This is done by looking at the part of 
your DNA that is responsible for the growth hormone receptor. DNA is the genetic 
material within the cell and is divided into functional units called genes which carry 
the instructions for making up the body. Each gene relates to a specific part of the 
body and we are only interested in the genes responsible for the growth hormone 
receptor, we will not be looking at the genes responsible for any other disease. This 
blood test is your only direct involvement in this study. We already have very clear 
records in your notes of the other information we need. In particular we will be 
looking at your growth hormone levels and IGF1 results, all of which is already 
documented in your notes. We will also collect data regarding your cholesterol and 
insulin levels, which is also documented within your notes.  
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 Do you have to take part? 
Participation in the study is entirely voluntary; it is up to you to decide whether or not 
to take part.  If you do, you will be given this information sheet to keep and be asked 
to sign a consent form. You are still free to withdraw at any time and without giving a 
reason.  A decision to withdraw at any time, or a decision not to take part, will not 
affect the standard of care you receive.  
You can withdraw from treatment but keep in contact with us to let us know your 
progress.  Information collected may still be used.  Any stored blood or tissue 
samples that can still be identified as yours will be destroyed on completion of the 
study. 
What will happen if you take part? 
We will need to arrange to meet in order for the consent form to be signed and any 
additional questions may be asked. We will then co-ordinate the additional blood 
tests to be withdrawn at the time of your next routine blood test on Francis Fraser 
ward. We also obtain results of fasting glucose and insulin (can be from previous 
blood tests if results available) and markers of body composition.  
Your clinical care will continue as usual within the Department of Endocrinology at 
St. Bartholomew’s Hospital.  
Possible benefits of participation 
We cannot promise the study will help you but the information we get might help 
improve the treatment of people with acromegaly in the future.  
What are the other possible disadvantages and risks of taking part? 
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Other than the discomfort of having a blood test (which will be taken at the time of a 
routine blood test anyway) we do not perceive there to be any other risks or 
disadvantages to the participants. Genetic analysis for the DNA responsible for the 
GH receptor will not affect your ability to obtain life or medical insurance, but if you 
do experience any problems as a result of this study the insurance company may 
contact our research team for verification.  
Results 
We plan to publish the results of this study in a medical journal and as part of an MD 
thesis in due course. No identifiable patient details will be included in any 
publication (ie names, date of birth etc) unless prior consent from each patient has 
been obtained.  
This study is being funded by Ipsen, a pharmaceutical company who make one of 
the medical treatments available for the treatment of acromegaly. As a result of this 
sponsorship they will have access to our study data and results, but they will not 
have access to any of your personal details. The study has been designed and will 
be run entirely by doctors working in the Department of Endocrinology at Barts and 
the London Trust. 
What happens when the research study stops? 
You will continue to receive your usual care at the endocrinology department at St 
Bartholomew's Hospital throughout the course of this study and after it concludes.  
What happens to the blood samples?  
We will extract your DNA and analyse the part responsible for the GH receptor. If 
the results of this study do not explain why growth hormone and IGF-I levels are 
discrepant in some patients, we may wish to test other genes that may provide the 
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answer, during the course of this study. No analysis of your DNA will take place that 
is not related to how growth hormone signals into IGF-I. Once the study has 
completed, we will destroy all samples.  
What happens to all data? 
The required clinical data (blood results etc) will be obtained from your hospital 
notes and all data will be stored in a file within a Barts and the London trust 
computer that will only be accessible by members of the research team.  
If you join the study, some parts of your medical records and the data collected for 
the study may be looked at by representatives of regulatory authorities and by 
authorised people from Barts and the London Trust, other NHS bodies to check that 
the study is being carried out correctly. All will have a duty of confidentiality to you 
as a research participant and nothing that could reveal your identity will be disclosed 
outside the research site. 
All information which is collected about you during the course of the research will be 
kept strictly confidential.  If you consent to take part in the research the people 
conducting the study will abide by the Data Protection Act 1998, and the rights you 
have under this Act.   
With your consent, we will inform your GP of your participation in this study but 
specific details regarding your results will not be disclosed without your consent.  
What happens if there is a problem? 
We would not expect you to suffer any harm or injury because of your participation 
in it.  If you are harmed by taking part in this study, there is no special compensation 
arrangement. If you are harmed due to someone’s negligence, then you may have 
grounds for legal action but you may have to pay your legal costs. Regardless of 
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this, if you wish to complain or have any concerns about any aspect of the way you 
have been approached or treated during the course of this study, the normal 
National Health Service complaints mechanisms should be available to you.  
Please contact Patient Advisory Liaison Service (PALS) if you have 
any concerns regarding the care you have received, or as an initial point of 
contact if you have a complaint.  Please telephone 020 7377 6335, minicom 020 
7943 1350, or email pals@bartsandthelondon.nhs.uk, you can also visit PALS by 
asking at any hospital reception. 
 
What if relevant new information becomes available?   
Sometimes during the course of a research project, new information becomes 
available about the treatment/drug that is being studied. If this happens, your 
research doctor will tell you about it and discuss whether you want to or should 
continue in the study.  If you decide not to carry on, your research doctor will make 
arrangements for your care to continue.  If you decide to continue in the study you 
will be asked to sign an updated consent form. Also, on receiving new information 
your research doctor might consider it to be in your best interests to withdraw you 
from the study.  He/she will explain the reasons and arrange for your care to 
continue. If the study is stopped for any other reason, you will be told why and your 
continuing care will be arranged. 
 
What if there is a problem and Contact Details for further information 
Further details can be obtained from: 
Dr V Moyes or Dr W Drake 
Department of Endocrinology, 
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St Bartholomew's Hospital 
West Smithfield 
London EC1A 7BE 
0207 601 7706 or via Barts and the London switchboard on 0207 377 7000  
email: veronica.moyes@bartsandthelondon.nhs.uk 
Who is organising and funding the research and where was it reviewed?   
This project has been organised by Dr WM Drake with Ipsen Ltd and has been peer 
reviewed. This study was given a favourable ethical opinion for conduct in the NHS 
by the East London and City REC
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CONSENT FORM  (Version 3  Dated 18/10/2007) 
 
Effect of Growth Hormone Genotype on Growth Hormone responsiveness in patients 
with Acromegaly  
 
 
 
 
 
Investigator:  Dr WM Drake, Dr VJ Moyes 
Centre Number:     Patient Identification Number for this trial: 
 
                                                              Please initial box 
to indicate agreement 
 
 
1. 
I confirm that I have read and understand the information sheet: Effect of 
Growth Hormone Genotype on Growth Hormone responsiveness in patients 
with Acromegaly, dated 18/10/7 (version 7) for the above study. I have had 
the opportunity to consider the information, ask questions and have had these 
answered satisfactorily. 
 
 
2. 
I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my medical care or legal rights  
being affected. 
 
 
3. 
I understand that relevant sections of any of my medical notes and data 
collected during the study may be looked at by responsible individuals from 
regulatory authorities or from the Barts and the London/ Queen Mary 
University of London, where it is relevant to my taking part in this research.  I 
give permission for these individuals to have access to my records.  
 
4. I agree to my GP being informed of my participation in the study. 
 
 
5. I agree to take part in the above study. 
 
 
6. I understand that my blood sample will be destroyed on completion of the 
study.  
 
 
 
 
________________________ ________________              __________________ 
Name of Patient Date Signature 
 
_________________________ ________________                ________________     
Name of Person taking consent Date Signature 
(if different from Investigator) 
 
_________________________ ________________              ________________ 
Investigator Date  Signature 
 
 
1 copy for Patient, 1 for Investigator and original to be kept in medical notes 
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      
Patient Information Sheet 
A Study to Determine the Optimum Serum IGF-I Range in Patients with 
Acromegaly Treated with Pegvisomant. 
You are being invited to take part in a research study.  Before you decide it is 
important for you to understand why the research is being done and what it will 
involve.  Please take time to read the following information carefully. Please ask us 
if there is anything that is not clear or if you would like more information.  Take time 
to decide whether or not you wish to take part. 
 
What is the purpose of our study? 
Pegvisomant is a relatively new drug and as a result of the way it works, the only 
way we can monitor treatment with pegvisomant is with the IGF1 level- a blood test 
that acts as a marker of growth hormone activity. Growth hormone levels cannot be 
measured as pegvisomant is a similar shape to growth hormone and so it is not 
possible to discriminate between the two with the current biochemical tests. We 
know from patients with acromegaly and also those with growth hormone deficiency, 
that IGF1 levels are not completely reliable in a proportion of patients. Monitoring of 
treatment with pegvisomant can therefore be difficult and there is a possibility that 
there are some patients on pegvisomant who are either under- or over-treated as a 
result of this. We would like to involve you in a study that will help us to understand 
what levels of IGF1 we should be aiming for to ensure that all patients are receiving 
just the right amount of pegvisomant. If we can work out the best levels to be aiming 
for this will not only help us but also will act as a guide for other doctors looking after 
patients on pegvisomant.  
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What it involves:  
If you agree to participate in the study we will meet in person to discuss any queries 
you may have and you will need to sign a consent form.  
In order for you to participate in this study, it is a requirement that you are already 
on a stable dose of pegvisomant. At the start of the study we will perform a number 
of assessments that demonstrate various aspects of your metabolism whilst on your 
usual dose of pegvisomant. These are: 
 Blood tests: 2 single blood tests and a series of 5 blood samples performed 
over 3 hours to measure your response to glucose and/or insulin. The total 
amount of blood taken during these tests is approximately 20-30mls, 
equivalent to 2 tablespoons of blood. 
 24 hour urine collection to measure substances called cortisone/cortisol, the 
balance of which is partly regulated by GH and IGF1 levels 
 Further measurements of IGF-I, two weeks after each change in dose of 
pegvisomant, until you reach the target level.  
 Body composition assessments with measurements of your waist and hips 
and by performing a DEXA scan that helps to determine your body 
composition.  
 Quality of life questionnaires  
 
Your dose of pegvisomant will then be increased (on average by 10-15mg) in order 
to slightly over-treat you. We will measure your IGF1 level (5ml blood test) that acts 
as a marker of the activity of your acromegaly and we are aiming for just below the 
normal range. Once we have achieved a suitable IGF1 level, we will continue this 
dose for 12 weeks and at the end of this time we will repeat the above 
measurements. By determining how the above measurements change and pin-
pointing when they change in relation to your IGF1 level, we will be able to 
determine the optimal range of IGF1 that we should be aiming for in the treatment 
with pegvisomant.  
Do you have to take part? 
253 
Participation in the study is entirely voluntary; it is up to you to decide whether or not 
to take part.  If you do, you will be given this information sheet to keep and be asked 
to sign a consent form. You are still free to withdraw at any time and without giving a 
reason. Information collected may still be used. A decision to withdraw at any time, 
or a decision not to take part, will not affect the standard of care you receive.  
 
Results 
We plan to publish the results of this study in a medical journal and as part of an MD 
thesis in due course. No identifiable patient details will be included in any 
publication (i.e. names, date of birth etc) unless prior consent from each patient has 
been obtained.  
Pfizer, the pharmaceutical company who make pegvisomant are providing funding 
for this study. As a result of this sponsorship they will have access to our study data 
and results, but they will not have access to any of your personal details. The study 
has been designed and will be run entirely by doctors working in the Department of 
Endocrinology at St. Bartholomew’s Hospital.  
Possible benefits of participation 
We cannot promise the study will help you but the information we get might help 
improve the treatment of people with acromegaly in the future.  
What are the other possible disadvantages and risks of taking part? 
This study will involve injecting larger doses of pegvisomant than you normally take, 
and so this may require more than one injection per day. There is a possibility that 
during the study, you may experience worsening of any side effects you currently 
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have with pegvisomant, or may develop new side effects. Potential side effects from 
pegvisomant use include diarrhoea or constipation, nausea, headaches and 
dizziness. It may also affect your glucose levels and if you are diabetic you may 
require less diabetes medication; we will regularly review this during the study. More 
severe side effects that have been reported are rare but include abnormal liver 
tests, although in all patients who have experienced this, liver tests have returned to 
normal once the pegvisomant has stopped. We will therefore have to monitor your 
liver tests during the study.  
Studies of pegvisomant have included some patients taking higher doses (more 
than 30mg per day) and there is no evidence that a higher dose increases the risk 
of side effects. If you do develop any symptoms such as fatigue whilst on the higher 
dose, please inform us straight away and you may need to withdraw from the study.  
Also the purpose of the study is to slightly over-treat you with pegvisomant and so 
we will be intentionally lowering your IGF1 level to below the normal range. As this 
study only lasts for 12 weeks and as we are only aiming for IGF1 levels which are 
just below the normal range, we would not expect to cause any symptoms of growth 
hormone deficiency. Symptoms tend to only occur when growth hormone deficiency 
is severe and include tiredness and lack of motivation.  
If you notice any new symptoms during the course of this study please inform your 
study doctor. If any symptoms or problems arise which are considered to be 
serious, this will be reported as per standard practice to the Medicines and Health 
Regulatory Agency.  
We will also be performing DEXA scans to monitor your body composition at the 
start and at the end of the study. These involve a low level of radiation, equivalent to 
the level you would be exposed to during a 2 hour short haul flight.  
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What happens when the research study stops? 
You will continue to receive your usual care at the endocrinology department at St 
Bartholomew's Hospital throughout the course of this study and after it concludes.  
What happens to the blood samples?  
The required tests will be performed within the biochemistry laboratory. After the 
completion of the study, the samples will be destroyed. 
What happens to all data? 
All data from this study will be stored in a file within a Barts and the London trust 
computer that will only be accessible by members of the research team.  
If you join the study, some parts of your medical records and the data collected for 
the study may be looked at by representatives of regulatory authorities and by 
authorised people from Barts and the London Trust, other NHS bodies to check that 
the study is being carried out correctly. All will have a duty of confidentiality to you 
as a research participant and nothing that could reveal your identity will be disclosed 
outside the research site. 
All information which is collected about you during the course of the research will be 
kept strictly confidential. If you consent to take part in the research the people 
conducting the study will abide by the Data Protection Act 1998, and the rights you 
have under this Act.   
With your consent, we will inform your GP of your participation in this study but 
specific details regarding your results will not be disclosed without your consent.  
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What if relevant new information becomes available?   
Sometimes during the course of a research project, new information becomes 
available about the treatment/drug that is being studied. If this happens, your 
research doctor will tell you about it and discuss whether you want to or should 
continue in the study.  If you decide not to carry on, your research doctor will make 
arrangements for your care to continue.  If you decide to continue in the study you 
will be asked to sign an updated consent form. Also, on receiving new information 
your research doctor might consider it to be in your best interests to withdraw you 
from the study.  He/she will explain the reasons and arrange for your care to 
continue. If the study is stopped for any other reason, you will be told why and your 
continuing care will be arranged. 
What happens if there is a problem? 
We would not expect you to suffer any harm or injury because of your participation 
in it.  If you are harmed by taking part in this study, there is no special compensation 
arrangement. If you are harmed due to someone’s negligence, then you may have 
grounds for legal action but you may have to pay your legal costs. Regardless of 
this, if you wish to complain or have any concerns about any aspect of the way you 
have been approached or treated during the course of this study, the normal 
National Health Service complaints mechanisms should be available to you.  
Please contact Patient Advisory Liaison Service (PALS) if you have 
any concerns regarding the care you have received, or as an initial point of contact if 
you have a complaint.  Please telephone 020 7377 6335, minicom 020 7943 1350, or 
email pals@bartsandthelondon.nhs.uk, you can also visit PALS by asking at any 
hospital reception. 
 
Contact Details for further information 
Further Information can be obtained from: 
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Dr Veronica Moyes  
Dept of Endocrinology,  
St Bartholomew’s Hospital 
West Smithfield, London EC1A 7BE 
Tel: 0207 601 8063    
Email: veronica.moyes@bartsandthelondon.nhs.uk 
 
Who is organising and funding the research and where was it reviewed?   
This project has been organised by Dr WM Drake with Pfizer and has been peer 
reviewed. This study was given a favourable ethical opinion for conduct in the NHS 
by the East London and City REC.
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CONSENT FORM  (Version 1  Dated 15/6/2007) 
 
Title of project:  A Study To Determine The Optimum Serum IGF-I Range In Patients 
With Acromegaly Treated With Pegvisomant.  
 
 
 
 
 
 
Investigator:  Dr WM Drake, Dr VJ Moyes 
Centre Number:     Patient Identification Number for this trial: 
 
                                                                 Please initial 
box to indicate agreement 
 
 
1. 
I confirm that I have read and understand the information sheet 
dated 04/10/07 (version 7) for the above study. I have had the opportunity to 
consider the information, ask questions and have had these answered 
satisfactorily. 
 
 
 
2. 
I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my medical care or legal rights  
being affected. 
 
 
 
3. 
I understand that relevant sections of any of my medical notes and data 
collected during the study, may be looked at by responsible individuals from 
regulatory authorities or from the Barts and the London/ Queen Mary 
University of London, where it is relevant to my taking part in this research.  I 
give permission for these individuals to have access to my records.  
 
 
4. I agree to my GP being informed of my participation in the study. 
 
 
5. I agree to take part in the above study. 
 
 
 
 
 
 
________________________ ________________                _________________ 
Name of Patient Date Signature 
 
 
 
_________________________ ________________                ________________ 
Name Date  Signature 
(if different from Investigator) 
 
 
_________________________ ________________              __________________ 
Investigator Date  Signature 
 
1 copy for Patient, 1 for Investigator and original to be kept in medical notes 
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AcroQoL Questionnaire 
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O R I G I N A L A R T I C L E
d3-GHR genotype does not explain heterogeneity in GH
responsiveness in hypopituitary adults
V. J. Moyes*,†, D. M.Walker*, S. Owusu-Antwi*, K. T. Maher*, L. Metherell†, S. A. Akker*, J. P. Monson*, A. J. L.
Clark† andW.M. Drake*
*Department of Endocrinology, St. Bartholomew’s Hospital and †Centre for Endocrinology, William Harvey Research Institute, Barts and
the London School of Medicine, London, UK
Summary
Objective Heterogeneity in growth hormone (GH) responsive-
ness in adult hypopituitary patients receiving recombinant human
GH (rhGH) is poorly understood; doses vary up to fourfold
between individuals. Deletion of exon 3 in the GH receptor (d3-
GHR) has been linked to enhanced rhGH responsiveness in chil-
dren. We investigated the role of the d3-GHR polymorphism in
determining adult rhGH responsiveness.
Methods One hundred and ninety-four patients treated with an
identical rhGH dosing protocol in a single centre were genotyped
for the d3-GHR, and the results correlated with changes in serum
IGF-I and clinical parameters of GH responsiveness after 6 and
12 months of GH replacement therapy.
Results Allele frequencies for homozygous full length (fl/fl), het-
erozygous d3 (fl/d3) and homozygous d3 (d3/d3) were 52%, 38Æ7%
and 9Æ3%, respectively, and were in Hardy–Weinberg equilibrium.
Baseline IGF-I and DIGF-I at 6 months were comparable between
groups. DIGF-I at 12 months was significantly greater in the d3/d3
group (P = 0Æ028). No difference was detected between fl/d3 and
fl/fl groups. Regression analyses of DIGF-I at 12 months and
DIGF-I/rhGH dose confirmed a significant relationship of d3/d3
genotype on rhGH response. There was no difference between
groups in maintenance rhGH dose between genotypes.
Conclusion Homozygosity for d3-GHR confers a marginal
increase in GH responsiveness at 12 months but without a detect-
able change in maintenance rhGH dose required. Both d3 alleles
are required to achieve this response; given that only 10% of the
population are d3 homozygotes, the d3GHR does not explain the
marked heterogeneity of GH responsiveness in hypopituitary
adults.
(Received 2 March 2009; returned for revision 24 March 2009;
finally revised 25 November 2009; accepted 12 December 2009)
Introduction
Since the original double-blind, placebo-controlled studies of
recombinant human growth hormone (rhGH) treatment for adult
growth hormone deficiency (GHD),1–5 it has become apparent that
doses of rhGH need to be individually tailored to patients to maxi-
mize clinical benefit and minimize the possible risks of prolonged
excess GH exposure.6 Most physicians experienced in the manage-
ment of hypopituitary patients employ a strategy of dose titration,
with monitoring of serum insulin-like growth factor-I (IGF-I), a
GH-dependent peptide, as the main marker of excess dosing. Using
such protocols, it is apparent that individual requirements for
rhGH vary considerably between patients. For example, in a report
of 50 consecutive patients treated with an identical dosing protocol
that aims to maintain serum IGF-I between the median and upper
end of the age-related reference range, median dose requirements
for males and females, respectively, were 0Æ8 IU (range 0Æ4–1Æ6) and
1Æ2 IU (0Æ8–2).7 Oestrogen is known to attenuate IGF-I production
and may partially explain the variability between genders, but this
does not explain why dose requirements vary fourfold and 2Æ5-fold
in male and female groups, respectively.7
The factors responsible for determining individual GH respon-
siveness are currently unknown, but an obvious candidate is the
GH receptor (GHR). The GHR gene is located on the short arm of
chromosome 5 (p13.1-p12) and contains nine coding exons, with
exons 3–7 encoding the extracellular ligand-binding domain.8,9 A
genetic polymorphism exists in the GHR resulting in the deletion
of exon 3 and loss of amino acid residues 7–28; the overall preva-
lence is 25–32% with a homozygosity rate of 9–14%.10,11 The
effects of the loss of these amino acids are unknown; modelling of
the residues by crystallography has been unsuccessful, but it
appears not to influence the binding of GH to the GHR in vitro.12,13
It has been speculated that this region may play a role in the confor-
mational changes during activation of the GHR dimer by GH.11
The presence of one or more d3-GHR alleles has been shown to
accelerate linear growth in children short for gestational age (SGA)
or with idiopathic short stature (ISS) treated with rhGH,11
although subsequent data have been conflicting.14–17 In adults with
GHD, similarly conflicting results exist. In one study of 99 patients,
a greater IGF-I response was demonstrated in subjects carrying at
least one d3 allele after 1 but not 5 years of rhGH treatment.18
Correspondence: Dr W.M. Drake, Department of Endocrinology, King
George V Wing, St. Bartholomew’s Hospital, West Smithfield, London
EC1A 7BE. Tel.: +44 (0) 207 601 8346. E-mail: w.m.drake@qmul.ac.uk
Clinical Endocrinology (2010) 72, 807–813 doi: 10.1111/j.1365-2265.2009.03768.x
 2010 Blackwell Publishing Ltd 807
However, in a separate recent report, no difference in rhGH
responsiveness was demonstrated between d3+ or – genotypes in
124 patients treated for 1 year.19 The reasons for these discordant
results in adults and children are not clear, although one possibility
is that by combining d3 homo and heterozygous groups for analy-
sis, the full effect of the d3-GHR may be wholly or partially con-
cealed. The aim of this study was to investigate whether, in the
clinical setting, the d3-GHR polymorphism is an important con-
tributor to variable GH responsiveness in adult hypopituitary
patients treated with an identical dosing regimen of rhGH. In par-
ticular, we were interested to investigate differences in GH respon-
siveness between d3-GHR homozygotes and heterozygotes as this
has not been explored in previous studies.
Patients andmethods
This study was approved by the local ethics committee, and written
informed consent was obtained from all patients. One hundred
and ninety-four adult patients with GHD from a single centre were
studied. All were treated with rhGH according to an identical dose
titration protocol, previously described,7 the stated aim of which
was to maintain a serum IGF-I between the median and the upper
end of the age-related reference range. The diagnosis of GHD was
confirmed by a peak serum GH concentration £ 9 mU/l (3 mcg/l)
during insulin-induced hypoglycaemia or on a glucagon stimula-
tion test.
Details of the cohort are shown in Table 1. No patients had any
identifiable reasons for altered IGF-I production, e.g. anorexia
nervosa, renal failure, liver failure or concomitant use of opiates,
DHEA supplements or levodopa. None had active Cushing’s syn-
drome at the commencement of GH; those patients with a diagno-
sis of Cushing’s were 3–22 years post cure/successful control of
cortisol excess.
Following initial titration of rhGH dose, standard clinical and
biochemical assessments were performed at 6 and 12 months
and annually thereafter. For the purposes of this study, 6-month
and 12-month clinical data, waist:hip ratio, fasting lipid profile and
change in quality of life (AGHDA questionnaire), biochemical
response to rhGH treatment (DIGF-I SDS) and maintenance dose
of rhGH required were all analysed with respect to GHR genotype.
Table 1. Clinical features and demographics of the cohort studied
n = 194
N %
Gender Male 81 41.8
Female Total 113 58.2
Oestrogen replete 88 45.3
Oestrogen deficient 25 12.8
Age at Diagnosis <20 10 5.1
21–30 15 7.7
31–40 41 21.1
41–50 56 28.8
51–60 42 21.6
>60 30 15.5
Pituitary Hormone Deficiency Isolated Growth Hormone Deficiency 20 10.3
Multiple Pituitary Hormone Deficiency 174 89.6
Cause of GHD Pituitary tumour/treatment Total 137 70.6
NFPA 58 29.8
PRL 34 17.5
GH 9 4.6
ACTH 36 18.5
Pituitary apoplexy 9 4.5
Inflammatory/Infective 9 4.5
Trauma 3 1.5
Congenital 2 1.0
Other CNS tumours 25 12.9
Other 8 4.1
Previous Radiotherapy Yes Total 124 63.9
EBRT 122 62.9
Gamma Knife Radiosurgery 5 2.6
No 69 35.6
Duration of rhGH Treatment Mean (months) 91
Range (months) 12–276
GHD, growth hormone deficiency; E2, oestrogen; NFPA, nonfunctioning pituitary adenoma; PRL, prolactinoma; GH, Acromegaly; ACTH, Pituitary-depen-
dent Cushing’s syndrome; CNS, central nervous system tumours; EBRT, external beam radiotherapy; rhGH, recombinant human growth hormone.
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To remove the potential confounding effect of rhGH dose, analyses
were repeated using the ratio of IGF-I change to rhGH dose (delta
IGF-I/rhGH dose) at 6 and 12 months.
Assays
IGF-I Assay: Between 1997 and 2005, an RIA kit (Diagnostic Sys-
tem laboratories Inc, Webster, TX, USA) with mean intra-assay
and interassay coefficients of variation (CVs) of 7Æ2% and 10Æ4%,
respectively, was used. From 2005 to present, serum IGF-I was
measured by an automated solid-phase, enzyme-labelled chemilu-
minescent immunometric assay (Siemens Medical Solutions Diag-
nostics, Gwynedd, Wales, UK), with intra-assay and interassay CVs
of less than 11% and 8%, respectively. For each individual patient,
baseline, 6-month and 12-month IGF-I measurements were
performed using the same assay (Table 4). To take into account,
the change in assay during the time in which these patients were
assessed and treated, data in this study have been analysed using
standard deviation scores (SDS), calculated as n-mean/SD using
age and gender related normative data obtained from our labora-
tory for each respective assay.
Serum GH was quantitated by an immunoradiometric assay
using Immulite 2000 (Siemen’s Medical Solutions Diagnostics),
with interassay and intra-assay CVs of 5%.
Molecular studies
Genomic DNA was extracted from peripheral blood leuco-
cytes using standard methods (BACC2 DNA extraction kit; GE
Healthcare, Little Chalfont, Buckinghamshire, UK). A simple
multiplex PCR was performed using three primers; forward
TGTGCTGGTCTGTTGGTCTG, reverse full length GGATGCTA
TGTCAGAGTCAG and reverse d3 GGTAAGTCACATAGA-
TACTG (Sigma–Aldrich, Gillingham, Dorset, UK). A standard
45-cycle amplification of the GHR-exon 3 region was per-
formed. Amplification products were analysed using 2% agarose
gel stained with ethidium bromide. The fl allele is represented by
a 521 bp fragment and the d3 allele by a 470 bp fragment
(Fig. 1).
Previous studies have suggested an over-estimation of the fre-
quency of d3/d3 homozygotes presumably attributed to the fact
that smaller PCR products are preferentially formed in a competi-
tive reaction.15 To exclude heterozygosity in the d3/d3 homozyg-
otes, a second PCR was performed with only forward and full
length reverse primers.
Statistics
Results are reported as mean value ± standard deviation (SD).
Statistical significance was accepted at a P value <0Æ05. One-way
anova with Fisher LSD post hoc analysis was performed to com-
pare rhGH response at 6 and 12 months, and the doses of rhGH
required between the 3 genotype groups: fl/fl, fl/d3 and d3/d3.
Comparison was also made of the change in biological parameters
of GH activity; waist:hip ratio, quality of life (AGHDA) score and
fasting lipid profile.
A stepwise multiple regression model was created to assess the
individual and cumulative effect of genotype on GH response in
conjunction with other potentially contributory factors: GH dose,
oestrogen and external pituitary irradiation. To exclude the con-
founding effect of GH dose, analyses (anova and multiple regres-
sion analysis) were performed using the ratio of delta IGF-I/GH
dose at 6 and 12 months. Analysis was performed using spss
(version 11.01; SPSS Inc, Chicago, IL, USA) for Windows XP
(Microsoft Corp, Portland, Oregon, USA).
Results
Genotyping
The frequencies of the 3 genotypes (fl/fl, fl/d3 and d3/d3) were
52%, 38Æ7% and 9Æ3%, respectively, and were in Hardy–Weinberg
equilibrium. Repeat PCR of d3/d3 patients using forward and full
length reverse primers resulted in reclassification of 2/20 (9%)
patients as heterozygotes (Fig. 1). Proportions of male and female
subjects were comparable between genotype groups.
Serum IGF-I concentrations
The vast majority of patients maintained serum IGF-I levels within
the ‘target range’ as previously reported. A very small number of
patients had serum IGF-I levels outside of the reference range at
the time of either 6 or 12 months (see SDS results in Table 2).
Appropriate adjustments of rhGH dose were made at the time in
clinical practice. Baseline IGF-I levels were comparable between all
3 genotype groups (Table 2).
(a) (b)
Fig. 1 Amplification products of multiplex PCR shown on agarose gel
stained with ethidium bromide. The fl allele is represented by a 521 bp frag-
ment and the d3 allele by a 470 bp fragment. (a) Lane 1 represents a geno-
mic DNA ladder; lane 2 represents fl/fl homozygote; lane 3 represents d3/d3
homozygote and lane 4 represents fl/d3 heterozygote. (b) Comparison of
PCR results for the same patient. Lane 1 is a genomic DNA ladder; lane 2
represents the results of 3 primer PCR demonstrating a single 470 bp band
(d3/d3); lane 3 represents the same patient’s result from a repeat PCR using
only forward and full length reverse primers with a 521 bp band is visible,
thereby confirming d3 heterozygosity.
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rhGH response at 6 months
Comparison of the IGF-I response to rhGH at 6 months demon-
strated no significant difference between the 3 genotype groups,
and the doses used were equivalent (Table 2, Fig. 2a). A multiple
linear regression model did not detect any individual or cumulative
relationship between genotype, rhGH dose, oestrogen or external
pituitary irradiation and DIGF-I SDS (Table 3). Comparison of the
ratio of DIGF-I to rhGH dose also demonstrated no significant
difference between genotype groups at 6 or 12 months (Tables 2
and 3).
rhGH response at 12 months
A significant difference between the fl/fl and d3/d3 genotype
groups was detected for DIGF-I achieved at 12 months using
Table 2. Comparison of results for the 3 GHR genotype groups using anova with Fisher LSD post hoc statistical analyses. Response to treatment is
demonstrated by DIGF-I and are reported as standard deviation scores (SDS). Further analyses of the ratio of IGF-I change to rhGH dose are included to
exclude the potential confounding effect of variability in rhGH dose. Data are reported as mean and (standard deviation)
fl/fl n = 101 fl/d3 n = 75 d3/d3 n = 18 anova P values
Gender
Male 43 32 6 fl/fl vs. fl/d3 fl/fl vs. d3/d3 fl/d3 vs. d3/d3
Female 58 43 12
IGF-I SDS
Basal )1Æ03 (1Æ36) )1Æ14 (1Æ25) )1Æ17 (1Æ19) 0Æ610 0Æ675 0Æ910
6 months 0Æ82 (1Æ68) 0Æ78 (1Æ60) 0Æ52 (1Æ55) 0Æ883 0Æ478 0Æ545
12 months 0Æ96 (1Æ49) 1Æ01 (1Æ61) 1Æ76 (1Æ52) 0Æ843 0Æ046 0Æ066
rhGH Dose (mg)
6 months 0Æ37 (0Æ17) 0Æ38 (0Æ16) 0Æ37 (0Æ13) 0Æ802 0Æ953 0Æ933
Range 0Æ1–1Æ0 0Æ1–0Æ9 0Æ1–0Æ7
12 months 0Æ41 (0Æ22) 0Æ41 (0Æ23) 0Æ43 (0Æ33) 0Æ906 0Æ701 0Æ658
Range 0Æ1–1Æ2 0Æ1–1Æ3 0Æ1–1Æ5
DIGF-I SDS
6 months 1Æ85 (1Æ88) 1Æ91 (1Æ49) 1Æ69 (1Æ63) 0Æ805 0Æ721 0Æ623
12 months 1Æ99 (1Æ49) 2Æ15 (1Æ74) 2Æ93 (1Æ29) 0Æ556 0Æ028 0Æ070
DIGF-I/rhGH Dose
6 months 4Æ98 (11Æ1) 5Æ89 (6Æ89) 5Æ20 (5Æ03) 0Æ784 0Æ786 0Æ671
12 months 5Æ80 (5Æ58) 5Æ93 (5Æ65) 10Æ2 (8Æ68) 0Æ882 0Æ004 0Æ007
DAGHDA
12 months 10Æ3 (6Æ66) 9Æ35 (6Æ00) 11Æ3 (5Æ75) 0Æ533 0Æ473 0Æ296
DWaist: Hip Ratio
12 months 0Æ02 (0Æ16) 0Æ57 (0Æ16) 0Æ03 (0Æ08) 0Æ116 0Æ749 0Æ547
DChol mmol/l
12 months 0Æ42 (1Æ26) 0Æ605 (1Æ17) 0Æ64 (1Æ44) 0Æ124 0Æ290 0Æ901
DTrig mmol/l
12 months 0Æ18 (1Æ13) 0Æ14 (0Æ95) 0Æ38 (0Æ86) 0Æ993 0Æ267 0Æ279
fl/fl, full length homozygotes; fl/d3, d3 heterozygotes; d3/d3, d3 homozygotes; rhGH, recombinant growth hormone; AGHDA, QOL score; Chol, cholesterol;
Trig, triglycerides.
(a) (b)
Fig. 2 Box plots to demonstrate the variability in DIGF-I response between GHR genotype groups. *denotes statistical significance (P < 0Æ05) between fl/fl
and d3/d3 groups using anova comparing DIGF-I at 12 months. NS denoted no statistical significance. (a) DIGF-I between baseline and 6 months.
(b) DIGF-I between baseline and 12 months.
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anova (P = 0Æ028). There was no difference detected between the
fl/fl and fl/d3 group (P = 0Æ556) or between the fl/d3 and d3/d3
groups (P = 0Æ07). The maintenance dose of rhGH required to
achieve target IGF-I was also comparable between genotype groups
(Table 2). Analysis of the ratio of IGF-I change to rhGH dose con-
firmed the significant difference in the d3/d3 group (P = 0Æ004
compared to fl/fl and 0Æ007 compared to fl/d3) using anova.
Multiple linear regression analysis confirmed the positive rela-
tionship between d3/d3 genotype and DIGF-I between baseline and
12 months (P = 0Æ029) compared to fl/fl genotype. There was no
significant relationship for fl/d3 genotype or rhGH dose. Repeat
multiple regression analyses assessing the ratio of IGF-I change to
rhGH dose confirm the significant effect of d3/d3 genotype
(P = 0Æ004) (Table 3).
Effect of oestrogen and pituitary irradiation
The influence of oestrogen and pituitary irradiation on long-term
rhGH response was also investigated as part of the multiple regres-
sion models; no significant relationship was detected for either var-
iable at 6 or 12 months. Regression analyses were performed in a
stepwise manner with nonsignificance demonstrated for oestradiol
with and without the inclusion of pituitary irradiation (for delta
IGF-I at 12 months, P = 0Æ171 without inclusion of pituitary irra-
diation and 0Æ422 including pituitary irradiation in the analyses.
For delta IGF-I/rhGH dose, P = 0Æ072 without inclusion of pitui-
tary irradiation and 0Æ089 including pituitary irradiation in the
analyses).
The vast majority of female hypogonadal patients were taking
oral rather than trans-dermal oestrogen; statistical power was
insufficient for subgroup analysis.
Biological markers of GH activity
Baseline biological markers were comparable between groups
(Table 2). Analysis of the change in AGHDA score, waist: hip ratio
and fasting lipid profile did not demonstrate any significant differ-
ence between genotype groups.
Discussion
To our knowledge, this is the largest study to date of the effect of
the d3-GHR genotype on GH responsiveness in hypopituitary
patients treated with GH. By studying 194 patients, all treated with
an identical dose titration regimen, we have been able to perform
an extensive statistical analysis, including an assessment of the
effects of d3 homo and heterozygosity; previous studies, both in
acromegaly and hypopituitarism,18,20,21 have grouped these
patients together. The data suggest that homozygosity for the
d3-GHR may confer a marginal increase in GH responsiveness at
Table 3. Results of multiple regression analyses investigating factors influencing GH responsiveness compared to full length homozygotes (fl/fl). Further
analyses of the effect of genotype on the ratio of IGF-I change to rhGH dose were performed assessing the change per unit dose. To confirm the relationship
between oestradiol and GH responsiveness, a stepwise regression analysis was performed including and excluding pituitary irradiation (RT); results
confirmed a lack of a statistical significance
Baseline–6 months Baseline–12 months
DIGF-I DIGF-I/Dose DIGF-I DIGF-I/Dose
b-Coeff P value b-Coeff P value b-Coeff P value b-Coeff P value
fl/d3 0Æ019 0Æ799 0Æ022 0Æ770 0Æ053 0Æ477 0Æ006 0Æ940
d3/d3 )0Æ023 0Æ755 )0Æ016 0Æ835 0Æ161 0Æ029 0Æ214 0Æ004
Oestrogen (excluding RT) 0Æ088 0Æ432 (0Æ473) )0Æ094 0Æ197 (0Æ136) 0Æ06 0Æ422 (0Æ171) )0Æ122 0Æ089 (0Æ072)
Pituitary Irradiation 0Æ094 0Æ231 0Æ107 0Æ144 0Æ046 0Æ528 0Æ043 0Æ549
GH Dose )0Æ059 0Æ203 N/A N/A 0Æ142 0Æ059 N/A N/A
R Squared 0Æ020 0Æ024 0Æ054 0Æ061
Table 4. This table shows delta IGF-I results (ng/ml) for each genotype for each assay, pre-2005 and post-2005. Cumulatively, we report the percentage
change in IGF-I achieved between baseline and 6 and 12 months
DIGF-I (ng/ml)
% Change IGF-I
0–6 months
% Change IGF-I
0–12 months
Assay 1 (pre-2005) Assay 2 (post-2005)
N 0–6 months 0–12 months N 0–6 months 0–12 months
fl/fl 79 88Æ8 (71Æ0) 82Æ9 (67Æ5) 22 82Æ8 (43Æ3) 89Æ9 (65Æ1) 101Æ3 101Æ7
fl/d3 59 106Æ0 (54Æ0) 108 (80Æ0) 16 79Æ0 (44Æ1) 93Æ0 (63Æ4) 123Æ4 120Æ4
d3/d3 15 85Æ7 (81Æ4) 110Æ3 (69Æ2) 3 100Æ0 (30Æ8) 83Æ0 (25Æ9) 124Æ7 138Æ5
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12 months, as demonstrated by an augmented IGF-I response from
baseline over this time period. There was no difference in the doses
of rhGH between groups and analyses of the ratio of change of
IGF-I to rhGH dose confirmed this significant effect, thereby sug-
gesting that a greater change in IGF-I was achieved for a given
rhGH dose in d3 homozygous subjects. These data are in keeping
with a previous report,18 although the smaller size of that study dic-
tated that d3 homozygotes and heterozygotes were analysed
together. Shorter-term GH responsiveness (DIGF-I between base-
line and 6 months, which includes the period of dose titration) was
comparable between groups; the reason(s) for the discrepancy
between responses at 6 and 12 months is not clear.
Given the enhanced GH responsiveness evident in the d3 homo-
zygous patients at 12 months, one might have expected this to
translate into a lower maintenance dose requirement for GH to
achieve an equivalent ‘target’ serum IGF-I. However, no statisti-
cally significant differences in rhGH dose requirements were
evident between genotype groups. One possible explanation for
this is the small number of d3 homozygotes: 20 patients, despite
the large scale of our study. A second, probable, contributory rea-
son is the design of the GH dose titration regimen used.7 Patients
commenced 0Æ8 IU (more recently, 0Æ3 mg) daily, with regular
measurement of serum IGF-I and dose adjustments as required,
aiming to maintain a value between the median and upper end of
the age-adjusted normal range. For the vast majority of male
patients, this starting dose resulted in a serum IGF-I within the ‘tar-
get range’, with no requirement for subsequent dose increments.
The ‘target range’ for this dose titration protocol is wide, for exam-
ple, the normal range for a patient aged 21–30 is 117–358 ng/ml,
with a median of 176, thereby giving a ‘target range’ of 182 ng/ml.
Although no increments in dose were needed for the majority of
patients above 0Æ8 or 1Æ2 IU for males and females, respectively, sta-
tistically significant differences in IGF-I values at 12 months were
noted between genotype groups, but within the target range. This
would suggest that, although heterogeneity in GH responsiveness
between genotype groups is evident at 12 months, this is not of
particular clinical relevance and does not explain the marked varia-
tion in rhGH doses observed in clinical practice.
Previous studies of the effect of the d3-GHR on GH responsive-
ness have largely been confined to children. Data have been con-
flicting with enhanced linear growth responses to injected GH
observed in some, but not all, patients with ISS, SGA, GHD and
Turner syndrome.11,14,17,22–24 Two recent studies of adult GHD
patients have shown similarly conflicting results. Enhanced IGF-
generation was demonstrated after 1 but not 5 years therapy with
GH in d3-GHR homozygotes and heterozygotes, in conjunction
with changes in fasting lipid profile.18 However, a more recent
study has demonstrated no differences in IGF-I response or reduc-
tions in body fat between d3 genotype groups after 1 year of rhGH
treatment.19 Conflicting data regarding IGF-I levels in response to
a GH stimulus have also been shown in adult acromegalic patients
both preoperatively and postoperatively.20,21 There are two possi-
ble reasons for the lack of concordance between studies. First, it is
possible that there is variability in the response of d3 homozygotes
and heterozygotes; we postulate that this may be because of func-
tional differences in the GHR formed. Assuming equivalent affinity
of receptor dimers, only 25% of the GHRs of heterozygous patients
will be d3/d3 homodimers. If a d3/d3 homodimer is required for
augmented GH responsiveness, then a d3 heterozygote will exhibit
only 25% of the ‘extra’ IGF-I generation capacity, an effect that
may not be detected in smaller studies. More detailed studies of the
transcriptional activity of hetero vs. homodimers are needed to
determine whether there is a difference in functional activity and
thus whether there is a partial increase in GHR response in d3
heterozygotes in comparison with d3 homozygotes. Second, repeti-
tion of the PCR with two primers has ensured that our classifica-
tion of subjects as d3 homozygotes or heterozygotes is robust;
previous studies have shown that 20% of d3 heterozygotes are mis-
classified as homozygotes without this additional step.15,16,25 As the
majority of previous studies have not performed this second PCR,
it is possible that a significant proportion of subjects have been
mislabelled. If GH responsiveness varies between d3 homozygotes
and heterozygotes, such genotype misclassifications may have con-
tributed to the inconsistency of published clinical data.
In conclusion, this large-scale extensive study of the effect of the
d3-GHR genotype on rhGH responsiveness in adult hypopituitary
patients has demonstrated an increase in rhGH responsiveness at
12 months. However, given only 10% of the population are homo-
zygous for d3-GHR and the marginal nature of the increased
response, this is unlikely to explain the marked variability in rhGH
dose requirements in this patient group, and further studies are
needed before more tailored approaches to rhGH dosing can be
developed.
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